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Summary 
The SmpA outer membrane lipoprotein of B. hyodysenteriae has several 
characteristics that indicate the potential to protect against swine dysentery (SD).   It 
localises to the outer membrane and antibodies directed against SmpA can prevent the 
growth of B. hyodysenteriae in vitro.   There is some variation observed in the distribution 
and expression of the SmpA lipoprotein, suggesting that vaccination with SmpA may not 
provide protection against challenge with a heterologous B. hyodysenteriae strain. 
 
This study has characterised the variation at the smpA locus, and in the process has 
identified a novel gene, smpB.   There is very low similarity between smpB and smpA, with 
the exception of an identical lipoprotein signal sequence.   This suggests that SmpB may be 
translocated to the outer membrane of B. hyodysenteriae in a similar fashion to SmpA.   The 
results described in this thesis indicate that strains of B. hyodysenteriae harbour either smpA 
or smpB, but not both, explaining the earlier results of Turner et al. (1991).   The presumed 
outer membrane location of SmpB lead to further investigations into its potential to protect 
mice from infection with B. hyodysenteriae. 
 
Swine Dysentery is a inflammatory disease of the swine colon.   Therefore it is believed 
that a mucosal immune response may provide increased protection against challenge.   In 
this study, vaccination of mice with recombinant SmpB elicited high levels of serum 
antibodies, induced the production of Interleukin-4 producing T lymphocytes and decreased 
the observed histological effects after challenge with virulent B. hyodysenteriae.   In efforts to 
increase the protected conferred by vaccination with SmpB, recombinant Salmonella 
typhimurium STM-1 vaccines were created to express SmpB or deliver DNA vaccines 
encoding SmpB.   Vaccination with these recombinant Salmonella vectors did not induce a 
measurable SmpB specific immune response.   Macrophage survival and plasmid stability 
studies indicated that this was due to instability of the expression plasmids in STM-1.   
Although SmpB will only ever protect against strains of B. hyodysenteriae harbouring smpB, 
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these results indicate that with further research, SmpB (and SmpA) may contribute to 
protection from SD. 
 
Toxin production is an important aspect of the pathogenesis of many pathogenic 
bacteria.   Vaccination with attenuated toxins is commonly used to prevent disease.   In this 
study, the B. hyodysenteriae β-haemolysin HlyA was used to vaccinate mice to determine 
the protection induced after challenge.   Vaccination of mice with recombinant HlyA induced 
significant levels of serum antibodies and lowered the observed pathological effects after 
challenge of vaccinated mice with virulent B. hyodysenteriae.   In an attempt to increase the 
mucosal immune response and therefore the protection afforded after vaccination with HlyA, 
recombinant S. typhimurium STM-1 strains were created to express HlyA or deliver DNA 
vaccines encoding HlyA.   Similar to the recombinant STM-1 vaccines expressing SmpB, a 
HlyA specific immune response was not observed by ELISA or ELISPOT analysis.   Plasmid 
stability trials revealed that the inability to induce a detectable HlyA specific immune 
response by recombinant STM-1 vaccination may be due to instability of the plasmids. 
 
Outer membrane proteins are often important components of vaccines against bacterial 
and viral pathogens.   Considering the variation observed in the smpA locus in this study 
resulting in the identification of smpB, further investigation into the distribution and 
conservation of outer membrane encoding genes in B. hyodysenteriae strains was 
undertaken.   In particular, the blpAEFG, vspABCD and vspEFGH clusters were analysed for 
their distribution.   It was demonstrated that genes that are B. hyodysenteriae specific 
(vspABCD and vspEFGH) displayed higher levels of polymorphism than those that are 
distributed amongst non-pathogenic species, such as B. innocens (which contains blpAEFG).   
This suggests that the variation in the vspABCD and vspEFGH clusters amongst B. 
hyodysenteriae strains may be a result of the exposure to the host immune system.   Further 
investigation was undertaken by PFGE analysis and 2D-gel electrophoresis, to analyse 
genomic and proteomic variation at a global level.   Although strains of B. hyodysenteriae 
produced several different electrophoretic types (ET) upon PFGE analysis, only limited 
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correlation between the PFGE ET, the polymorphisms in vspABCD and vspEFGH and the 
presence of smpA/smpB were observed. 2D-gel electrophoresis analysis of outer membrane 
preparations of two B. hyodysenteriae strain revealed several distinct differences in the outer 
membrane between B. hyodysenteriae strains.   The observed differences in the proteins 
contained in the outer membrane of B. hyodysenteriae is important for vaccine design, as the 
induction of cross protection between strains of B. hyodysenteriae is essential for a effective 
vaccine. 
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Chapter 1 – Literature Review. 
 
1.1 Introduction. 
Swine dysentery (SD) is a porcine disease of the gastrointestinal tract, affecting mainly 
post-weaning piglets in fattening vats.   Characterised by inflammation and necrosis of the 
large intestine and an excess of mucous production, the disease is responsible for 
considerable economic losses due to weight loss and dehydration. 
 
The bacteria responsible for SD was isolated in the early 1970s (Harris et al., 1972b; 
Taylor & Alexander, 1971) and was capable of reproducing SD in healthy pigs (Harris et al., 
1972a; Kinyon et al., 1977; Whipp et al., 1979).   Originally named Treponema 
hyodysenteriae, genetic comparison to Treponema pallidum revealed few similarities and the 
organism was renamed Serpulina hyodysenteriae (Miao et al., 1978; Stanton et al., 1991).    
Genetic and biochemical similarities to Brachyspira aalborgi resulted in the later unification of 
the Brachyspira and Serpulina genera (Ochiai et al., 1997).   The current name of the 
spirochaete that causes SD is Brachyspira hyodysenteriae. 
 
SD is characterised by the production of lesions in the colon resulting in malabsorption 
of fluids from the intestinal lumen.   This presents as bloody, mucous filled diarrhoea that 
rapidly results in weight loss and dehydration in infected swine.   The pathogenesis of SD 
has not been completely characterised (ter Huurne & Gaastra, 1995).   Various pathogenic 
mechanisms have been investigated but no cohesive pathogenic mechanism has been 
established. 
 
The lack of understanding of the pathogenesis of B. hyodysenteriae combined with the 
unknown host immune response makes prevention of SD a challenge.   There is no 
widespread vaccination program for the control of the disease and prevention of SD currently 
relies upon the use of antimicrobials as in-feed medication or the treatment of outbreaks 
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(Burch, 1982; Karlsson et al., 1999; Laine et al., 2004; O'Connor et al., 1979; Olson & 
Rodabaugh, 1976; Olson, 1986; Pickles, 1982; Taylor, 1980).   The prophylactic use of 
antibiotics, especially in the human food chain is undesirable as antibiotic resistance is 
becoming much more widespread (Buller & Hampson, 1994; Gresham et al., 1998; Karlsson 
et al., 1999; Karlsson et al., 2001; Karlsson et al., 2002; Karlsson et al., 2004; Lobova et al., 
2004; Molnar, 1996; Pringle et al., 2004). The prudent use of antibiotics to treat veterinary 
disease is important as there is a correlation between antibiotic resistance in food animals 
and in human commensal flora (Smith et al., 2002).    The development of an effective and 
cheap vaccination regime would prevent the widespread use of antibiotics. 
 
The use of attenuated live bacterial vectors has shown promise in the prevention of 
several diseases.   The delivery of heterologous antigens by these bacteria can result in 
direct presentation of the antigen to the gastric associated lymphoid tissue (GALT), leading 
to a mucosal immune response (Allen et al., 2000; Chen & Schifferli, 2000; Roland et al., 
2005; Sbrogio-Almeida et al., 2004; Sirard et al., 1999).   Attenuated Salmonella enterica 
serovar typhimurium is one such bacterium that has been widely investigated for its use as a 
vector vaccine (Husseiny & Hensel, 2005a; Loessner & Weiss, 2004; Weiss, 2003; Xu & 
Ulmer, 2003). 
 
 
1.2  Brachyspira hyodysenteriae. 
1.2.1 Genetics of Brachyspira hyodysenteriae. 
A physical map based on restriction sites has been constructed for B. hyodysenteriae 
B78T.   The genome is a single circular 3.2 Mb chromosome with a G+C content of 
approximately 25% (Miao et al., 1978; Zuerner & Stanton, 1994).   Little sequence data is 
available on the genome of B. hyodysenteriae.   The areas of the genome that have been 
sequenced focus on potential virulence factors or diagnostic loci. 
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There is evidence that the B. hyodysenteriae genome undergoes frequent 
recombination events (Atyeo et al., 1999a; Trott et al., 1997; Zuener et al., 2004).   The 
recombinant nature of B. hyodysenteriae is supported by observations that no single locus is 
linked to the electrophoretic type or serotype (Lee et al., 1993; Stanton et al., 1996).    
Despite the recombinant nature of B. hyodysenteriae, certain ‘epidemic clones’ displaying 
common electrophoretic types are more widespread worldwide than others (Atyeo et al., 
1999a; Trott et al., 1997).   These ‘epidemic clones’ possibly have some evolutionary 
advantage conferred upon them by the recombination events that created them. 
 
The B. hyodysenteriae genome contains a 15kb region encoding for a defective 
generalised transducing phage VSH-1 (Humphrey et al., 1997; Matson et al., 2005; Stanton 
et al., 2003).   The VSH-1 phage, while unable to package DNA for its own replication (hence 
defective) has been shown to mediate the transfer of ~7kb random genomic fragments.   
Inter-strain transfer of antibiotic resistance has been demonstrated in vitro, and this was 
thought to be mediated by VSH-1 (Stanton et al., 2001).   The widespread presence of VSH-
1 in other Brachyspira strains may allow the efficient transfer of genes between strains within 
a species (Calderaro et al., 1998; Humphrey et al., 1995). 
 
Despite the presence of a bacteriophage there is a general lack of molecular biological 
techniques for the manipulation of the B. hyodysenteriae chromosome.   Several knock-out 
mutants have been created using suicide vectors and electroporation-mediated allelic 
exchange (Hyatt et al., 1994; Kennedy et al., 1997b; Li et al., 2000; Rosey et al., 1995; 
Rosey et al., 1996).   Further investigation into molecular biology techniques and sequence 
characterisation of the complete B. hyodysenteriae genome would greatly enhance research 
into SD. 
 
 Figure 1.1: Phylogeny tree of Spirochaetes. 
Phylogeny tree of B. hyodysenteriae, based on 16s rRNA sequences. B. hyodysenteriae, along with 
the closely related B. innocens, occupies a unique clade in the family of Spirochaetes. (Olson et al., 
2000). The marker bar represents 5 changes per 100 nucleotides. 
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1.2.2 Taxonomy and Typing. 
B. hyodysenteriae and B. innocens comprise a distinct group on the spirochaete 
phylogenetic tree (Figure 1.1) (Paster et al., 1991).   Current methods of serotyping revealed 
9 groups of B. hyodysenteriae displaying varying LPS epitopes (Baum & Joens, 1979; 
Hampson, 1990; Hampson et al., 1994).   Group 1 Brachyspira spp. contains the beta-
haemolytic B. hyodysenteriae strains that cause SD.   The species most closely related to B. 
hyodysenteriae, B. innocens belongs to group 3.   Serpulina intermedia and Brachyspira 
murdochii belong to groups 2 and 5.   There have been some proposed changes to the 
serotyping system of B. hyodysenteriae (Hampson et al., 1989), based on the cross-reactivity 
of certain serotypes in the current scheme.  
 
Due to the impracticality of the serotype based typing system, several DNA-based 
methods of typing B. hyodysenteriae have been investigated (Barcellos et al., 2000; Harel et 
al., 1994; Jensen et al., 1992).   Molecular methods of typing B. hyodysenteriae such as 
restriction enzyme analysis (REA) and pulsed field gel electrophoresis (PFGE) are more 
discriminatory than serotyping, however they encounter the problem of potentially complex 
electrophoresis patterns that must be differentiated (Atyeo et al., 1999a; Combs et al., 1992; 
Sotiropoulos et al., 1994).   PFGE analysis showed promise in being able to segregate 
different genetic groups, however the process is much more time consuming than serotyping 
(Atyeo et al., 1999a; Rayment et al., 1997).    
 
Analysis of the 23S rRNA genes of B. hyodysenteriae strains by PCR-RFLP clustered 
B. hyodysenteriae isolates into the same groups as serotyping (Barcellos et al., 2000).   
However, typing using the 16S rRNA genes was not able to distinguish between pathogenic 
B. hyodysenteriae and the potentially pathogenic S. intermedia (Pettersson et al., 1996; 
Stanton et al., 1996).   Multilocus enzyme electrophoresis (MEE) analysis of several strains 
also gave unclear typing results.   Although several strains from different serogroups 
displayed different electrophoresis patterns, the 16S rRNA sequence was almost identical 
(~98%) (Stanton et al., 1996).  
  
  b) 
 
Figure 1.2: Structure of a Spirochaete 
Figure 1.2a: Schematic diagram of the structure 
with the underlying flagella or axial filaments (AF
TEM of a Spirochaete, again showing the OS, AF
image shows how loosely attached the outer me
Figure 1.2c: Photomicrograph of B. hyodysente
(Davis, 2002b). 
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While MEE and 16S rRNA analysis are not entirely effective methods of typing B. 
hyodysenteriae, methods that utilise the whole genome such as PFGE and REA yield results 
that correspond closely to the established groupings of serotypes (Atyeo et al., 1999a; 
Rayment et al., 1997).   
 
1.2.3 Structure of Brachyspira hyodysenteriae. 
Spirochaetes have a structure that is unique amongst bacteria.   Members of the group 
Spirochaetales possess an outer membrane (OM) covering the protoplasmic cylinder that 
consists of the cell membrane, wall, cytoplasm and endoflagella (Figure 1.2).   The loosely 
attached outer sheath and endoflagella are invariably found in all spirochaetes, and 
distinguish spirochaetes from other helical shaped bacteria (Blaha & Gunther, 1985; Holt, 
1978).   The OM of spirochaetes contain many lipoproteins involved in functions such as iron 
uptake (Dougard et al., 1999), antigenic variation (McCaman et al., 1999), adhesion, host 
defence resistance and environmental adaptation (Haake, 2000).  
 
1.2.3.1  Outer Membrane Structure. 
The OM of spirochaetes has a typical Gram-negative structure, with some variations 
distinguishing them from other Gram-negative bacteria.   The OM is only weakly attached to 
the underlying peptidoglycan layer, producing a more labile membrane easily disrupted by 
environmental changes (Holt, 1978).   This is because the peptidoglycan layer, unlike in 
other Gram-negative genera is not covalently attached to the outer membrane (Joseph et al., 
1973).   The OM forms the outer layer of the protoplasmic cylinder by covalent attachments 
of lipoproteins on the inner membrane such as the periplasmic iron-binding proteins 
(Dougard et al., 1999; Holt, 1978). 
 
As the OM is the interface between the spirochaete and its host environment it may 
interact with host defence mechanisms (Holt, 1978).   This role is supported by the discovery 
of many putative outer membrane proteins encoded by genes such as the vspABCD, 
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vspEFGH and blpABCD clusters that consist of multiple similar genes that may be involved 
in immune avoidance.   The proteins encoded by the vspABCD, vspEFGH and blpABCD 
operons are thought to localise to the outer membrane and are available to the host immune 
system (Gabe et al., 1998).   The discovery of an iron transport system in B. hyodysenteriae 
that contains three periplasmic iron-binding proteins (Dougard et al., 1999) suggests that the 
space between the outer sheath and protoplasmic cylinder serves a similar function to the 
periplasmic space (Holt, 1978). 
 
1.2.3.2  Outer Membrane Proteins. 
Outer membrane proteins perform an important role in the pathogenesis of a 
spirochaete, such as adhesion, iron absorption and host immune avoidance (Cullen et al., 
2004; Dougard et al., 1999; Haake, 2000; Lin et al., 2002).   Several putative outer 
membrane proteins have been characterised in B. hyodysenteriae, including SmpA and 
BmpB and the gene clusters blpABCE, vspABCD and vspEFGH which encode outer 
membrane proteins.  
 
1.2.3.2.1 SmpA. 
Adsorption of convalescent swine serum with B. innocens antigens lead to the 
discovery of a 16 kilodaltons (kDa) protein present only in B. hyodysenteriae (Sellwood et al., 
1989; Thomas & Sellwood, 1993).   SmpA was low in abundance but highly antigenic 
(Sellwood et al., 1989).   Anti-SmpA antibodies could prevent the growth of B. 
hyodysenteriae in vitro and immunogold labelling revealed that SmpA was surface exposed, 
suggesting a use for SmpA in prevention and detection of SD (Sellwood et al., 1989; Thomas 
& Sellwood, 1992). 
 
Variation in the expression of SmpA has been observed (Thomas et al., 1992).   Initially 
this variation was attributed to the stage of growth at which the cells were harvested or 
regulation of expression in differing culture media (Thomas et al., 1992).   Subsequent 
experiments showed that SmpA was not detectable at certain periods during a SD infection, 
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specifically after the onset of clinical disease (Sellwood et al., 1995).   Environmental 
regulation of outer membrane lipoproteins is widely used by spirochaetes (Haake, 2000) and 
may account for this observation. 
 
Investigations of the distribution of smpA amongst B. hyodysenteriae indicated some 
sequence variation amongst different strains, with only some strains reacting on DNA-DNA 
hybridisation, and others displaying different restriction patterns (Turner et al., 1995).   As 
some strains of B. hyodysenteriae displayed two bands during DNA-DNA hybridisation, it 
was hypothesised that a second locus similar to smpA existed on the B. hyodysenteriae 
chromosome (Turner et al., 1995).   However, no further studies were performed to 
investigate the sequence variation of smpA between strains. 
 
The growth inhibition by anti-SmpA antibodies, surface localisation and the presence of 
SmpA-specific antibody in convalescent swine sera all indicate SmpA may be an important 
antigen in protection from SD.    The inability to detect SmpA expression in vivo does not 
preclude the use of SmpA for prophylactic applications or for detection of SD.   As SmpA is 
expressed early in infection (Sellwood et al., 1995) vaccines utilising this antigen may still 
protect against SD and may be preferable to antigens only expressed later during infection. 
 
1.2.3.2.2 BmpB. 
A monoclonal antibody produced against a 30kDa antigen lead to the discovery of a 
second B. hyodysenteriae outer membrane lipoprotein (Lee & Hampson, 1996). The 
lipoprotein BmpB shares sequence similarity with outer membrane proteins of unknown 
function from other Gram-negative bacteria such as Pastuerella haemolytica and Escherichia 
coli (Lee et al., 2000). 
 
Polyclonal sera raised against recombinant BmpB reacted with cell envelope 
preparations of a range of Brachyspira species and strains (Lee et al., 2000).   The cross 
reactivity between B. hyodysenteriae and B. innocens was explained by shared structural 
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proteins inducing cross-reacting antibodies (Lee et al., 2000).   However, Western blots 
performed with the original monoclonal antibody that found no reaction with non-B. 
hyodysenteriae strains suggesting the epitope recognised by this antibody is not conserved 
across species (Lee & Hampson, 1996).   Any potential diagnostic assays based around 
BmpB will need to take into account the reactivity of polyclonal sera with B. innocens, and 
any monoclonal antibodies will also need to be screened for cross-reactivity. 
 
It has recently been discovered that bmpB is present in B. innocens, albeit in only one 
strain, B256 (La et al., 2005).   No other strain of B. innocens contained bmpB or it was 
sufficiently different to not react during DNA-DNA hybridisation.   The presence of bmpB in B. 
innocens B256 may be due to a recent transduction event, as both these species contain 
homologues of the VSH-1 bacteriophage (Matson et al., 2005; Stanton et al., 2003).   The B. 
innocens BmpB did not react with the original monoclonal antibody used to discover BmpB in 
B. hyodysenteriae (Lee & Hampson, 1996), however polyclonal antisera raised against 
recombinant BmpB did react with B. innocens (La et al., 2005), suggesting only partial 
epitope conservation as was originally thought (Lee et al., 2000). 
 
Recent studies indicate that vaccination with BmpB can provide partial protection 
against SD (La et al., 2004).   Of the swine vaccinated with recombinant His-tagged BmpB, 
~30% fewer developed SD compared to the non-vaccinated controls.   It has been revealed 
that bmpB is identical to blpA, as discussed below (La et al., 2005).   This means that bmpB 
is actually part of a gene cluster of unknown function, and although it has been shown to be 
protective in mice and pigs, the presence of three similar genes possibly involved in antigenic 
variation may limit the usefulness of BmpB.   Further studies into the blpABCD operon, 
investigating its function and regulation will help to establish whether or not BmpB/BlpA can 
be used as a protective antigen. 
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1.2.3.2.3 Brachyspira lipoprotein operon (blpAEFG). 
Screening of a genomic library of B. hyodysenteriae B204 revealed a gene cluster 
encoding four outer membrane proteins, blpA, blpE, blpF and blpG sharing 61-80% 
nucleotide sequence identity (Cullen et al., 2003).   Cullen et al. postulated that the blp gene 
products might share sequence similarity with the 30kDa BmpB protein but as sequence data 
was unavailable at the time the hypothesis remained untested (Cullen et al., 2003).   It was 
later discovered that BlpA is the BmpB lipoprotein (See BmpB above).   Only expression of 
blpA/bmpA was detected in vitro and convalescent swine sera reacts with recombinant 
BlpA/BmpA indicating that is an immunostimulatory antigen (Cullen et al., 2003). 
 
As the commensal B. innocens also contains blpAEFG, the gene products are probably 
not involved in virulence.   However, the blpAEFG gene products may contribute to 
colonisation of the intestine as that ecological niche is shared with B. hyodysenteriae, or may 
be involved in nutrient acquisition like the bitABCDEF cluster (Dougard et al., 1999).   The 
four proteins encoded by the blp operon have 30-39% sequence identity with 30kDa proteins 
from a variety of pathogens including Campylobacter jejuni, Staphylococcus aureus, 
Haemophilus influenzae, Salmonella typhimurium and various Streptococcus spp (Cullen et 
al., 2003).   Isogenic sfbA (the blp homolog) mutants of Salmonella typhimurium were 
avirulent in mice but were still able to elicit an immune response (Pattery et al., 1999).   
Mutants of the 29kDa H. influenzae homolog were able to colonise the mucosal epithelium, 
but had impaired bacteremic ability (Chanyangam et al., 1991).   These mutants of blpAEFG 
homologs support the role for blpAEFG gene products in colonisation of the intestine.    
 
The development of molecular techniques, in particular knock-out mutagenesis 
techniques and their application to the bmpA/blpA gene in B. hyodysenteriae is a potential 
route for creating an avirulent mutant capable of eliciting an immune response. 
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1.2.3.3  Variable Surface Proteins (vspABCD and vspEFGH). 
A series of 8 highly conserved genes organised into two clusters has been discovered 
in B. hyodysenteriae using degenerate probes based on the N-terminal sequence of a 
purified outer membrane protein (Gabe et al., 1998; McCaman et al., 1999; McCaman et al., 
2003).   The vspABCD operon consists of the vspA, vspB, vspC and vspD genes encoding 
proteins of ~40kDa sharing 80-90% sequence similarity.    Each of the proteins has an 
identical N-terminal coding region, presumably a signal sequence directing the proteins to 
the same cellular location.   The proteins have alternating hydrophobic and hydrophilic 
domains suggestive of transmembrane proteins (McCaman et al., 1999).    
 
As none of these four predicted proteins matched the N-terminal sequence from the 
original purified protein and degenerate probes reacted with more than band on a Southern 
Blot (Gabe et al., 1998; McCaman et al., 1999), the search was extended to try to identify the 
fifth vsp gene.   This search led to the discovery of vspH, the gene encoding the original 
sequenced protein and a second locus consisting of another three genes designated vspE, 
vspF and vspG. The vspEFGH operon shows larger sequence variations between the four 
genes when compared to the similarities in the vspABCD cluster.   Similar to the blpAEFG 
cluster only one protein, VspH, is detected in vitro (McCaman et al., 2003). 
 
There are precedents found in Campylobacter jejuni and Salmonella typhimurium 
flagella genes (Aldridge et al., 2006; Wassenar et al., 1995) and Borrelia hermsii lipoproteins 
(Kitten & Babour, 1992).   The discovery of the iron-transport system in B. hyodysenteriae 
encoded by three similar genes (Dougard et al., 1999) and the linked lipoprotein operon blp 
demonstrates that the presence of multiple copies of similar genes is not restricted to the vsp 
operons and may be common in Brachyspira species.   Supporting the theory that the vsp 
genes are duplicated in order to evade the host immune system, there are conserved 
hydrophobic regions interspersed with variable hydrophilic regions.   The highly conserved 
regions are necessary to retain the structure and function of the protein, but the variation is 
enough to alter the antigenic specificity.    The variable hydrophilic regions are presumably 
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surface exposed (Gabe et al., 1998; McCaman et al., 2003).   The function of the eight 
copies of the vsp genes is unknown, but limited sequence similarity (7 amino acid (AA) 
residues over a 25 AA sequence) has been discovered with some bacterial aspartases 
(McCaman et al., 2003).  However, aspartases are cytoplasmic proteins and there are no 
known reasons that duplication of aspartases would be beneficial to a pathogen, suggesting 
that any similarity is coincidental. 
 
1.2.4 EndoFlagella. 
One characteristic that separates spirochaetes from other prokaryotic organisms is the 
presence of endoflagella (Paster et al., 1991).   Spirochaete endoflagella are contained in the 
periplasmic space between the outer membrane and the protoplasmic cylinder (Charon et 
al., 1992; Holt, 1978).   The general structure of the spirochaetal periplasmic endoflagella 
consists of an internal core with its covering sheath proteins, and an insertional apparatus.   
At the membrane insertion point a hook mechanism and insertional disks anchor the 
endoflagella into the protoplasmic cylinder.   The periplasmic flagella wrap around the 
protoplasmic cylinder, often overlapping in the centre of the cell (Charon et al., 1992; Holt, 
1978). 
 
B. hyodysenteriae possesses seven to nine endoflagella attached to the ends of the 
protoplasmic cylinder and covered by the OM.   There are five genes involved in the 
synthesis of B. hyodysenteriae endoflagella (Boyden et al., 1989; Koopman et al., 1992a).   
There are three core proteins that are 37, 34 and 32 kDa in size, designated FlaB1, FlaB2 
and FlaB3, and two sheath proteins FlaA1 and FlaA2 (Koopman et al., 1992a; Koopman et 
al., 1992b).   The two sheath proteins are 44 kDa and 35 kDa and share sequence similarity 
but have different N-terminal signal sequences (Fisher et al., 1997b; Koopman et al., 1992a; 
Li et al., 1993).   The core proteins show high levels of similarity and are conserved across 
Brachyspira species (Fisher et al., 1997a; Koopman et al., 1992a).   The gene encoding FlaA 
subunit shows variation across B. hyodysenteriae strains and RFLP of flaA can be used to 
type strains into similar groups as LOS serotyping (Fisher et al., 1997b). 
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Knock-out mutagenesis of either flaA1 or flaB1, while altering the motility of the 
bacterium did not prevent the assembly of flagella, indicating a level of redundancy when 
assembling flagella (Rosey et al., 1995).   Further investigations indicated that slight 
morphological changes in the flagella were caused by mutations in flaA1, flaB1, flaB2 or 
flaB3 (Li et al., 2000).   These studies confirmed that FlaA forms a sheath around a FlaB 
core. 
 
The presence of multiple homologs of core and sheath protein is unusual, especially as 
there is no evidence that the flagella undergo antigenic variation even though FlaA and FlaB 
are immunodominant antigens.   Phase variation in B. hyodysenteriae flagella genes has not 
been observed as it has in Campylobacter jejuni so the presence of multiple types of flagella 
remains a mystery.  
 
1.3 Swine Dysentery. 
SD is prevalent in many major pig producing areas of the world.   Studies in various parts of 
the world indicate that the incidence of infected swine in herds can be as high as 33% 
(Mhoma et al., 1992).   One investigations in the U.K. revealed that the incidence of B. 
hyodysenteriae causing disease is 16% (Thomson et al., 2001).   B. hyodysenteriae can 
cause subclinical disease, so the actual presence of B. hyodysenteriae in herds may be 
higher than the 16% causing disease (Thomson et al., 2001). 
 
1.3.1 Detection of Brachyspira hyodysenteriae. 
The detection of B. hyodysenteriae in swine from infected herds is important for the 
rapid treatment and prevention of clinical signs and the identification of swine carrying the 
pathogen.   The reliance of farms on the prophylactic use of antibiotics for the control of SD 
means diagnosis of B. hyodysenteriae is not considered important unless there are clinical 
signs.   Considering the long incubation time of the pathogen, by this time the infection has 
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spread throughout the herd.    The development of a cheap method to reliably detect B. 
hyodysenteriae would allow the screening of swine for exposure status before being 
introduced to an unexposed herd.   The ability of B. hyodysenteriae to establish subclinical 
infections (Hampson et al., 1992; Liven, 1979), increases the importance of quick, cheap and 
sensitive diagnosis techniques. 
 
Bacterial culture combined with biochemical analysis is the current method used to 
diagnose SD (Calderaro et al., 2005; Hommez et al., 1998).   Bacterial culture has several 
drawbacks. The first is the time required to isolate and identify this slow growing organism 
(Calderaro et al., 2005).   Of secondary concern is the propensity for false negatives as a 
result of any residual in-feed antibiotics present in the swine at the time of sampling 
(Calderaro et al., 2005). 
 
The application of ELISA (Egan et al., 1983; Kramomtong et al., 1996; La & Hampson, 
2001; Smith et al., 1991; Wright et al., 1989) for the detection of B. hyodysenteriae is limited 
by the lack of knowledge regarding which antigens are immunogenic during SD.   Various 
antibodies have been investigated and can identify Brachyspira spp. to the genus level 
(Achacha & Mittal, 1995; Achacha & Mittal, 1996; Egan et al., 1983; Lee & Hampson, 1995; 
Smith et al., 1991) however cross-reactivity with non-pathogenic Brachyspira spp. found as 
commensals in swine severely limits the usefulness of these antibodies.   Monoclonal 
antibodies have been used for the serotyping of B. hyodysenteriae and B. innocens strains 
(Achacha & Mittal, 1995), however cross reactivity between B. hyodysenteriae and the 
commensal B. innocens was observed.    
 
Rational choice of monoclonal antibodies for the detection of B. hyodysenteriae 
antigens shows promise against antigens such as BmpB (Lee et al., 2000).   Antibodies 
directed against SmpA have been evaluated for detection of B. hyodysenteriae infection.    
The specificity of SmpA for B. hyodysenteriae and not B. innocens was promising (Thomas & 
Sellwood, 1992), but the lack of expression in vivo (Sellwood et al., 1995) and the apparent 
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differences between strains (Turner et al., 1995) limited its usefulness for the detection of 
SD. 
Polymerase chain reaction (PCR) has been used to differentiate B. hyodysenteriae 
from other organisms (Atyeo et al., 1998; Atyeo et al., 1999b; Elder et al., 1994; Elder et al., 
1997; La et al., 2003; Leser et al., 1997; Rohde et al., 2002; Suh & Song, 2005).   A major 
drawback of most of the PCR systems developed to date is the requirement for culture of B. 
hyodysenteriae from stool samples, with the accompanying time requirement.   To offset this 
drawback, a PCR system was devised where the template was B. hyodysenteriae cells 
purified directly from faeces (La et al., 2003; La et al., 2006).   Although sensitivity is 
generally much better than culture, the PCR-based detection systems developed so far have 
also not evaluated the specificity of the PCR (Leser et al., 1997).   This shortcoming has 
recently been addressed, and DNA based detection systems have been found to be 
sensitive and specific methods for detection of B. hyodysenteriae (Atyeo et al., 1998; La et 
al., 2006).   The PCR did not amplify a product in 107 other strains of bacteria isolated from 
the porcine intestine (Atyeo et al., 1998).   Other PCRs may result in a similar specificity, 
however this does need to be tested before these PCR systems are used to detect B. 
hyodysenteriae. 
 
Fluorescent in situ hybridisation (FISH) showed promise for the detection of B. 
hyodysenteriae in formalin fixed tissue samples (Boye et al., 1998; Jensen et al., 1998).   
The use of an RNA probe for FISH of formalin-fixed colon samples confirmed the specificity 
of the probe for the target organism (Boye et al., 1998).   The advantage of targeting rRNA 
for detection is that there is no direct environmental regulation of the encoding genes (Boye 
et al., 1998).    However, bacteria that have entered stationary phase may have too low a 
rRNA content to produce a signal during FISH (Boye et al., 1998).    
 
The use of FISH to detect B. hyodysenteriae does have some disadvantages.   While 
the technique is sensitive, specific and rapid during growth phase, FISH does require a 
skilled microscopist and knowledge of the pathology of SD to locate the organism (Boye et 
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al., 1998).   Furthermore, FISH was only used on formalin fixed colon sections (Boye et al., 
1998).   The difficulty of obtaining colon samples without sacrificing the swine will greatly limit 
this technique.   Evaluation of FISH for the detection of B. hyodysenteriae in stool samples 
may increase its applications.  
 
1.3.2 Site of infection. 
B. hyodysenteriae colonise the intestinal tract of swine, preferentially the large intestine 
but also the small intestine and the caecum.   The luminal surface of the colon consists of a 
layer of colonic epithelium covering the vascular connective tissue called the lamina propria 
(Figure 1.3).   The surface of the large intestine has an abundance of narrow pits called 
crypts of Lieberkühn, which contain stem cells responsible for rejuvenation of the colonic 
epithelium (Figure 1.3). 
 
The colonic epithelium consists of two main cell types that are relevant to SD, 
enterocytes and goblet cells.   Enterotyces are absorptive cells, responsible for nutrient 
uptake and regulation of fluid content in the large intestine and make up the majority of cells 
in the large intestine.   Goblet cells secrete mucous into the intestinal lumen (Deplancke & 
Gaskins, 2001; Oliver & Specian, 1990; Specian & Oliver, 1991).   Differentiated from stem 
cells, goblet cells mature in the crypt of Lieberkühn on their journey to the apex of the crypt 
(Wong et al., 2000). 
 
In swine, the colon is responsible for the reabsorption of fluid.   As much as 50% of the 
extracellular fluid in a pig is presented to the large intestine daily (Argenzio et al., 1980; Low 
et al., 1978), which has a enormous absorptive capacity of 1.5 moles of Na+ and 8.6 L of 
H2O per day (Argenzio & Whipp, 1979).   Considering the role of the large intestine it is not 
surprising that disruption of its integrity causes the clinical signs of SD. 
 
 
 
  
 
 
 
 
Figure 1.3: Structure of the Intestinal Epithelium. 
Structure of the colonic epithelium showing the crypts of Lieberkühn, marked as intestinal gland. 
(http://www.yoursurgery.com/procedures/colectomy/images/ColonWall.jpg). 
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1.3.3 Pathological effects of Swine Dysentery. 
SD is characterised by a coagulative necrosis of the mucosal epithelium (Hughes et al., 
1975; Whipp et al., 1979).    Sloughing of the epithelium results in the formation of lesions 
and the malabsorption of fluids from the colonic lumen (Albassam et al., 1985; Jensen et al., 
1998; Olson, 1981; Wilcock & Olander, 1979a; Wilcock & Olander, 1979b). 
 
During infection of swine with B. hyodysenteriae the surface of the large intestine 
undergoes morphological changes, developing a corrugated, furrowed appearance (Kennedy 
& Strafuss, 1976; Teige et al., 1981).   Concurrently, entrances to the Crypts of Lieberkühn 
become dilated and the crypts are significantly lengthened (Kinyon et al., 1977).   The base 
of the crypt becomes distended with the accumulation of glycoproteins (Olson, 1981; Teige 
et al., 1981).   There is frequently a copious discharge of mucous into the lumen from the 
affected crypts (Hughes et al., 1975; Hughes et al., 1977; Kennedy & Strafuss, 1976; Olson, 
1981). 
 
Hyperplasia of goblet cells after infection is observed and during the initial stages of SD 
there is a rapid depletion of mucigen from goblet cells (Kinyon et al., 1977; Wilcock & 
Olander, 1979b).   The sudden expulsion of mucus from goblet cells has been well 
characterised in response to numerous stimuli including bacterial products such as LPS and 
host derived cytokines such as IL-8 (Smirnova et al., 2003).   The hyperplasia of goblet cells 
and increased secretion of glycoproteins would cause the increase in mucus production seen 
during SD (Albassam et al., 1985; Hughes et al., 1975; Wilcock & Olander, 1979b). 
 
Colonic epithelial cells become necrotic and extrude into the lumen resulting in the 
formation of lesions (Kinyon et al., 1977; Whipp et al., 1979).   Colonic enterocytes that are 
not completely destroyed exhibit shortened microvilli, loosening of the intercellular 
attachments and the formation of pores in the luminal membrane (Albassam et al., 1985; 
Hughes et al., 1975; Kennedy & Strafuss, 1976; Teige & Nordstoga, 1979; Teige et al., 
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1981).   Intracellularly, dilation and vesiculation of the endoplasmic reticulum and swelling 
and degeneration of mitochondria occurs (Teige & Nordstoga, 1979). 
 
There are also changes beneath the epithelium, specifically luminal bacteria 
accumulating in phagocytic cells and swelling and permeability changes of minute blood 
vessels in the lamina propria (Kinyon et al., 1977).  The permeability changes are severe 
enough to allow erythrocytes and fibrinogen to collect in the lumen (Hutto & Wannemuehler, 
1999; Kinyon et al., 1977), contributing to the blood and fibrin in the stool.   The swollen 
vessels in the lamina propria frequently contain tightly packed red cells and an accumulation 
of platelets, polymorphonuclear leucocytes and fibrin-like material (Hughes et al., 1975; 
Hughes et al., 1977; Teige & Nordstoga, 1979).   The colonic wall thickens during SD, with 
inflammation of the serosal surface at the sites of mesentery attachment (Hughes et al., 
1975; Hughes et al., 1977). 
 
Based on these pathological changes, Hughes et al. proposed a sequence of events 
for the pathogenesis of SD (Hughes et al., 1977).   In this model, B. hyodysenteriae produces 
a toxin while in close proximity to the colonic mucosa.   This toxin triggers hyperemia of the 
capillaries in the lamina propria and production of mucous from goblet cells in the Crypts of 
Lieberkühn.   As a result of the hyperemia the crypt shoulders swell and begin to leak serum.   
Necrosis of the epithelium caused by proliferation of B. hyodysenteriae and the production of 
toxins results in epithelial cell erosion and the formation of lesions with subsequent infiltration 
of B. hyodysenteriae past the epithelium.   Following the erosion of the crypt shoulders, the 
underlying capillaries are damaged causing haemorrhage into the lumen and subsequent 
mucohaemorrhagic dysentery.   This is supported by a recent study (Jensen et al., 1998), 
which showed that intense invasion of the lamina propria occurred around necrotic foci.   The 
lesions that develop during the disease are well characterised at the macroscopic and 
microscopic level, but why and how these lesions develop still remains largely unknown. 
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1.3.4 Symptoms of Swine Dysentery. 
The pathological effects previously discussed manifests in infected swine in several 
ways.  After an incubation period of 6 to 15 days, initial clinical signs of SD are fever, 
abdominal pain and weight loss (Kinyon et al., 1977; Whipp et al., 1979).   These mild clinical 
signs often go unnoticed, with the disease not being perceived until the onset of diarrhoea. 
 
Mild cases of SD, which are more common than severe, are characterised by mucoid 
diarrhoea with concurrent depression of growth rates.   The diarrhoea observed during SD 
progresses through several stages (Whipp et al., 1979).   Initially faeces appear “loose and 
stringy” followed by the presence of sometimes very large quantities of mucous (Whipp et al., 
1979).    Faeces at this stage have been described as “translucent, amber coloured faeces”, 
and some pigs exhibit faeces with a “scrambled eggs appearance” (Whipp et al., 1979).   
Swine displaying severe SD rapidly lose weight, becoming gaunt and dehydrated (Kinyon et 
al., 1977).   As the disease progresses, the faeces become reddish-black as blood and 
necrotic colonic epithelium are present in the faeces (Whipp et al., 1979). 
 
1.4 Pathogenesis of Brachyspira hyodysenteriae. 
The pathogenesis of SD is not completely understood.   Some aspects have been studied, 
particularly focusing on the localisation of Brachyspira in the host intestine and the effects of 
infection on the mucosal epithelium and lamina propria.   More research needs to be 
performed in the area of host-pathogen interaction, particularly at the molecular level, to 
identify which proteins are involved in the virulence of B. hyodysenteriae. 
 
1.4.1 Motility and Chemotaxis. 
The motility of B. hyodysenteriae enables the bacterium to penetrate and multiply in the 
thick intestinal mucous.  This allows B. hyodysenteriae to colonise the mucous filled areas of 
the intestine where other organisms are unable to initiate an infection (Kennedy & Strafuss, 
1976; Kennedy et al., 1988).   Mutant B. hyodysenteriae lacking some endoflagella subunits 
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were unable to colonise mice as efficiently as wild type B. hyodysenteriae indicating motility 
is essential for pathogenesis (Kennedy et al., 1997a). 
 
B. hyodysenteriae has been shown to be attracted to constituents of pig mucus 
(Kennedy & Yancey, 1996; Milner & Sellwood, 1994).   This attraction may contribute to 
colonisation of the mucosal surface and subsequent pathogenic effects without close 
association of the spirochaete with the epithelium.   B. hyodysenteriae has been observed to 
preferentially colonise the mucus covering the epithelium and the mucus filled Crypts of 
Lieberkühn (Kennedy et al., 1988), suggesting that colonisation of the mucus mediated by 
motility and chemotaxis may be the primary mode of epithelial association.   However, some 
studies have found B. hyodysenteriae directly attached to the epithelium during intestinal 
colonisation (Jensen et al., 1998; Kubo et al., 1979; Teige et al., 1981). 
 
1.4.2 Intestinal Colonisation and Invasion. 
B. hyodysenteriae are often observed in close association with the epithelium during 
SD and are found in large numbers in the lesions.   The mucus gel covering the surface of 
the intestine and the mucus filled crypt of Lieberkühn are the primary sites of colonisation 
during infection (Jensen et al., 1998; Teige et al., 1981).   Considering the chemotactic 
attraction of B. hyodysenteriae by components of swine mucus (see previous section), it is 
not surprising that colonisation of the colonic crypts occurs.   As the crypts contain stem cells 
responsible for the regeneration of the mucosal epithelium, the colonisation of the crypts of 
Lieberkühn by a pathogenic bacterium that causes necrosis of intestinal cells would disrupt 
the rejuvenation of absorptive epithelial cells in the intestine. 
 
Recent studies using FISH found B. hyodysenteriae in the epithelium and the lamina 
propria (Jensen et al., 1998). While they did not find any intracellular spirochaetes, they 
showed that B. hyodysenteriae closely and randomly associated with the epithelium which 
contrasted with an earlier study concluding that colonisation of the mucus was the primary 
form of intestinal association (Kennedy et al., 1988). 
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Intracellular invasion of the epithelium by B. hyodysenteriae during SD has been 
reported (Albassam et al., 1985; Kubo et al., 1979; Teige & Nordstoga, 1979) yet other 
groups have been unable to find any adhesive spirochaetes, let alone invasive ones 
(Kennedy et al., 1988).    Intracellular spirochaetes were more often found in damaged, 
necrotic enterocytes  than healthy epithelial cells suggesting that B. hyodysenteriae may only 
be able to invade opportunistically (Albassam et al., 1985; Teige & Nordstoga, 1979).   While 
the mechanism of intracellular invasion of B. hyodysenteriae is still unclear, colonisation of 
the mucus lining and the crypts of Lieberkühn and infiltration of spirochaetes past the 
columnar epithelium into the lamina propria are well-documented aspects of SD. 
 
1.4.2.1 Haemolysin Production. 
The production of large zones of β-haemolysis on blood agar plates distinguishes B. 
hyodysenteriae from non-pathogenic Brachyspira species (ter Huurne & Gaastra, 1995).   
Haemolysis has been investigated as a potential virulence factor in the development of SD.   
There have been conflicting reports of the size of the protein (or proteins) responsible for 
haemolysis, ranging from 8.9kDa (Hsu et al., 2001; Hutto & Wannemuehler, 1999) to 19kDa 
(Kent et al., 1988), 29kDa (Muir et al., 1992), 68kDa (Knoop, 1981) and 74kDa (Saheb et al., 
1980).   It is assumed that either the different methods of purification and analysis used 
influenced the apparent molecular weight or B. hyodysenteriae produces more than one β-
haemolysin. 
 
The β-haemolysin is oxygen resistant, heat labile, stable over a wide pH range, 
requires a stabilising agent (RNA-core, the RNase resistant fraction of yeast RNA) for 
purification, and associates with lipids, as activity was nullified by lipase (Hyatt & Joens, 
1997a; Saheb et al., 1980).   These characteristics are also found in Streptolysin S produced 
by group A Streptococcus and parallels have been drawn between these two toxins (Binek et 
al., 1995; Kent et al., 1988). Furthering the biochemical similarities, Streptolysin S inhibitors 
also inhibit the B. hyodysenteriae β-haemolysin (Kent et al., 1988; Knoop, 1981).  
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Neither the precise role of haemolysins in the pathogenesis of SD, nor the mechanism 
by which the haemolysin affects intestinal epithelial cells has been elucidated.   It is thought, 
however, that the haemolysin lyses cells by forming pores in the target membrane (Hyatt & 
Joens, 1997a).  The haemolysin undoubtedly contributes to the pathological effects of SD, as 
purified haemolysin can generate similar pathology to that observed in SD (Hutto & 
Wannemuehler, 1999; Lysons et al., 1991; ter Huurne & Gaastra, 1995). 
 
1.4.2.2  Role in Disease. 
Investigations into the contribution of the haemolysin towards pathogenesis of SD 
showed that exposure of swine to native haemolysin resulted in lesions typical of SD (Lysons 
et al., 1991).   Exposure of the ileum to the β-haemolysin resulted in the almost complete 
destruction of the villi with large amounts of exfoliated epithelial cells with an accumulation of 
goblet cells at the damaged areas. 
 
The effect of purified haemolysin on the colon was less consistent, with only some pigs 
affected with sloughing and flattening of the colonic epithelium and oedema in the lamina 
propria (Lysons et al., 1991).   Considering that the colon is severely affected during SD the 
lack of pathological effects is remarkable and emphasises the importance of other B. 
hyodysenteriae virulence factors.   The contribution of the haemolysin to the pathology of SD 
may therefore revolve around the colonisation of the intestines with the subsequent delivery 
of β-haemolysin to areas inaccessible to protein alone, or the pathological effects of the 
colon is not caused by the haemolysin. 
 
In efforts to better characterise the β-haemolysin various genes that have been linked 
to haemolysin production have been investigated including tlyA, tlyB, tlyC and hlyA (Hsu et 
al., 2001; Muir et al., 1992; ter Huurne et al., 1994). 
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1.4.2.3  TlyA Haemolysin. 
Screening of genomic libraries of B. hyodysenteriae for haemolytic colonies resulted in 
the discovery of a 29kDa protein, designated TlyA (Muir et al., 1992).   This protein was 
found to be present in all strongly haemolytic strains of B. hyodysenteriae and absent in non-
pathogenic, weakly haemolytic strains.   The TlyA protein is cytotoxic for epithelial cells as 
well as haemolytic when expressed in E. coli and may be important in SD (Muir et al., 1992; 
ter Huurne et al., 1994).   The generation of a tlyA- mutant did not totally diminish the 
haemolytic properties of B. hyodysenteriae again indicating that more than one haemolysin is 
produced by B. hyodysenteriae (ter Huurne et al., 1992).   However, the TlyA mutant was 
completely avirulent in swine, confirming TlyA has a critical function in the pathogenesis of B. 
hyodysenteriae (Hyatt et al., 1994). 
 
Several differences have been found between the activity of TlyA and purified native 
haemolysin (Hyatt & Joens, 1997a).   Combined with the discovery of the HlyA haemolysin 
(Hsu et al., 2001), the status of TlyA as a haemolysin of B. hyodysenteriae has been 
questioned.   It is possible that tlyA encodes a regulatory protein that can induce the 
expression of a latent E. coli haemolysin (Hsu et al., 2001).  This phenomenon has been 
observed with slyA of Salmonella, once thought to encode a haemolysin but later found to be 
a regulatory gene activating a latent E. coli , and by extension, Salmonella, haemolysin 
(Ludwig et al., 1995; Oscarsson et al., 1996; Wyborn et al., 2004). 
 
In support of the role of TlyA in haemolysis, a gene encoding a toxin with sequence 
similarity to tlyA has been discovered in Mycobacterium tuberculosis (Wren et al., 1998).   
The M. tuberculosis homologue was able to convert non-haemolytic strains of 
Mycobacterium to haemolytic phenotypes and was haemolytic when expressed in E. coli.   
Without a doubt TlyA is involved in pathogenesis, whether as a regulatory protein or as an 
active haemolysin.   The discovery of hlyA (Section 1.1.3.5.4) in weakly haemolytic B. 
pilosicoli may reinstate TlyA to a more prominent role in β-haemolysis during SD.  
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1.4.2.4  TlyB and TlyC Haemolysins. 
Two further Haemolysins were soon discovered, tlyB and tlyC encoding cytotoxic 
and haemolytic proteins of 93kDa and 30kDa respectively (ter Huurne et al., 1994).   The 
TlyB protein shows sequence similarity with the Clp proteins (ter Huurne et al., 1994), which 
are a class of regulatory proteins and proteases (Frees et al., 2005; Iyoda & Watanabe, 
2005; Tomoyasu et al., 2005).   This raises doubts over whether or not tlyB encodes an 
actual haemolysin or a regulatory protein involved in the processing of a haemolysin (Hsu et 
al., 2001).   In E. coli ClpB is a chaperone involved in the processing of proteins (Barnett et 
al., 2005; Chow et al., 2005), suggesting that TlyB performs a similar role in B. 
hyodysenteriae.   The TlyC haemolysin shares no sequence similarity to any known protein. 
 
1.4.2.5  HlyA Haemolysin. 
Although the discovery of tlyA, tlyB and tlyC and their expression in E. coli suggested 
that they encode haemolysins, differences between purified native haemolysin and 
recombinant TlyA has been discovered (Hyatt & Joens, 1997a).   Purification and sequencing 
of the native haemolysin lead to the discovery of hlyA (Hsu et al., 2001).   The HlyA 
haemolysin is an 8.93kDa rod shaped protein that is haemolytic when expressed in E. coli.  
The recombinant HlyA was found to be resistant to trypsin digestion but susceptible to other 
proteases and lipases. This corresponds to experimental data on the native B. 
hyodysenteriae haemolysin (Hyatt & Joens, 1997a; Kent et al., 1988; Saheb et al., 1980).  
 
The biochemical properties and mode of action of the native haemolysin has been 
likened to the Streptolysin S (SLS) which has biochemical similarities to HlyA (Kent et al., 
1988; Lemcke & Burrows, 1982). Streptolysin S lyses cells via pore formation in a manner 
similar to that of complement of the innate immune system (Carr et al., 2001).   There is 
evidence suggesting that the native B. hyodysenteriae haemolysin also lyses cells by pore 
formation, furthering the similarities to SLS (Hyatt & Joens, 1997a).   Streptolysin S and HlyA  
also both require RNA-core, a RNase resistant fraction of yeast RNA, for purification (Kent et 
al., 1988; Loridan & Alouf, 1986). 
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The HlyA haemolysin contains a phosphopantetheine binding motif (Hsu et al., 2001) 
indicating that HlyA binds lipids in a similar way to acyl carrier proteins (ACPs).   Acyl carrier 
proteins are ubiquitous proteins that comprise 0.25% of total soluble protein in E. coli, and 
can bind fatty acids of various lengths (Stanley et al., 1998).   The E. coli ACP is a 9kDa 
protein (the same size as HlyA), in which the amino acids 31 to 71 are involved in binding 
fatty acids (Mayo & Prestgard, 1985).   Acyl carrier proteins carry fatty acids as thioester 
intermediates attached to the terminal sulfhydryl group of a phosphopantetheine group, 
which is then bound to a serine residue (Magnuson et al., 1993a).   Acylation of toxins is well 
characterised and essential for activity of RTX toxins (Bauer & Welch, 1996; Herlax & Bakas, 
2003; Lally et al., 1999).   The acylation of RTX toxins during translation requires the 
presence of an acyl-transferase (HlyC) and an acetylated ACP (acyl-ACP) for the formation 
of a functional toxin (Herlax & Bakas, 2003).  Toxins produced in the absence of acyl-
transferase or acyl-ACP are biologically inactive emphasising the importance of acylation in 
toxin function (Stanley et al., 1998). 
 
Initially hlyA was found only in B. hyodysenteriae and not in non-haemolytic 
Brachyspira spp., which greatly supported its role as a haemolysin (Hsu et al., 2001).   
Recent investigations have found hlyA in the weakly haemolytic B. pilosicoli (Zuener et al., 
2004).   The gene was very similar to that of B. hyodysenteriae suggesting that the difference 
in phenotype was most likely at the regulatory level, or that variation in the flanking fabG and 
fabF results in differences in the lipidation of HlyA (Zuener et al., 2004).   The discovery of 
HlyA does not diminish the importance of tlyA in the pathogenesis of SD.   The reduced 
virulence of tlyA deficient mutants (Hyatt et al., 1994) indicates that the protein is important in 
virulence, irrespective of whether it encodes a regulatory protein or a haemolysin.   The 
generation of an HlyA mutant in both B. hyodysenteriae and B. pilosicoli would establish the 
contribution of HlyA to haemolysis. 
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What is known beyond doubt is that the β-haemolysin plays an important role in the 
pathogenesis of B. hyodysenteriae.  Most evidence supports the role of HlyA as the β-
haemolysin with the tly genes undoubtedly being involved in some aspect of the haemolytic 
phenotype.   The discovery of hlyA in B. pilosicoli suggests it is either involved in modification 
of the β-haemolysin as in E. coli or is regulated or modified differently in the various strains of 
Brachyspira.   More studies need to be performed on the β-haemolysin of B. hyodysenteriae 
to determine how many haemolysins are produced and their contribution to pathogenesis.  
 
1.4.3 Protease Activity. 
Amino-peptidase, trypsin and chymotrypsin-like activities have been observed amongst 
various B. hyodysenteriae strains (Mikx, 1991), as well as in other spirochaetes such as 
Treponema denticola (Grenier et al., 1990).   An outer membrane-associated serine protease 
has been discovered in several species of pathogenic and non-pathogenic Brachyspira spp., 
including B. hyodysenteriae (Muniappa & Duhamel, 1997).   The presence of the protease in 
a commensal strain suggests that the protease does not directly contribute to disease but 
may be required for survival in the intestinal environment. 
 
In Treponema denticola the chymotrypsin-like protease, also outer membrane-
associated, was shown to degrade collagen, laminin and fibronectin.   As these are 
constituents of the basement membrane, the protease may be involved in tissue damage 
and colonisation during disease (Grenier et al., 1990).   Even though present in commensal 
strains, the serine protease from B. hyodysenteriae may be involved in tissue damage, 
dissociation of the epithelial cells and damage to the cellular membranes or extracellular 
matrix proteins (Muniappa & Duhamel, 1997).   Damage may occur when combined with 
other virulence factors not present in commensal strains such as attachment to the 
epithelium and the production of cytotoxins and haemolysins. 
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It has been found that streptolysin S (SLS) from group A Streptococcus spp. interacts 
synergistically with the streptococcal cysteine protease and host derived proteases to 
produce tissue damage (Nizet, 2002).   Extending the analogy of the β-haemolysin from B. 
hyodysenteriae being similar to SLS, the β-haemolysin from B. hyodysenteriae may act 
cooperatively with proteases (both bacteria and host derived) to contribute to the epithelial 
damage observed in SD. 
 
1.4.4 Brachyspira Iron Transport System. 
The operon bitABCDEF has been discovered in B. hyodysenteriae and encodes a 
periplasmic ATP-binding cassette (ABC) iron transport system (Dougard et al., 1999).    The 
six genes have some sequence similarity to iron transport systems in other gram-negative 
bacteria.   All ABC transport systems consist of a periplasmic binding protein that interacts 
with the substrate and presents it to an ATP-binding integral membrane protein complex 
(Dean, 2005).   The bit operon encodes a protein containing ATP-binding motifs (BitD), two 
hydrophobic integral membrane proteins (BitE and BitF), and three membrane lipoproteins 
(BitA, BitB and BitC) with similarity to periplasmic iron binding proteins. 
 
The three membrane lipoproteins (BitA, BitB and BitC) are thought to have arisen 
through a duplication event, conferring a selective advantage in the acquisition of iron from 
various sources in vivo (Dougard et al., 1999).   The limited amount of iron in the host is not 
readily available to the pathogen (Litwin & Calderwood, 1993).   The majority of intracellular 
iron is found as haemoglobin, heme, ferritin and hemosiderin.   The small amounts of iron 
found extracellularly are bound by the proteins lactoferrin and transferrin (Aisen & Leibman, 
1972).   Some bacteria secrete proteins called siderophores to sequester the iron from the 
environment (Neilands, 1981).   However, B. hyodysenteriae does not secrete siderophores 
and therefore must acquire iron using a different mechanism (Li et al., 1995).    
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Other sources of iron in vivo are host iron binding proteins (i.e. degraded products from 
haemoglobin), transferrin (in blood) or lactoferrin (in secretions).   B. hyodysenteriae would 
have access to haemoglobin from lysed red blood cells and this may serve as a source of 
iron.   It has been proposed that the variations observed in BitA, BitB and BitC would be to 
acquire iron from these various host sources (Dougard et al., 1999).   The bitABCDEF 
operon is only found in B. hyodysenteriae, not B. pilosicoli or B. innocens, indicating that is 
plays an important role in SD (Dougard et al., 1999).   Of these species only B. 
hyodysenteriae has significant β-haemolytic activity supporting the theory that haemolysis is 
important to liberate host iron for utilisation by B. hyodysenteriae.   There is precedence for 
the usage of erythrocytes for nutrients, more specifically the uptake of lipids by B. 
hyodysenteriae (Stanton & Cornell, 1987). 
 
Regardless of how B. hyodysenteriae sequesters iron from the host or from which 
source in vivo, the acquisition of iron in an iron-limiting environment has been recognised as 
a virulence factor in microbial pathogenesis (Dougard et al., 1999; Litwin & Calderwood, 
1993).   Furthermore vaccination with components of iron transport systems has conferred 
protection against challenge, indicating a possible vaccine candidate (Jomaa et al., 2005). 
Further studies into the role and regulation of iron in the pathogenesis of B. hyodysenteriae 
infection and the contribution of haemolysis to iron acquisition would further the 
understanding of how B. hyodysenteriae survives in the host. 
 
1.5 Prevention of Swine Dysentery. 
1.5.1 Host Immune response to Swine Dysentery. 
Understanding the host immune response to B. hyodysenteriae infection is important in 
preventing and treating the disease.   It has long been acknowledged that a humoral immune 
response resulting in B. hyodysenteriae specific antibody is generated during SD.   However, 
the cell-mediated immune response has received much attention recently, in particular the T 
lymphocyte response to infection. 
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1.5.1.1  Humoral Immune response. 
Humoral immune responses to B. hyodysenteriae have long been acknowledged as 
contributing to recovery from infection, and the systemic and mucosal antibody response has 
been well characterised (Rees et al., 1989a; Rees et al., 1989b; Waters et al., 1999a).  
 
Infection of swine with B. hyodysenteriae results in a detectable increase in the levels 
of B. hyodysenteriae specific serum IgG, IgM and IgA, and the local production of secretory 
IgA at the mucosal surface (Rees et al., 1989a; Rees et al., 1989b).   The IgA response at 
mucosal sites did not persist long after exposure to B. hyodysenteriae, but rather was 
produced only during the infection.   Similarly, the production of IgG tended to correlate with 
the onset and duration of clinical symptoms, not necessarily a protective immune response, 
and the differentiation of B cells into memory cells would possibly contribute to the protective 
response to secondary exposure (Rees et al., 1989a; Rees et al., 1989b).   This emphasises 
the importance of a cell mediated response, as well as the humoral response, for protection 
from infection with SD. 
 
1.5.1.2  Cell-Mediated Immune response. 
There is a significant increase in the lymphocyte count during SD indicating that the cell 
mediated immune system is activated and contributes to the clearance of the pathogen 
(Jenkins & Klesius, 1981; Jonasson et al., 2004; Nibbelink & Wannemuehler, 1990). 
Parenteral Vaccination of pigs with proteinase-digested B. hyodysenteriae also resulted in a 
significant increase in the B. hyodysenteriae specific proliferation of lymphocytes (Waters et 
al., 1999a; Waters et al., 1999b; Waters et al., 2000b).   Following vaccination various 
subsets of lymphocytes were investigated, with the most significant blastogenic response by 
peripheral blood lymphocytes, not colonic lymphocytes (Waters et al., 1999a; Waters et al., 
1999b).    After challenge of vaccinated swine, proliferation of colonic lymphocytes was 
observed suggesting that vaccination primes these lymphocytes and that colonic 
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lymphocytes are important in protection from infection after vaccination (Waters et al., 
1999b). 
 
Interferon gamma (IFN-γ) is a well-recognised indicator of a cell-mediated immune 
response.   Peripheral blood lymphocytes produce a significant IFN-γ response to in-vitro B. 
hyodysenteriae exposure in vaccinated swine (Waters et al., 1999a).   Although the colonic 
lymphocytes had a significant blastogenic response to challenge, the production of IFN-γ by 
these lymphocytes was not significant (Waters et al., 1999b).   The production of IFN-γ during 
SD has been attributed to CD4+ T lymphocytes (Waters et al., 1999b).   The importance of 
CD4+ T lymphocytes was confirmed by the proliferation of CD4+ T cells in vaccinated pigs in 
response to antigenic challenge (Waters et al., 1999a). 
 
Vaccination with proteinase-digested B. hyodysenteriae resulted in a change in the 
ratio of B. hyodysenteriae specific CD8αα+ and CD4+ T lymphocytes, with a greater 
proportion of CD8αα+/CD4-, CD8αα+/CD4+ and γδ T lymphocytes present in vaccinated 
groups compared to non-vaccinated groups (Waters et al., 1999a; Waters et al., 1999b).   
Stimulation of in vitro cultures of blood mononuclear cells from convalescent swine also 
induced proliferation of CD8αα+/CD4-, CD8αα+/CD4+ and γδ T lymphocytes subsets 
(Waters et al., 2000a).   Furthermore, removal of CD4+ T lymphocytes resulted in the 
reduction of the proliferative response of T lymphocytes indicating that the proliferative 
response of CD8αα+ T lymphocytes is dependent on CD4+ T lymphocytes (Waters et al., 
2000a; Waters et al., 2000b).   These subsets of CD8+ and CD4+ T lymphocytes appear to 
be important in vaccination against and recovery from SD. 
 
It is clear that CD8αα+ T lymphocytes are important in SD (Waters et al., 1999a; 
Waters et al., 1999b; Waters et al., 2000b).   Although B. hyodysenteriae has been observed 
in the cytoplasm of goblet cells and damaged epithelial cells in vivo it is largely considered an 
extracellular pathogen (See Section 1.4.2), which makes a CD8αα+ T cell response unusual.   
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How proteins from B. hyodysenteriae are processed for MHC-I presentation and why CD8+ T 
lymphocytes respond to this extracellular pathogen is not known. 
 
T lymphocytes expressing γδ determinants also appear to be important in both 
vaccination against SD and recovery from natural SD (Jonasson et al., 2004; Waters et al., 
1999a).   Healthy swine with initial lower levels of CD8αα+ T lymphocytes and higher levels 
of γδ T lymphocytes are more likely to develop SD than swine with high CD8αα+ T 
lymphocytes and low γδ T lymphocytes levels (Jonasson et al., 2004).   However, when pigs 
that developed SD first displayed symptoms, the swine that remained healthy had shifted the 
lymphocyte subpopulations in favour of γδ T lymphocytes. 
 
Gamma-Delta T lymphocytes are responsible for the proliferation of intestinal epithelial 
cells and protection of the intestinal mucosa (Chen et al., 2002; Holtmeier, 2003; Komano et 
al., 1995).   Contrary to the role of γδ T lymphocytes in protection of the intestinal mucosa, 
swine with higher levels of γδ T lymphocytes were more susceptible to SD (Jonasson et al., 
2004).   Gamma-Delta T lymphocytes can also downregulate CD8+ T lymphocyte function 
and IFN-γ production (Steele et al., 2002).   It is possible that swine with elevated levels of γδ 
T lymphocytes before infection suppress the proliferation of CD8+ T lymphocytes and IFN-γ, 
both of which are important for resolution of infection. 
 
The T lymphocyte subsets expressed in swine during infection appear to predispose 
some swine to the development of disease. It is becoming clearer as more information is 
available that for resolution of SD both a humoral immune response and an appropriate cell 
mediated immune response is required.   Any vaccination strategy against SD should 
consider the immune effectors responsible for protection of swine against natural SD, in 
particular CD4+, CD8αα+ and γδ T lymphocytes as well as IFN-γ. 
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1.5.2 Control of Swine Dysentery. 
With the observed increase in antibiotic resistance of B. hyodysenteriae alternative 
methods of control of SD need to be investigated.   The immunity of convalescent swine to 
subsequent challenge (Joens et al., 1979; Joens et al., 1983) and the passive transfer of 
immunity from convalescent to naïve swine (Joens et al., 1985) established that protection 
from SD is possible.   Priming the host immune system by vaccination with specific antigens 
has the potential to protect uninfected swine against SD. 
 
Current control practices for SD involve the use of in-feed antibiotics (Glock, 1984; 
Hamdy, 1978; Olson, 1977; Olson, 1986; Pickles, 1982), with few if any farms routinely 
vaccinating against SD despite several vaccines commercially available that provide partial 
protection (Diego et al., 1995; Robertson et al., 1991).   B. hyodysenteriae is developing 
resistance to several types of commonly used antibiotics for the prevention of SD (Karlsson 
et al., 1999; Lobova et al., 2004; Uezato et al., 2004).   Vaccination against SD becomes 
more desirable as the resistance of B. hyodysenteriae to treatment increases. 
 
Vaccination against SD has met with varying success with most vaccines providing 
only partial, if any, protection (Davis et al., 2005; Diego et al., 1995; Fernie et al., 1983; 
Hampson et al., 1993; La et al., 2004; Olson et al., 1994; Waters et al., 1999a; Waters et al., 
1999b).   With the limited knowledge about the immune response induced and how the host 
recovers from infection (See Section 1.5.1), creating rational vaccines against SD is difficult.   
Considering that an inflammatory response may actually contribute to the disease, it is 
possible to inadvertently exacerbate the disease by inducing an inappropriate immune 
response (Olson et al., 1994; Sacco et al., 2000). 
 
The outer membrane of B. hyodysenteriae has been thoroughly investigated as a 
potential source of protective antigens (Joens & Marquez, 1986; Trott et al., 2001; 
Wannemuehler et al., 1988).   Various genes have been identified which encode outer 
membrane proteins (Section 1.2.3.2).   SmpA (Thomas & Sellwood, 1993) and BmpB (Lee et 
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al., 2000) are two outer membrane lipoproteins with some potential for prophylactic uses.   
However, the down-regulation of SmpA expression during infection and the sequence 
variation theorised may limit its usefulness (Sellwood et al., 1995; Turner et al., 1995).   No 
investigations to date have been performed on the possible protection induced by SmpA.   
Recombinant BmpB has been shown to partially protect pigs from challenge (La et al., 2004).   
However, BmpB has recently been shown to be the same as BlpA, one of a series of four 
paralogous outer membrane proteins (Cullen et al., 2003; La et al., 2005).   Although only 
blpA has been shown to be expressed in vitro (Cullen et al., 2003), the possibility of antigenic 
or phase variation amongst these four genes may render BmpB useless as a vaccine. 
 
Despite the lack of molecular techniques for manipulating the B. hyodysenteriae 
genome, several knockout mutants have been created that display reduced virulence.   The 
putative haemolysin TlyA has been inactivated as have the flagella encoding flaA and flaB  
genes (Hyatt et al., 1994; Kennedy et al., 1997a).   Although the inactivation of tlyA did not 
totally alleviate the haemolytic phenotype, initial vaccine trials with this tlyA deficient mutant 
showed reduced caecal lesions in the murine model of SD (Hyatt et al., 1994; ter Huurne et 
al., 1993).  When swine were inoculated with the tlyA deficient mutant none developed SD, 
implying that the TlyA haemolysin is an important virulence factor in the development of SD 
(Hyatt et al., 1994).   When pigs inoculated with the tlyA deficient mutant were then exposed 
to wild type B. hyodysenteriae, 40% to 50% of swine developed SD.   The dual flaA- flaB- 
mutant was severely attenuated in the murine model of SD, being unable to colonise the host 
(Rosey et al., 1996).   The mutant may be avirulent and have potential as a vaccine, however 
the immunogenicity and protection induced by this mutant was not investigated in mice or 
swine.   While the dual mutant may be unable to cause disease, the inability to colonise the 
intestine and establish an infection may not expose the swine to the vaccine long enough to 
induce immunity. 
 
Throughout the studies of vaccination against SD, the induction of only partial 
protection is a constant factor.   It may be necessary to use more than one antigen (protein 
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or LPS) in a multivalent vaccine to provide adequate protection.    Directly targeting the 
GALT in order to induce a mucosal immune response may also provide increased protection 
against what is primarily an intestinal pathogen.   The significant immune response induced 
by some vaccines with only partial protection conferred suggests that the type of immune 
response is not appropriate for protection against SD.   A mucosal IgA response in particular 
may provide better protection than what has been previously observed. 
 
1.6  Salmonella enterica serovar typhimurium. 
Salmonella enterica serovar typhimurium (S. typhimurium) is a gram-negative, 
facultative anaerobe that is capable of invading and multiplying within a diverse array of 
eukaryotic cells from a range of hosts (Finlay & Falkow, 1989; Finlay & Brumell, 2000b; Hsu, 
1989b).   In humans infection produces a self limiting gastroenteritis termed Salmonella 
enteritis however in mice a typhoid-fever like disease is produced (Finlay & Brumell, 2000b).    
 
The ability of S. typhimurium to invade host somatic and immune cells makes them 
ideal candidates for the delivery of heterologous antigens and DNA vaccines.   The aim of 
this discussion is not to provide in-depth analysis of murine typhoid fever nor Salmonella 
enteritis, which have been reviewed elsewhere (Hsu, 1989a; Lalmanach & Lantier, 1999a; 
Mastroeni et al., 2001).   Neither is it to provide a detailed description of the use of 
attenuated Salmonella spp. as vector vaccines.   This section is designed to provide a 
background on the use of attenuated Salmonella spp. to deliver foreign antigens and how the 
pathogenesis of S. typhimurium makes it an ideal candidate for this role.  
 
1.6.1 M cell Structure and Function. 
S. typhimurium infects mice by the faecal-oral route.   Therefore it must first penetrate 
the intestinal mucosa, which has its own defences, both innate and adaptive.   A 
compartment of the host immune system, the GALT protects the intestinal surface.   
Organised follicles of the GALT are referred to as Peyer’s patches (PP), which contain an 
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extensive network of macrophages, dendritic cells (DCs), CD4+ T cells and B cells (Neutra et 
al., 1996).   The epithelium covering the PP in the intestine is referred to as the follicle-
associated epithelium (FAE).   The FAE contains absorptive enterocytes and ‘Manifold’ or M 
cells (Mach et al., 2005; Neutra et al., 1996) (Figure 1.4a).   The basal surface of M cells is 
invaginated to an extent that a pocket is formed.   This pocket contains B and T lymphocytes 
as well as the occasional antigen-presenting cell (Neutra et al., 1996) (Figure 1.4a).   M cells 
transfer antigens and micro-organisms from the intestinal lumen to the immune cells in the 
PP underneath (Neutra et al., 1996) (Figure 1.4b).   Once the phagocytes underneath the M 
cell has been activated by the antigen, they migrate to the regional lymph node.   This is the 
first step in initiating an immune response to an intestinal pathogen such as S. typhimurium. 
 
1.6.2 Pathogenesis of murine typhoid fever. 
Salmonella typhimurium pathogenesis has been mostly studied in mice as the murine 
model is considered analogous to human typhoid fever.   While the pathogenesis will differ in 
different hosts as evidenced by the observed disease, the pathogenesis in the mouse model 
will be discussed here. 
 
The first interactions between S. typhimurium and the intestinal mucosa occur at the M 
cells (Jones et al., 1994).   Infection by S. typhimurium triggers apoptosis in M cells, creating 
a gap in the FAE that allows infection of adjacent epithelial cells (Jones et al., 1994).   A type 
III secretion system is used by S. typhimurium to induce target cell membrane ruffling which 
drives internalisation (Collazo & Galan, 1997).   The mechanisms responsible for the 
cytoskeleton rearrangements that induce internalisation are becoming clearer (Fu & Galan, 
1998; Hayward & Koronakis, 2002; Zhou et al., 1999).   Although these molecular 
mechanisms have not been demonstrated in vivo, the similarities between in vivo and in vitro 
infected cells suggests the mechanism is similar (Finlay & Brumell, 2000b).  
 
The destruction of M cells (Hersh et al., 1999; Jones et al., 1994) allows access to the 
underlying immune cells and dissemination into deeper tissues of the host.    Phagocytosis of 
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S. typhimurium by host macrophages and dendritic cells present in the Peyer’s patches is an 
important step in the dissemination of S. typhimurium.   The fate of Salmonella inside 
macrophages and dendritic cells differ.   Salmonella are able to survive as well as replicate 
inside a macrophage whereas there is evidence that Salmonella are able to persist but not 
replicate inside a DC (Garcia-del Portillo et al., 2000; Jantsch et al., 2003).   Macrophages 
are more efficient than DCs at clearing organisms from an infected host (Kalupahana et al., 
2005b) although DCs are more efficient at stimulating an immune response (Sundquist et al., 
2004).   Compared to macrophages fewer experiments have been performed investigating 
the role of DCs in S. typhimurium infection so their exact role is unclear at this stage. 
 
After phagocytosis of S. typhimurium by macrophages or DCs, S. typhimurium is 
trafficked to the mesenteric lymph nodes, where the infection spreads.   The migratory nature 
of DCs may implicate them in a critical role of this stage of the disease.   During the resulting 
typhoid-like fever the infection spreads through the efferent lymphatics to the vena cava 
causing a bacteraemia.   The S. typhimurium are removed from the bloodstream by 
phagocytes in the spleen and liver, focusing the infection at these sites.   The multiplication 
of S. typhimurium in the spleen and liver, both intra- and extracellularly can lead to the death 
of the mouse through the presence of high levels of endotoxin. 
 
1.6.3 Pathogenesis of Salmonella enteritis in swine. 
S. typhimurium can cause a different disease in several hosts, including pigs, cattle 
and humans (Santos et al., 2003; Tsolis et al., 1999b).   The murine model is convenient for 
laboratory investigations into swine diseases involving attenuated Salmonella vectors.   The 
application of S. typhimurium delivered heterologous antigens for the protection from swine 
diseases however must consider the relevant disease.   In swine, as in cattle and humans, S. 
typhimurium causes Salmonella enteritis. 
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The genes required for the development of Salmonella enteritis differ from that required 
for the establishment of murine typhoid.   The genes associated with SPI-1, which mediate 
invasion in murine typhoid (Galan & Curtiss, 1989), are also important for establishing 
Salmonella enteritis (Tsolis et al., 1999a; Zhang et al., 2002).   However, the genes in SPI-2 
which allow S. typhimurium to persist in macrophages are not required for the establishment 
of Salmonella enteritis (Cirillo et al., 1998; Tsolis et al., 1999a). 
 
The steps in establishing Salmonella enteritis are somewhat similar to murine typhoid.   
The preference for M cell invasion observed in mice does not appear to be prominent in 
Salmonella enteritis, with invasion of the FAE and ordinary villi occurring equally (Meyerholz 
et al., 2002; Santos et al., 2002; Schauser et al., 2004).   Even though invasion of the 
epithelium appears to be non-discriminatory, subepithelial invasion occurred first in the FAE 
and invasion of the PP was more prominent than the lamina propria (Schauser et al., 2004).   
The invasion of epithelial cells triggers programmed cell death in the invaded cell and in 
nearby non-infected cells, leading to necrosis of the epithelium (Schauser et al., 2005). 
 
After infiltration of the PP, the disease models diverge somewhat.   In pigs, humans 
and cattle, the macrophages lining the lymphatic sinuses in the regional lymph nodes 
successfully limit the spread of the infection.   This results in Salmonella gastroenteritis and 
acute diarrhoea, but no bacteraemia with systemic infection.   Despite the lack of detailed 
information regarding Salmonella enteritis in pigs, it is known that phagocytes are naturally 
infected and therefore S. typhimurium can be used to deliver heterologous antigen to swine.   
Furthermore the indiscriminate invasion of the intestinal epithelium during Salmonella 
enteritis may allow a more diverse immune response than in the murine model, where 
invasion is largely restricted to phagocytes. 
 
1.6.4 Murine immune response to Salmonella typhimurium. 
In order to understand the immune response against a heterologous antigen delivered 
by attenuated Salmonella typhimurium, it is important to understand the host immune 
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response against the vector itself.   The host immune response in murine typhoid consists 
mainly of a mononuclear leukocyte response that facilitates pathogen dissemination in the 
host with concurrent activation of Th1 immune effectors (reviewed in (Mastroeni et al., 2001).   
Certain lymphocyte subsets are important in S. typhimurium infection, particularly in recall of 
immunity. 
 
Several inflammatory cytokines are produced early in infection with S. typhimurium 
(Lalmanach & Lantier, 1999a).   Tumour Necrosis Factor Alpha (TNF-α) plays an important 
role in resistance to S. typhimurium infection (Mastroeni et al., 1993; Nakano et al., 1990).   
The production of TNF-α stimulates T lymphocytes and contributes to the activation of 
macrophages which is critical for resistance to S. typhimurium.   Various other cytokines are 
upregulated in response to S. typhimurium infection, including both IL-12 and IL-18 (Dybing 
et al., 1999; John et al., 2002).   The production of IFN-γ is upregulated by TNF-α, IL-12 and 
IL-18, and IFN-γ is an essential cytokine in the host immune response to S. typhimurium 
(Gordon et al., 2005; Muotiala & Makela, 1993).   The activation of bactericidal capabilities of 
the macrophage by IFN-γ in a positive feedback loop increases the clearance of intracellular 
pathogens. 
 
The interaction of S. typhimurium and host phagocytes is critical for host resistance 
(Yrlid et al., 2001b).   Dendritic cells (DC) have received much attention in anti-Salmonella 
immunity recently as they are highly migratory and can stimulate naïve lymphocytes, a 
function not performed efficiently by macrophages (Sundquist et al., 2004).   Close contact 
between DCs and M cells in the FAE and PPs (Figure 1.4) is often observed and may play 
an important role in the initial response to S. typhimurium as the sub-epithelial dome of the 
PPs contains large numbers of certain DCs sub-populations (Iwasaki & Kelsall, 2001; Kelsall 
& Strober, 1996).   The DCs of the PP, spleen and lymph nodes are invaded with S. 
typhimurium during infection (Hopkins et al., 2000; Yrlid & Wick, 2002).   The presence of S. 
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typhimurium in DCs of the mesenteric lymph nodes implicates them in dissemination of S. 
typhimurium from the PPs.    
 
The role of DCs in activating the immune response does not diminish the importance of 
macrophages, which are more efficient at clearing the pathogen from the host (Kalupahana 
et al., 2005b).   The number of DCs infected with S. typhimurium is incredibly low (Yrlid & 
Wick, 2002), so the primary phagocytic cell during infection is the macrophage.   S. 
typhimurium are able to induce apoptosis in macrophages during infection, and there is 
evidence that peptides regurgitated from macrophages are phagocytosed by bystander DCs 
(Sato & Iwasaki, 2005), potentially circumventing this method of immunosuppression. 
Several subsets of lymphocytes are important in the immune response to S. 
typhimurium with S. typhimurium specific CD4+ and CD8+ T lymphocytes both activated (Lo 
et al., 1999; Mittrucker et al., 2002).   Both CD4+ and CD8+ T cells are involved in recall of 
immunity in previously exposed animals (Kirby et al., 2004; Mittrucker et al., 2002). T 
lymphocytes (CD4+) are responsible for the production of several inflammatory cytokines 
(IFN-γ and TNF-α) that increase the bactericidal capabilities of macrophages (Mittrucker & 
Kaufmann, 2000).   These CD4+ T lymphocytes also contribute to the proliferation of B 
lymphocytes and the induction of CD8+ T lymphocytes (Mittrucker & Kaufmann, 2000). 
 
The contribution of cytotoxic (CD8+) T lymphocytes (CTL) to recall of immunity is less 
characterised than CD4+ T lymphocytes.   The presentation of antigens via MHC class I 
occurs after the proteolytic processing of cytosolic heterologous proteins.   How MHC Class I 
presentation occurs when the pathogen remains in the phagosome and does not invade the 
cytoplasm is an area of interest.   There are alternative methods of MHC Class I presentation 
by antigen presenting cells (APCs), including cross priming by DCs and a vacuolar 
alternative pathway which is activated by IFN-γ (Guermonprez et al., 2003; Houde et al., 
2003a; Houde et al., 2003b; Martin-Orozco et al., 2001).   These alternative methods may be 
important in CTL activation in S. typhimurium infection.  
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High levels of antibodies are produced during infection of mice with S. typhimurium 
(Allen et al., 2000; Harrison et al., 1997; Matsiota-Bernard et al., 1993).   Several 
immunoglobulin subtypes, IgG, IgM and IgA are all produced, however secretory IgA has 
attracted the most interest for it’s role in prevention of infection with S. typhimurium (Michetti 
et al., 1992; Michetti et al., 1994).   The classical Th2 cytokine, IL-4, is not induced in S. 
typhimurium infection (VanCott et al., 1996).   The antibody response observed seems to be 
mediated via IL-6 and IL-10, which can compensate for the lack of IL-4 (Okahashi et al., 
1996; VanCott et al., 1996). 
 
The cytokines produced during S. typhimurium infection, IL-12, TNF-α and IFN-γ are 
responsible for directing the host immune system towards a primarily Th1 cell mediated 
response consisting of activated macrophages and CD8+ and CD4+ T lymphocytes.   
However, the importance of secretory IgA in protection from challenge indicates that IL-10 
and IL-6, the predominant Th2 cytokines observed during infection, are just as important.   
The immune response directed against S. typhimurium makes it an ideal vector for 
vaccination with heterologous B. hyodysenteriae antigen.   The priming of CD4+ and CD8+ T 
lymphocytes and the production of secretory IgA are similar to the immune response 
observed upon challenge with virulent B. hyodysenteriae (See Section 1.5.1). 
 
1.6.5 Porcine Immune response to Salmonella typhimurium. 
Similar to the situation regarding the pathogenesis, little research has been performed 
on the immune response induced in swine following infection with or vaccination against 
Salmonella typhimurium.   However, this hosts response must be considered in designing 
vaccines targeted at swine involving attenuated S. typhimurium. 
 
The host immune response in Salmonella enteritis consists mainly of increased 
numbers of neutrophils as opposed to mononuclear phagocytes (Santos et al., 2003).   
Depletion of neutrophils and administration of anti-inflammatory agents almost completely 
 47
abolishes the diarrhoea (Giannella et al., 1975; Giannella, 1979), emphasising the role of 
host factors in the disease.   Further evidence of the requirement of several S. typhimurium 
derived PMN chemoattractants supports the role of host responses in the development of 
diarrhoea (Santos et al., 2001), and in the establishment of the infection. 
 
The antibacterial action of inflammatory cells is regulated by several cytokines 
(Lalmanach & Lantier, 1999b), which is consistent with the cytokine profile induced in swine 
in response to S. typhimurium (Cho & Chae, 2003; Splichal et al., 2002).   Several 
inflammatory cytokines, IFN-γ, TNF-α, IL-1, IL-6 and IL-8 are induced in response to S. 
typhimurium infection (Cho & Chae, 2003; Splichal et al., 2002).   It was also demonstrated 
that these cytokines were absent from the colon of infected swine that did not develop 
lesions, indicating that these play an important role in disease (Cho & Chae, 2003). 
 
In spite of the lack of information regarding the porcine immune response, certain 
correlations between the swine and mouse model can be made.   The induction of IFN-γ and 
TNF-α indicates that macrophages are being activated and measurements of IL-12 or IL-18  
levels would allow further inferences about the activation of macrophages to be made.   The 
production of IL-6 in swine suggests that a humoral immune response also occurs in swine, 
however without information regarding the presence of the classical humoral inducing 
cytokines IL-4 and IL-5, the importance of IL-6 is unknown.   Studies regarding the induction 
of CD4+,CD8+ and γδ T lymphocytes and secretory antibodies by S. typhimurium infection in 
swine would allow inferences to be made concerning the use of S. typhimurium as a vector 
vaccine in pigs. 
 
1.7 Salmonella vector vaccines 
Attenuation of pathogens is well established as a method to create safe, effective 
vaccines.   Aromatic amino acid dependent S. typhimurium mutants provide significant 
protection against challenge (Hormaeche et al., 1990; Hormaeche et al., 1991; O'Callaghan 
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et al., 1990; Okahashi et al., 1996; VanCott et al., 1996), and even some protection against 
heterologous challenge with related organisms (O'Callaghan et al., 1990). 
 
There are several methods of targeting M cells for delivery to the GALT (reviewed in 
(Ann Clark et al., 2001).   Possibly one of the most effective yet one of the hardest to 
regulate, especially for human use, is the use of recombinant attenuated Salmonella as 
vectors.    Attenuation of S. typhimurium can be achieved using several genetic modifications 
including removal of virulence factors and essential metabolic enzymes (Mastroeni et al., 
2001).   The use of attenuated Salmonella strains for the delivery of heterologous antigens is 
well documented (Bachtiar et al., 2003; Everest et al., 1995; Gentschev et al., 2002; Schodel 
& Curtiss, 1995; Stocker, 2000).   Attenuated S. typhimurium is a common species for this 
use as the natural route of infection (Section 1.6.2 and 1.6.3) results in the induction of a 
robust immune response. 
 
1.7.1 Delivery of Heterologous Antigens. 
The creation of recombinant, attenuated S. typhimurium strains for the delivery of 
heterologous antigens from pathogens of medical and veterinary importance has shown 
promise for mucosal vaccination (Arnold et al., 2004; Chen & Schifferli, 2000; Djavani et al., 
2001; Nayak et al., 1998; Vecino et al., 2002).   The delivery of traditional subunit vaccines 
for the induction of mucosal immunity involves the use of carrier molecules or adjuvants to 
increase the immunogenicity and does not specifically target immune cells.   An advantage of 
using attenuated S. typhimurium for the delivery of heterologous antigens is the exposure of 
the vaccine to immune cells of the GALT.   The pathogenesis of S. typhimurium (Section 
1.6.2 and 1.6.3) ensures that the vaccine is exposed to a large array of immune cells, 
including macrophages, dendritic cells, B lymphocytes and T lymphocytes (Finlay & Brumell, 
2000a; Kalupahana et al., 2005a).   This method of vaccination usually results in a strong, 
often protective immune response (Chatfield et al., 1997; Kang et al., 2002). 
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The type of immune response elicited by the heterologous antigen is the same as 
would be directed against the vector.   As has been discussed (Section 1.6.4 and 1.6.5) the 
immune response against S. typhimurium consists mainly of a cell-mediated immune 
response, with induction of CD4+ and CD8+ T lymphocytes.   Vaccination against pathogens 
that require a cell-mediated immune response, such as intracellular pathogens, would suit 
the use of S. typhimurium as a recombinant vector.   However, the induction of secretory IgA 
and IgG by S. typhimurium allows this system to be used for non-invasive pathogens that 
can be targeted by a humoral response (Karem et al., 1995). 
 
Although the immune response generated against antigens delivered by S. 
typhimurium vectors is often strong (Nayak et al., 1998), occasionally a poor immune 
response is observed.   The plasmids encoding the heterologous protein are often 
considered the cause of a poor immune response, due to either stability problems or too 
much metabolic burden (Coulson et al., 1994; Dunstan et al., 2003; Garmory et al., 2002; 
Husseiny & Hensel, 2005b; Knodler et al., 2005; Maskell et al., 1987).   Therefore several 
methods of inserting the heterologous gene into S. typhimurium in a stable fashion have 
been investigated.   Chromosomal integration is one such method that offers stable 
expression of the antigen (Cardenas & Clements, 1993; Husseiny & Hensel, 2005a; Strugnell 
et al., 1990). 
 
The regulation of expression of the heterologous gene is another method that has been 
investigated in order to decrease the metabolic load on the recombinant vaccine before it 
enters the host (Dunstan et al., 1999; Husseiny & Hensel, 2005b; Marshall et al., 2000).   
Suppressing the expression of the antigen and thereby decreasing the metabolic load on the 
organism in vitro has been shown to be effective for delivery of antigens (Chatfield et al., 
1997; Dunstan et al., 1999; Marshall et al., 2000).   This can be achieved by incorporating in 
vivo regulated promoters into the expression vector.   The use of such promoters can also 
influence the immune response induced.   For example, the cytokine profile secreted by 
CD4+ T lymphocytes differs between mice vaccinated with antigens expressed from  
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inducible or constitutive promoters, and must be considered when choosing an appropriate 
promoter (Medina et al., 2000). 
 
A method of inducing secretion of heterologous antigen by S. typhimurium utilises the 
E. coli haemolysin secretion system (Gentschev et al., 1997; Gentschev et al., 2001).   
Secretion of recombinant antigens from Listeria monocytogenes by this mechanism provided 
complete protection against challenge (Gentschev et al., 2001; Hess et al., 1996).   This 
compares to cytosolic expression of the antigen, which elicited no protection, mainly due to 
the lack of CTL responses (Hess et al., 1996).   In particular, combined expression of 
recombinant HlyA from Listeria monocytogenes (which confers the ability to destroy the 
phagosome membrane and escape into the cytoplasm) with a second heterologous antigen 
greatly enhanced the CTL response against the antigen (Catic et al., 1999). 
 
A different method of delivery of heterologous antigens involves the delivery of not 
recombinant antigen, but of DNA that encodes the antigen in a manner that allows 
expression by the host cell (Gentschev et al., 2001; Gentschev et al., 2002). 
 
1.7.2 Delivery of DNA Vaccines. 
Vaccination with plasmids containing antigens under the control of eukaryotic 
promoters is called DNA vaccination.   DNA vaccines are expressed in the host cells after 
uptake of the plasmid (Donnelly et al., 1997; Gurunathan et al., 2000).   DNA vaccines are 
effective at delivering antigen and eliciting an immune response against eukaryotic or viral 
antigens (Chen et al., 1998; Sasaki et al., 1998) that often require post-translational 
modifications not available in prokaryotic expression systems.   This method of antigen 
delivery has also been successfully used to deliver prokaryotic antigen to host cells, such as 
the expression library immunisation against Mycoplasma and delivery of the Mycobacterium 
antigens hsp65 (Lai et al., 1995; Tascon et al., 1996). 
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There are several methods of introducing DNA vaccines into the host.    Traditional 
methods include intra-muscular injection and subcutaneous injection using a gene gun.   
Injection of DNA vaccines into host muscle tissue results in a strong CTL response (Ulmer et 
al., 1993), whereas delivery of DNA vaccines via microparticle injection results in a 
predominantly humoral response (Tang et al., 1992).   However, neither method induces a 
strong mucosal response without some type of adjuvant or vector (McCluskie & Davis, 
1999a; McCluskie & Davis, 1999b). 
 
There are several methods of delivering DNA vaccines directly to the GALT to induce 
mucosal immunity (Hobson et al., 2003; McCluskie & Davis, 1999a).   The injection of DNA in 
aqueous solution (“naked”) directly into the MALT at several sites to induce a sIgA response 
(Sasaki et al., 1998).   However, the transfection of tissues other than muscle is relatively 
inefficient and “naked” DNA faces several impenetrable barriers at the mucosal surfaces 
(Hobson et al., 2003).   Other methods including liposomes (Felgner et al., 1996), 
microparticles (Chen et al., 1998; O'Hagan et al., 2004), mucosal adjuvants (Kuklin et al., 
1997) and cytokine co-administration (Chien-Hsiung et al., 1999) have all been investigated 
to increase the mucosal response.   Another method of delivering DNA vaccines to the MALT 
is by attenuated S. typhimurium. 
 
The delivery of DNA vaccines by attenuated intracellular pathogens has been 
thoroughly reviewed (Dietrich & Goebel, 2000; Dietrich et al., 2003).   An advantage of using 
attenuated S. typhimurium to deliver DNA vaccines is the direct transfection of host immune 
cells resulting in both antigen presentation and co-stimulation of T lymphocytes, both a 
requirement for an immune response.   The transfer of DNA has been observed in both 
macrophages (Darji et al., 2000a) and dendritic cells (Paglia et al., 1998) infected with S. 
typhimurium harbouring DNA vaccines.   The mechanism by which the DNA is transferred 
from the phagosome to the cytosol remains unknown.   Transfer of phagocytosed proteins for 
MHC Class I presentation has been shown, demonstrating that transfer of molecules from 
phagosome to cytosol is possible (Rodriguez et al., 1999).   The transfer of DNA vaccines by 
 52
bacterial ghosts suggests that the mechanism for DNA translocation is characteristic of the 
host cell, not the pathogen (Lubitz, 2001).    
 
Delivery of DNA vaccines by S. typhimurium has been used to elicit both cellular and 
humoral immunity against antigens from pathogenic bacteria (Darji et al., 2000a; Pasetti et 
al., 1999), viruses (Flo et al., 2001), as well as tumours (Paglia et al., 1998).   Considering 
the different immune responses induced by different methods of delivering DNA vaccines, 
delivery by S. typhimurium must be investigated separately.   Initial studies revealed that the 
immune response against DNA-vaccine encoded antigen consisted mainly of CTL and CD4+ 
T lymphocytes secreting Th1 cytokines as well as low levels of antigen specific antibodies 
(Darji et al., 2000a; Flo et al., 2001).   Delivery of DNA vaccines using this method proved far 
superior to S. typhimurium delivery of heterologous antigen.   However, the generation of 
specific antibodies using this system is generally poor, often requiring several vaccinations 
before serum antibodies are detectable (Darji et al., 2000b). 
 
The detection of CTL responses and Th1 CD4+ T cells to S. typhimurium delivered 
DNA vaccine is not surprising considering the route of infection (Section 1.6.2).   The direct 
transfection of APCs with the subsequent delivery of the DNA vaccine to the cytosol would 
result in antigen translation and processing through the MHC class I presentation system.   
This would directly stimulate CD8+ CTL.   How the antigens are processed for MHC class II 
presentation and a humoral response also needs to be explained.   A mechanism of cross 
presentation of bystander DCs by apoptotic macrophages has been suggested (Weiss, 
2003).   Although cross presentation is usually associated with MHC Class I presentation, 
antigen transfer from one cell to another for antigen presentation in association with MHC 
class II molecules is well accepted (Heath & Carbone, 2001; Inaba et al., 1998; Weiss, 2003; 
Wild et al., 1999).   The induction of a CTL response by DNA vaccination would result in the 
lysis of transfected cells and the release of cytosolic, soluble antigen that could be 
endocytosed by bystander DCs and B cells, producing a Th2 immune response (Dyer et al., 
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2004).   Both cross presentation and direct transfection may contribute to the immune 
response. 
 
The limitations of this method of delivering DNA vaccines (the low humoral immune 
response) may be the result of the restriction of transfection to macrophages and dendritic 
cells (Weiss, 2003).   A method of enhancing the immune response by co-expression of a L. 
monocytogenes haemolysin can be applied to the delivery of DNA vaccines (Catic et al., 
1999; Gentschev et al., 2001; Spreng et al., 2000).   Escape of the S. typhimurium from the 
phagosome to the cytosol meditated by recombinant L. monocytogenes HlyA enhanced the 
immune response, a result of an increase in the delivery of the plasmid to the cytosol (Catic 
et al., 1999).   These experiments show that it is possible to modulate the immune response 
to S. typhimurium delivered DNA vaccines, and further experiments need to be performed to 
optimise this system. 
 
Regardless of the limitations of the presentation of DNA vaccines by S. typhimurium, it 
is an efficient way of generating a CTL response.   Methods to increase the antigen 
expression and the humoral response, in particular secretory IgA production need to be 
developed in order to protect against intestinal pathogens.   Such investigations indicate that 
DNA vaccination can result in the induction of all the components required for a humoral 
immune response (Rush et al., 2005) so it should be possible to rationally enhance the 
humoral response to DNA vaccination. 
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1.8 Research Aims 
 
The research aims of this thesis were: 
1) To determine the presence of several virulence determinants in B. hyodysenteriae 
5380. 
2) To evaluate the ability of B. hyodysenteriae 5380 to establish an infection in 
C3H/HeJ mice. 
3) To determine the ability of several virulence determinants of B. hyodysenteriae to 
induce a protective immune response in C3H/HeJ mice. 
4) To evaluate the ability of DNA vaccines encoding B. hyodysenteriae proteins to 
induce a protective immune response. 
5) To assess the ability of S. typhimurium to express B. hyodysenteriae proteins and 
deliver DNA vaccines encoding B. hyodysenteriae proteins. 
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Chapter 2 – Materials and Methods. 
2.1 General Procedures 
All solutions were prepared in deionised H2O filtered through a Millipore Milli-Q® water 
system unless otherwise specified.   All media and glassware was sterilised by autoclaving at 
121°C for 20 mins unless otherwise specified.   All solutions were dispensed using 
Finnpipette micropipettes for all volumes from 0.5 µL to 10 mL.   Glassware was washed 
using Pyroneg detergent followed by a rinse in tap water then a final rinse in deionised H2O. 
 
2.2 General Chemicals and Equipment  
10X PCR Buffer Invitrogen, USA 
10X Ligase Buffer Promega, USA 
Acetic Acid, Glacial BDH Chemicals, Australia 
Acrylamide-bis-Acrylamide (40%) BDH Chemicals, Australia 
Acetone BDH Chemicals, Australia 
Agarose (DNA Grade) Progen Industries, Australia 
Albumin, Bovine serum Sigma-Aldritch Pty. Ltd., USA 
Ammonium Acetate Ajax Chemicals Ltd, Australia 
Ammonium Chloride BDH Chemicals, Australia 
Ammonium hydroxide BDH Chemicals, Australia 
Ammonium Persulfate Bio-Rad Laboratories, USA 
Ampicillin CSL, Melbourne 
Anaerogen Oxoid Australia Pty. Ltd. 
Bacteriological Agar Oxoid Australia Pty. Ltd. 
Balance 
 (i) Analytical Balance Sartorius GMBH, Germany 
 (ii)Balance (0.1-500g) U-Lab, Australia 
Bromophenol blue  BDH Chemicals, Australia 
 56
C3H/HeJ Mice ARC, Australia 
C3H/HeJARC Mice ARC, Australia 
Capillary tubes Becton Dickenson & Co., USA 
Carrier Ampholytes Bio-Rad laboratories, USA 
Cell Counter Propper MFG Co., USA 
Cell strainer BD Biosciences, USA 
Centrifuge 
 (i) Microcentrifuge Zentrifugen, Germany 
 (ii) Bench Top Centrifuge Beckman, USA 
 (iii) High Speed Centrifuge Beckman, USA 
Centrifuge Tubes 
(i) 1.5 mL Eppendorf Tubes Sarstedt, Germany 
(ii) 10 mL Centrifuge Tubes Greiner Labortechnik, Germany 
(ii) 15 mL Centrifuge Tubes Greiner Labortechnik, Germany 
 (iii) 50 mL Centrifuge Tubes Greiner Labortechnik, Germany 
4-Chloro-1-Napthanol Sigma-Aldritch Pty. Ltd., USA 
Coomassie Brilliant Blue R-250 Bio-Rad Laboratories, USA 
Coomassie Brilliant Blue G-250  Bio-Rad Laboratories, USA 
Copper Sulfate Ajax Chemicals Ltd., Australia 
Coverslips Mediglass, Australia 
Criterion  Bio-Rad Laboratories, USA 
Cryovials (1.8 mL) Nalgene Company, USA 
L-Cysteine BDH Chemicals, Australia 
Deoxynucleoside triphosphates (dNTPs) Roche Diagnostics, Germany 
DIG DNA Labelling and Detection Kit Roche Diagnostics, Germany 
Dithiothreitol (DTT) Bio-Rad Laboratories, USA 
DNA Ligase (T4) Roche Diagnostics, Germany 
DNA Polymerase (Amplitaq) Perkin Elmer, USA  
Dye-terminator Sequencing Mix V3.1 Monash University, Australia 
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Electrophoresis Units 
(i) DNA 
  a) Mini-gel Pharmacia LKB, Sweden 
  b) Midi-gel Bio-Rad Laboratories, USA 
  c) Maxi-gel Pharmacia LKB, Sweden 
(ii) Protein 
  a) Mini Protean II gel system Bio-Rad Laboratories, USA 
  b) Maxi Protean gel system Bio-Rad Laboratories, USA 
  c) Protean IEF Cell Bio-Rad Laboratories, USA 
ELISA 96 well plate  Greiner Bio-One, Austria 
ELISPOT plates Millipore, USA 
Ethylenediamine tetra acetic acid (EDTA)  BDH Chemicals, Australia 
Ethanol  BDH Chemicals, Australia 
Ethidium Bromide Roche Diagnostics, Germany 
Filter (Acrodisc 0.2µm, 0.45µm) Gelman Sciences USA 
Folin-Ciocalteus’ reagent Ajax Chemicals Ltd., Australia 
D-Glucose BDH Chemicals, Australia 
Glycerol BDH Chemicals, Australia  
Glycine BDH Chemicals, Australia 
Goat anti-mouse IgG Bio-Rad Laboratories, USA 
Goat anti-rabbit IgG Bio-Rad Laboratories, USA 
HEPES Buffer Cytosystems Pty Ltd, Australia 
Hydrochloric Acid (32%) Eqicell Products P/L, Australia 
Hydrogen Peroxide (30%) BDH Chemicals, Australia 
IL-4 Capture Antibody Abcam, UK 
IL-4 Biotin Conjugated Antibody BD Pharmingen, USA 
Incubator, for tissue culture Forma Scientific, USA 
IFN-γ Capture Antibody Abcam, UK 
IFN-γ Biotin Conjugated Antibody BD Pharmingen, USA 
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Imidazole Sigma-Aldritch Pty. Ltd., USA  
Iodoacetamide Bio-Rad Laboratories, USA  
IPTG Sigma-Aldritch Pty. Ltd., USA 
Isoamyl alcohol BDH Chemicals, Australia 
Isopropanol BDH Chemicals, Australia 
Kanamycin Sigma-Aldritch Pty. Ltd., USA  
Klenow Enzyme Roche Diagnostics, Germany 
Lambda DNA  Pharmacia LKB, Australia 
Lithium Chloride BDH Chemicals, Australia 
Low Melting Point Agarose Progen Industries, Australia 
Lysozyme Roche Diagnostics, Germany 
Magnesium Chloride Perkin Elmer, USA  
Maleic Acid BDH Chemicals, Australia 
β-mercaptoethanol Bio-Rad Laboratories, USA 
Methanol BDH Chemicals, Australia 
Mulleur Hinton Broth Oxoid Australia Pty. Ltd. 
Mulleur Hinton Agar  Oxoid Australia Pty. Ltd. 
Microscopes  
 (i) Light Microscope Olympus Optical 
 (ii) Phase Contrast Microscope Nikon Kogaku KK, Japan 
Microscope Slides LOMB Scientific Co., Australia 
Microtitre Plate (96 well, flat bottom) Nunc, Denmark 
NBT/BCIP substrate solution Roche Diagnostics, Germany 
Needle (19g, 21g) Terumo Pty. Ltd., Australia  
New Calf Serum  Cytosystems Pty Ltd, Australia 
Nitrocellulose membrane (Hybond-C) Amersham, USA 
Nylon Membrane (Hybond-N) Amersham, USA 
Parafilm Pechiney Plastic Packaging, Inc., USA 
PCR Buffer (10X) Roche Diagnostics, Germany 
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Penicillin/Streptomycin Thermo Trace, USA 
Petri Dish Nunc, Denmark 
pH Meter Radiometer, Denmark 
Phenol BDH Chemicals, Australia 
Phenol/Chloroform/Isoamyl Alcohol BDH Chemicals, Australia 
Phenylmethylsulfonylfluoride Sigma-Aldritch Pty. Ltd., USA 
Phosphate Buffered Saline Oxoid Australia Pty. Ltd. 
Polyethylene Glycol 8000 Sigma-Aldritch Pty. Ltd., USA 
Potassium Acetate  BDH Chemicals, Austalia 
Potassium Chloride BDH Chemicals, Australia 
Potassium Hydrogen Carbonate BDH Chemicals, Australia 
Pronase Roche Diagnostics, Germany  
Restriction Enzymes 
 AluI, BamHI, HindIII, SpeI, Promega, USA 
 XhoI, Sau3AI, PstI, BglII, Promega, USA 
Rnase  Roche Diagnostics, Germany 
RPMI Thermo Trace, USA 
Salmon Sperm DNA Roche Diagnostics, Germany 
SB-14 Bio-Rad laboratories, USA 
SeeBlue Protein Standards Bio-Rad Laboratories, USA 
Sheep Blood Oxoid Australia Pty. Ltd. 
Silver Nitrate Sigma-Aldritch Pty. Ltd., USA 
Skim Milk Bonlac Foods Ltd., Australia 
Sodium Chloride BDH Chemicals, Australia 
Sodium Citrate BDH Chemicals, Australia 
Sodium Dodecyl Sulphate (SDS) BDH Chemicals, Australia 
Sodium hydroxide BDH Chemicals, Australia 
Sodium Lauryl Sulfate BDH Chemicals, Australia 
Sonicator Branson Sonic Power Co., USA 
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Spectinomycin UpJohn, Australia 
Sucrose  BDH Chemicals, Australia 
Sulfuric Acid BDH Chemicals, Australia 
Syringe (1 mL, 3 mL, 5 mL, 10 mL, 20 mL, 50 mL) Terumo, Pty. Ltd., Australia 
TEMED Bio-Rad laboratories, USA 
TMB substrate reagent BD Pharmingen, USA 
Tissue Culture Flask (25 cm2, 50 cm2, 75 cm2) Nunc, Denmark 
Trans-blot electrophoretic transfer cell Bio-Rad laboratories, USA 
Transilluminator (UV) Bio-Rad laboratories, USA 
Tributylphosphine Sigma-Aldritch Pty. Ltd., USA 
Tris-Base  Roche Diagnostics, Germany 
Tris-HCl Roche Diagnostics, Germany 
Triton-X 100 Sigma-Aldritch Pty. Ltd., USA 
Triton-X 114 Sigma-Aldritch Pty. Ltd., USA 
Trypan Blue Sigma-Aldritch Pty. Ltd., USA 
Trypticase soya broth Oxoid Australia Pty. Ltd. 
Tryptone Oxoid Australia Pty. Ltd. 
Tween® 20  Sigma-Aldritch Pty. Ltd., USA 
Yeast extract Oxoid Australia Pty. Ltd. 
Whatman paper Whatman, England 
X-Gal Sigma-Aldritch Pty. Ltd., USA 
XLD Medium Oxoid Australia Pty. Ltd. 
Xylene cyanol  Bio-Rad Laboratories, USA 
 
 61
2.3 Bacteriological Methods 
2.3.1 Media and Antibiotics 
2.3.1.1 Antibiotic stock solutions 
Ampicillin was dissolved in sterile water at a concentration of 100 mg/mL.   Kanamycin 
was dissolved in sterile water at a concentration of 50 mg/mL.   These stock solutions were 
stored at –20°C. 
 
2.3.1.2 Kent Media 
Trypticase Soya Broth (3% w/v), D-Glucose (0.05% w/v), Yeast Extract (0.07% w/v), 
and L-cysteine (0.02% w/v) was dissolved in 1 Litre of deionised H2O, then autoclaved at 
standard conditions.   After the media had cooled, New Calf Serum (5% v/v) was added.  If 
broth wasn’t used immediately, Kent Media was boiled to regenerate anaerobic conditions. 
 
2.3.1.3 Luria Bertoni Agar 
Tryptone (1% w/v), Yeast Extract (0.5% w/v), NaCl (0.5% w/v) and Bacteriological Agar 
(1% w/v) was dissolved in deionised H2O and autoclaved at standard conditions. 
 
2.3.1.4 Luria Bertoni Agar Containing Kanamycin 
Tryptone (1% w/v), Yeast Extract (0.5% w/v), NaCl (0.5% w/v) and Bacteriological Agar 
(1% w/v) was dissolved in deionised H2O and autoclaved at standard conditions.  Kanamycin 
(100 mg/mL) was added to a final concentration of 50 µg/mL and poured into Petri Dishes. 
 
2.3.1.5 Luria Bertoni Broth 
Tryptone (1% w/v), Yeast Extract (0.5% w/v), and NaCl (0.5% w/v) was dissolved in 
deionised H2O and autoclaved at standard conditions. 
 
 
 
 62
2.3.1.6 Luria Bertoni Broth containing Kanamycin 
Tryptone (1% w/v), Yeast Extract (0.5% w/v), and NaCl (0.5% w/v) was dissolved in 
deionised H2O and autoclaved at standard conditions.  Before use, Kanamycin (100 mg/mL) 
was added at a final concentration of 50 µg/mL. 
 
2.3.1.7 Mulleur Hinton Agar 
Meuller Hinton Agar (2.1% w/v) powder was dissolved in deionised H2O and 
autoclaved at standard conditions, then dispensed into petri dishes. 
 
2.3.1.8 Mulleur Hinton Agar Containing Ampicillin 
Meuller Hinton Agar (2.1% w/v) powder was dissolved in deionised H2O and 
autoclaved at standard conditions.  After the media had cooled, Ampicillin (100 mg/mL) was 
added at a final concentration of 100 µg/mL, then dispensed into petri dishes. 
 
2.3.1.9 Mulleur Hinton Broth 
Meuller Hinton Broth powder was dissolved in deionised H2O (2.1% w/v) and 
autoclaved at standard conditions. 
 
2.3.1.10 Mulleur Hinton Broth Containing Ampicillin 
Meuller Hinton Broth powder was dissolved in deionised H2O (2.1% w/v) and 
autoclaved at standard conditions.   Before use, Ampicillin (100 mg/mL) was added at a final 
concentration of 100 µg/mL. 
 
2.3.1.11 Sheep Blood Agar 
Trypticase Soya Broth (3% w/v) and Bacteriological Agar (1% w/v) were dissolved in 
deionised H2O and autoclaved at standard conditions.   After the agar had cooled, Sheep 
blood (5% w/v) was added to the agar and the medium poured into petri dishes. 
 
 
 63
2.3.1.12 Sheep Blood Agar (with Spectinomycin & Kanamycin) 
Trypticase Soya Broth (3% w/v) and Bacteriological Agar (1% w/v) were dissolved in 
deionised H2O and autoclaved at standard conditions.   Sheep blood (5% w/v) and Antibiotics 
(Spectinomycin Sulfate 760 µg/mL final concentration, Kanamycin 100 µg/mL final 
concentration) were added to the cooled agar and the medium poured into petri dishes. 
 
2.3.2 Bacterial Strains Used 
B. hyodysenteriae strains used in this study were 5380, P18A, B204, B8044, 8930, 
Williams A, R7273, T10A, A1, B78T, vld, WAA1, G131, Y32, B169 and FMV-189.   
Brachyspira spp. were routinely grown on SBA/Spectinomycin.   For broth culture, 
Brachyspira spp. were grown in Kent media for 4 days at 37°C under anaerobic conditions.   
Cultures were incubated anaerobically for 4 days at 37°C.  Anaerobic conditions were 
generated using AnaeroGen satchels from Oxoid.  
 
The E. coli strains Top10F’, DH5α and BL21 were used for hosts of pCR2.1, 
pBluescript, pVR1020, pVRMCP3 and pRSET-A..   S. typhimurium LT2 was used for 
stabilisation of expression vectors prior to vaccination.   S. typhimurium STM-1 was used as 
hosts for expression vectors for vaccination experiments.   S. typhimurium and E.coli strains 
were grown on LB agar plates or MH agar plates.  For culture in liquid medium, S. 
typhimurium and E.coli were grown in LB Broth or MH Broth.  
 
2.4 DNA Methods. 
2.4.1 Buffers and Reagents. 
2.4.1.1 6x Loading Buffer. 
Sucrose (40% w/v), Bromophenol Blue (0.25% w/v) and Xylene Cyanol (0.25% w/v) 
dissolved in deionised, sterile H2O. 
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2.4.1.2 Anti-DIG Antibody Solution. 
Anti-DIG antibody (1:5000 Dilution) in Blocking solution. 
 
2.4.1.3 Blocking reagent Stock Solution. 
Blocking Reagent (10 g) was added to 100 mL Maleic Acid Buffer.  The Blocking 
Reagent was dissolved on a heat plate for 1 h at 65°C with constant stirring.   After the 
Blocking Reagent has completely dissolved, the solution was autoclaved and stored at 4°C. 
 
2.4.1.4 Blocking Solution. 
1% Blocking reagent (From 10% Stock Solution) diluted in Maleic Acid Buffer. 
 
2.4.1.5 Detection Buffer. 
Tris-HCl  (100mM, pH 9.5) and 100 mM NaCl dissolved in dH2O. 
 
2.4.1.6 Denaturation Solution. 
Sodium Hydroxide (0.5 M) and  Sodium Chloride (1.5 M) dissolved in dH2O. 
 
2.4.1.7 Depurination Solution. 
0.25 M HCl diluted in dH2O 
 
2.4.1.8 ESP solution. 
EDTA (0.5 M), N-lauryl sarcosine (1% w/v) and Proteinase K (1 mg/mL), dissolved in 
H2O. 
 
2.4.1.9 Fluoride/TE solution 
Phenyl methyl sulfonyl fluoride (18.6 mg/mL) was added to 1 mL of isopropanol.   TE 
(25 mL) was added aseptically, and the solution was warmed at 37°C for 15 min. 
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2.4.1.10 FSB solution. 
MnCl2·4H2O (45 mM), CaCl2·2H2O (10 mM), KCl, (100 mM), Hexamminecobalt 
Chloride (3 mM), Potassium Acetate (10 mM), Glycerol (10% v/v) dissolved in H2O, pH to 
6.4, filter sterilised, and stored at 4°C 
 
2.4.1.11 Isopropyl-β-D-galactopyranoside (IPTG) (0.1 M) Stock Solution. 
IPTG (1.2 g) was dissolved in 50 mL of sterile water, filter sterilised and stored at 4°C 
 
2.4.1.12 Maleic Acid Buffer. 
Maleic Acid (0.1 M) and Sodium Chloride (0.15 M) dissolved in dH2O and autoclaved. 
 
2.4.1.13 Maleic Acid Wash Buffer. 
Tween® 20 (0.3% w/v) in Maleic Acid Buffer 
 
2.4.1.14 Neutralisation solution. 
Tris-HCl (0.5 M ,pH 7.5) and Sodium Chloride (3 M) dissolved in dH2O. 
 
2.4.1.15 PFGE lysis buffer. 
Tris-HCl (6 mM), NaCl (1 M) and EDTA (100 mM) dissolved in dH2O.    Store at 4C and 
sterilise before use.   To complete buffer prior to use, add Sodium Deoxycholate (0.2% w/v), 
N-lauryl sarcosine (0.5% w/v) and Lysozyme (1 mg/mL). 
 
2.4.1.16 PIV buffer. 
Tris base (10mM) and NaCl (1 M) dissolved in deionised H2O, pH 8.0, and autoclaved. 
 
2.4.1.17 Standard Hybridisation Buffer. 
SSC (5X), 0.1% N-lauroylsarcosine, 0.02% SDS and 1% Blocking Reagent (From 10% 
stock solution) diluted in dH2O. 
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2.4.1.18 20X SSC. 
Sodium Chloride (3 M) and Sodium Citrate (0.3 M) dissolved in dH2O, adjusted to pH 
7.0 and autoclaved. 
 
2.4.1.19 2X SSC wash buffer. 
SSC (2X) and 0.1% SDS diluted in dH2O. 
 
2.4.1.20 0.5X SSC wash buffer. 
SSC (0.5X ) and 0.1% SDS Diluted in dH2O. 
 
2.4.1.21 Substrate Solution. 
NBT/BCIP substrate solution  (80 µL) diluted in 10 mL of detection buffer. 
 
2.4.1.22 TAE Buffer 50X. 
Tris-base (24.2% w/v), glacial acetic acid (5.17% w/v) and EDTA (1.86% w/v) were 
dissolved in deionised water.   This was diluted to 1X before use. 
 
2.4.1.23 TBE Buffer 5X 
Tris base (0.445 M), Boric acid (0.445 M) and EDTA (12.5 mM) dissolved in H2O and 
adjusted to pH 8.0. 
 
2.4.1.24 TE buffer 
Tris-base (10 mM) and EDTA (1 mM) was dissolved in water.   The pH was adjusted as 
required with HCl then autoclaved. 
 
2.4.1.25 X-gal Stock solution. 
X-gal (100 mg) was dissolved in 5 mL of N,N’-dimethylformamide and stored at –20°C. 
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2.4.2 DNA Extraction Techniques. 
2.4.2.1  Chromosomal DNA Preparation. 
Cultures were grown in 10 mL of LB overnight at 37°C.  Cells were obtained by 
centrifuging 10 mL of the overnight culture at 5000 x g for 5 min.   Cell pellets were 
resuspended in 1 mL of TEG/Lysozyme, and incubated on ice for 5 min.   Lysis was 
achieved by adding 1.5 mL of SDS solution, and after mixing by inversion tubes were 
incubated on ice for 5 min.    RNase was added at 20 µg/µL, and the solution was incubated 
at 37°C for 30 min.   Pronase was added at a final concentration of 20 µg/µL and the mixture 
was incubated for another 30 min.   Miniprep Solution 3 was added (2000 µL) and tubes 
were mixed by inversion.   The lysate was incubated on ice for 10 min. 
 
The supernatant was recovered after centrifugation at 5000 x g for 10 min at 4°C.   An 
equal volume of Phenol/Chloroform/Isoamyl was added to the supernatant and mixed by 
inversion.   Phase separation was achieved by centrifugation at 5000 x g for 5 min.  The 
aqueous phase was recovered and the PCI wash repeated 2 more times, or until no white 
interphase could be seen.   Chromosomal DNA was precipitated by the addition of 2 volumes 
of 100% Ethanol and 0.1 volumes of 3 M Sodium Acetate, pH 5.6.   DNA pellets were 
washed in 500 µL 70% Ethanol before being resuspended in 50 µL of water. 
 
2.4.2.2  Plasmid Miniprep. 
Cultures were grown in 10 mL of LB overnight at 37°C.  Cells were obtained by 
centrifuging 1 mL of the overnight culture at 5000 x g for 5 min.   Cell pellets were 
resuspended in 100 µL of Miniprep Solution 1, and incubated on ice for 5 min.   Lysis was 
achieved by adding 150 µL of Miniprep Solution 2, and after mixing by inversion tubes were 
incubated on ice for 5 min.   Miniprep solution 3 was added (200 µL) and tubes were mixed 
by inversion.   The lysate was incubated on ice for 10 min.   Protein and chromosomal DNA 
was pelleted by centrifgation at 16100 x g for 10 min at 4°C.  The supernatant was recovered 
and an equal volume of Phenol/Chloroform/Isoamyl was added and mixed by inversion.   
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Phase separation was achieved by centrifugation at 16100 x g for 5 min.    Plasmid DNA was 
precipitated by the addition of 2 volumes of 100% Ethanol and 0.1 volumes of 3M Sodium 
Acetate pH5.6.   DNA pellets were washed in 500 µL 70% ethanol before being resuspended 
in 30 µL of water. 
 
2.4.2.3  Plasmid Maxiprep by PEG Precipitation. 
LB broths (1 L) were inoculated from a glycerol stock.   The cultures were grown at 
37°C until stationary phase was reached.   Cells were harvested by centrifugation at 6000 x g 
for 20 min at 4°C.   The pellet was resuspended in 50 µL of cold Maxiprep Solution 1 and cell 
clumps were removed with a pipette.   Cell lysis was accomplished by the addition of 100 µL 
of Maxiprep Solution 2 and the lysate was mixed by inversion and stored on ice.   The pH 
was neutralised by the addition of 75 µL of Maxiprep Solution 3, which was mixed by 
inversion and stored on ice for 5 min.   The solution was centrifuged at 10000 x g for 30 min 
and the supernatant was filtered through 4 layers of filter paper.   The supernatant was 
incubated on ice for 10 min after the addition of 0.6 volumes of isopropanol.   DNA was 
recovered by centrifugation at 5000 x g for 10 min at 4°C.  The pellet was resuspended in 5 
mL of TE buffer and 1 volume of cold 5 M LiCl was added to precipitate RNA. 
 
After a 5 min incubation on ice, RNA was pelleted at 5000 x g for 10 min at 4°C.   To 
the supernatant, 1 volume of isopropanol was added and incubated on ice for 5 min.   DNA 
was pelleted by centrifugation at 5000 x g for 10 min at 4°C and resuspended in TE buffer 
containing 20 µg/mL RNase.  After a 30 min incubation at RT, an equal volume of PEG 
solution was added at left at room temperature for 1 h.   Low molecular weight DNA was 
pelleted by centrifugation at 5000 x g for 20 min at 4°C.   DNA was dried thoroughly, 
resuspended in 5 mL of TE and left to dissolve overnight at 4°C.   Phenol Chloroform Isoamyl 
extractions were performed 3 times or until no white interphase could be seen.   DNA was 
precipitated using 2 volumes of ethanol and 0.1 volumes of 3 M Sodium Acetate, pH 5.6.  
After centrifugation at 5000 x g for 10 min at 4°C, the pellet was resuspended in PBS (5 mL). 
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Triton X-114 extractions were performed to remove E. coli endotoxin.   Triton X-114 
was added to a concentration of 1% v/v.   Tubes were mixed by inversion and placed on ice 
for 5 min.   The solutions were then placed at 37°C to separate the phases.   Centrifugation 
at 5000 x g for 10 min pelleted the Triton X-114 and the aqueous phase was retained.   The 
procedure was repeated 3 times.   Plasmid DNA was precipitated by the addition of 2 
volumes of ethanol and 0.1 volume of 3 M sodium acetate, pH 5.6.   DNA was dissolved in 
500 µL of water and stored at –20°C. 
 
2.4.2.4  Purification of DNA from Agarose gel. 
Purification of DNA from agarose gel using the Geneclean kit was performed according 
to the manufacturers instruction.   Briefly, the DNA band was excised from the gel and 
weighed.   Sodium Iodide (~5 M, 3 gel volumes) and 5 µL of 3M Sodium Acetate (pH 5.2) 
was added to the gel slice, and the agarose was melted at 55°C.   Glassmilk (5 µL) was 
added, mixed by vortexing and allowed to stand for 5 min at room temperature with frequent 
agitation.   The Glassmilk was recovered by centrifugation at 10000 x g for 30 s.   The 
Glassmilk was washed 3 times with 500 µL of New Wash solution, and recovered by 
centrifugation at 10000 x g for 30 s.   To recover the DNA, the Glassmilk was dried then 
resuspended in 10 µL of dH2O.  After 5 min at room temperature, the Glassmilk was pelleted 
by centrifugation at 10000 x g for 2 min and the dH2O collected. 
 
2.4.2.5  Determination of DNA concentration. 
Concentration of isolated DNA was determined by O.D. measurements at 260 nm and 
280 nm, and then converting to DNA concentration using the ratio 1.0 O.D. to 50 µg/mL 
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2.4.3 PCR. 
2.4.3.1  Design of Primers. 
Primers were designed using Sci Ed Central Primer Designer 4 V 4.2.   Due to the low 
GC content of B. hyodysenteriae, a GC content of 15-50% with a corresponding Tm of 40-
80°C was  considered acceptable.    
 
2.4.3.2  General PCR procedure. 
PCR was performed using the following protocol: 
10X Buffer ................................................................ 2.5 µL 
MgCl2.......................................................................... 2 µL 
Forward Primer .............................................. 1 µL (20 nM) 
Reverse Primer .............................................. 1 µL (20 nM) 
dNTP Mix ................................................................. 0.5 µL 
DNA (50ng) ................................................................. 1 µL 
Taq polymerase .......................................................0.15 U 
DH2O ..................................................................... 16.5 µL 
Total Volume ............................................................. 25 µL 
 
The details of the cycling conditions are provided in the results section for each PCR. 
 
2.4.3.3  General Expand PCR procedure. 
PCR was performed using the following protocol: 
10X Buffer ................................................................... 5 µL 
Forward Primer .............................................. 2 µL (20 nM) 
Reverse Primer .............................................. 2 µL (20 nM) 
dNTP Mix ................................................................. 0.5 µL 
DNA (50ng) ................................................................. 1 µL 
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Taq polymerase .......................................................0.15 U 
DH2O ........................................................................ 33 µL 
Total Volume ............................................................. 50 µL 
 
The details of the cycling conditions are provided in the results section for each PCR. 
 
2.4.3.4  DNA Sequence Characterisation. 
PCR was performed using the following protocol: 
 
10X Buffer ................................................................... 5 µL 
Forward Primer .............................................. 2 µL (20 nM) 
Reverse Primer .............................................. 2 µL (20 nM) 
dNTP Mix ................................................................. 0.5 µL 
DNA (50ng) ................................................................. 1 µL 
Taq polymerase .......................................................0.15 U 
DH2O ........................................................................ 33 µL 
Total Volume ............................................................. 50 µL 
 
The details of the cycling conditions are provided in the results section for each PCR. 
 
2.4.4 Recombinant DNA Techniques. 
2.4.4.1  Cloning of PCR Products. 
Antigen genes were inserted into PCR2.1 according to the manufacturers protocol.  
Briefly, the PCR product was analysed by gel electrophoresis and the concentration 
estimated.   The PCR product (1 µg) was mixed with 10x Ligation Buffer (1 µL), pCR Vector 
(2 µL), T4 DNA Ligase (1 µL), and the reaction was made up to 10 µL with dH2O.   The 
ligation was incubated overnight at 16°C.  The ligation tubes were centrifuged briefly, then 
placed on ice.   Vials of One Shot® competent cells were thawed on ice.   The cells were 
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mixed with 2 µL of the ligation, and incubated on ice for 30 min. The cells were then heat 
shocked for 30 s in a 42°C water bath. 
 
Following transformation, 250 µL of SOC was added to the vial, and the cells were 
allowed to recover at 37°C for 1 h.   Transformations (10 µL and 100 µL) were then spread 
plated onto LB agar containing X-gal and either 50 µg/mL Kanamycin or 50 µg/mL Ampicillin.  
Plates were incubated overnight at 37°C, and white colonies were selected for analysis. 
 
2.4.4.2  Restriction Enzmye Digestion. 
DNA was digested using the following formula: 
DNA ............................................................................................... 1 µg 
10X Buffer...................................................................................... 1 µL 
BamHI..............................................................................................1 U 
H2O .....................................................................................Up to 10 µL 
 
Digestions were performed in a total volume of 10 µL and incubated at 37°C for at least 
4 h.   Digests were then run on an agarose gel in preparation for extraction. 
 
2.4.4.3  Ligation of DNA. 
DNA was ligated using the following formula: 
Plasmid ................................................................... 100 ng 
Insert DNA............................................................. Variable 
10 Ligase Buffer .......................................................... 1 µL 
T4 DNA ligase ...............................................................1 U 
 
Ligations were made up to 10 µL using dH2O.   The amount of insert DNA was 
calculated using the following formula. 
 
ng of vector X size of insert (kb) X 3 = ng of insert 
 size of vector (kb)  1 
 
2.4.4.4  Electroporation of E. coli. 
A 200 mL LB broth was inoculated with 2 mL of an overnight culture.   The 200 mL 
culture was grown for 2 to 3 h at 37°C until mid-log phase, an O.D.600 of 0.06, was reached.   
The culture was incubated on ice for 1 h, before the cells were harvested by centrifugation at 
8000 x g for 20 min at 4°C.   Cells were washed twice in ice-cold dH2O, once in ice-cold 10% 
glycerol and finally resuspended in 160 µL of 10% glycerol.   Cells were dispensed into 40 µL 
aliquots and stored at –70°C. 
 
Aliquots of competent cells were thawed on ice, and 2 µL of the ligation reaction was 
added.   Cells were mixed by pipetting, and the mixture was transferred to a pre-chilled 
electroporation cuvette.   A charge of 2.5 V and 400 mA was passed through the cuvette and 
electroporations with a time constant of greater than 4.5 ms were transferred to a microfuge 
tube.   LB broth (1 mL) was added to the cells, and the tranformations were transferred to a 
37°C waterbath for 1 h.   Cells were plated out onto LB agar plates containing the 
appropriate antibiotic. 
 
2.4.4.5  Chemical Transformation of E. coli. 
A 200 mL LB broth was inoculated with 2 mL of an overnight culture.   The 200 mL 
culture was grown for 2 h at 37°C until approximately mid-log phase, an O.D.600 of 0.06, 
was reached.   Cells were harvested by centrifugation at 5000 x g for 20 min at 4°C.   Cells 
were washed in 40 mL of ice-cold FSB.  After centrifugation at 5000 x g for 20 min at 4°C, 
cells were resuspended in 2 mL of FSB.   Aliquots of 200 µL were dispensed into microfuge 
tubes and stored at –70°C. 
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Aliqouts of competent cells were thawed on ice, and 10 µL of the ligation reaction was 
added to 200 µL of competent cells.   The cells were mixed by pipetting, and incubated on 
ice for 30 min.   To perform the tranformation, competent cells were transferred to a 42°C 
water bath for 90 s.   Transformations were incubated on ice for 2 min, then 1 mL of LB broth 
was added.  Transformants were allowed to recover at 37°C for 1 h before 100 µL of each 
reaction was plated onto LB agar containing the appropriate antibiotic 
 
2.4.4.6  Knock-out mutagenesis smpB. 
SmpA was excised from PCR2.1-smpA by digestion with SpeI and XhoI at 37°C 
overnight, followed by agarose gel electrophoresis and excision from the agarose gel using 
Geneclean.   Concurrently, pBluescript SK- was digested with SpeI and XhoI (removing the 
HindIII site in the MCS) overnight at 37°C, then the enzyme inactivated by incubation at 65°C 
for 10 min.   The smpA gene was ligated with pBluescript overnight at 16°C.   After isolation 
of pBluescipt-smpA, the vector was linearised with HindIII, and the Kanamycin cassette cut 
out of pMW2.   The Kanamycin gene was inserted into smpA, and used to transform B. 
hyodysenteriae. 
 
B. hyodysenteriae were grown for 4 days, and the cells harvested by scraping the 
plates with cell spreaders.   Cells were pelleted by centrifugation at 5000 x g for 10 min at 
4°C and washed twice in PBS.   The cells were finally resuspended in 4 mL of PBS and kept 
on ice until use.   To transform B. hyodysenteriae, plasmid (10 µg) was added to the 4 mL of 
competent cells.   This mix was added to a TSA/Sheep Blood plate and incubated to 7 h at 
37°C under anaerobic conditions.   After this incubation, the liquid was drawn off the top of 
the plate, and the cells were harvested by centrifugation at 5000 x g for 10 min at 4°C.   The 
cells pellet was resuspended in 100 µL of PBS and spread onto TSA/Sheep blood plates 
containing 100 mg/mL  Kanamycin.   The plates were incubated at 37°C for 4 days under 
anaerobic conditions, and any kanamycin resistant colonies subcultured for further analysis. 
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Electrocompetent B. hyodysenteriae were prepared by flooding 3 SBA plates of B. 
hyodysenteriae with sterile, ice cold deionised H2O.   The cells were harvested by 
centrifugation at 5000 x g for 10 mins.   The cell pellets were washed 3 times in sterile, ice 
cold deionised H2O, once in ice cold 10% glycerol before being resuspended in 200 µL of ice 
cold 10% glycerol.    A charge of 2.5 V and 400 mA was passed through the cuvette and 
electroporations with a time constant of greater than 4.5 ms were transferred to a microfuge 
tube. 
 
2.4.5 Pulsed Field Gel Electrophoresis. 
B. hyodysenteriae were grown on SBA/Spectinomycin for 3 days at 37°C.   The cells 
were harvested from 3 plates by flooding with 5 mL of PBS, and suspending the cells with a 
cell scraper.   The cells were washed by centrifugation at 5000 x g for 5 min and 
resuspended in 10 mL of PBS.   Finally, the cells were isolated by centrifugation at 5000 x g 
for 5 min and resuspended in 250 µL of PIV buffer on ice. 
 
The cell suspension was mixed with an equal volume of 2% low melting point agarose 
(dissolved in PIV buffer) and poured into sterile, pre-chilled moulds.   The plugs were allowed 
to set, then placed in 0.5 mL PFGE lysis buffer overnight at 37°C.   The following day, the 
plugs were allowed to harden at 4°C for 20 min, placed in 0.5 mL of ESP solution and 
incubated at 50°C overnight.   The following day, the plugs were hardened at 4°C for 20 min, 
then incubated in 0.5 mL of Fluoride/TE solution at 37C for 2 hours.   The plugs were then 
washed 6 times in TE buffer over 6 h at 37°C.   Plugs were stored in TE Buffer at 4°C for up 
to 6 months. 
 
A portion of the DNA plug was cut and washed in 1X RE buffer.   The plug portion was 
then placed in 80µL of restriction enzyme solution, consisting of  5µL (25U) of MluI, 8µL of 10 
X RE buffer, 5µL of 1 mg/mL bovine serum albumin (BSA) and 62 µL of sterile deionised 
H2O.   The DNA was digested for 24 h at 37°C.   A 1% agarose midigel was set in 1X TBE.   
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A portion (1 mL) of the molten agarose was reserved and kept at 55°C.   Following RE 
digestion, the DNA plugs were inserted into the wells of the set, chilled agarose gel and the 
wells were sealed with the reserved, molten agarose.   The agarose gel was then subjected 
to PFGE at 180 V for 18 h with the pulse time ramped from 1 to 20 s.   The gel was stained in 
ethidium bromide and examined by UV transillumination. 
 
2.4.6 DNA-DNA hybridisation. 
2.4.6.1  Probe Synthesis. 
The smpA and smpB probes were synthesised from B. hyodysenteriae P18A and B. 
hyodysenteriae 5380.   Briefly, 3 µg of template was diluted to 15 µL with dH20.   The mixture 
was heated to 100°C to denature the template, then chilled on ice.   Klenow enzyme (1 µL), 
10x DNA labelling mix (2 µL) and primers (2 µL) were then added to the reaction and 
incubated at 37°C overnight.   After incubation, the probe was denatured by boiling for 10 
min, and diluted in Southern Blot hybridisation Solution at a concentration of 10-25 ng/mL. 
 
The concentration of the probe was determined by a spot test with DIG-labelled control 
DNA.   The DIG-labelled control DNA was diluted to 1 ng/µL.  From this stock, five 1:10 serial 
dilutions were made, creating a set of standards ranging from 1 ng/µL to 0.01 pg/µL.   After 
estimating the concentration of experimental probe from the DIG System User’s Guide for 
Filter Hybridisation, the experimental probe was diluted to approximately 1 ng/µL. From this 
stock, five 1:10 serial dilutions were made. 
 
A piece of nylon membrane was spotted with 1 µL of these standards in one row, then 
with 1 µL of the experimental probe on a second row.   The membrane was then cross-linked 
under UV light for 5 mins.   The membrane was washed in 2X SSC Wash Buffer briefly, then 
incubated for 30 min in Blocking Solution at room temperature. The membrane was then 
incubated in Anti-DIG Antibody Solution for 30 min at room temperature.   The membrane 
was washed twice for 15 min each with Wash Buffer at room temperature to remove any 
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unbound antibody.   The membrane was equilibrated in Detection Buffer for 2 min, and then 
incubating in Substrate Solution developed the colour.  To stop the colour development, the 
membrane was washed with dH2O.   The intensity of the experimental probe spots was then 
compared to the standard DIG-Labelled Control DNA spots to determine the probe 
concentration. 
 
2.4.6.2  Southern Blot Procedure. 
A total of 20 µg of genomic DNA was digested with 3 U/µg of enzyme in a total volume 
of 50 µL.  The digested was incubated at 37°C for 20 h.   Following digestion, 12 µL of 6x 
loading buffer was added to the digestion.   The DNA digests were subjected to 
electrophoresis in a 1% agarose gel for 3 h at 5 V.    Following electrophoresis at 50 V for 3 
hours, the gel was washed in Depurination solution for 10 min then rinsed with water.   The 
gel was washed twice in Denaturing Solution for 10 min each, followed by two 15 min 
washes in Neutralisation Solution.   Capillary transfer was used to convey the DNA to the 
nylon membrane.  Briefly, a glass plate was placed on rubber stoppers inside a glass baking 
dish.   The baking dish was filled to with 10X SSC.  Whatman paper was cut slightly larger 
that the glass plate, soaked in 10X SSC and the ends of the paper were allowed to hang into 
baking tray.   The gel was placed face down on the wet Whatman paper, followed by a piece 
of Nylon membrane about 1mm larger than the gel, and two pieces of Whatman paper.   
Parafilm was placed on any exposed wick.   A stack of paper towels was placed atop the 
Whatman paper, and a glass plate was used to weigh down the paper.   Transfer was 
allowed to proceed for approximately 16 h. 
 
The DNA was cross-linked to the membrane by UV irradiation for 5 min.   The 
membrane was pre-hybridised for 2 h at 65°C in Standard Hybridisation Solution. The probe 
was diluted in Standard Hybridisation Solution, added to the membrane and incubated at 
65°C overnight.   The membrane was washed twice with 2X SSC Wash Buffer for 5 min at 
room temperature, then washed twice in 0.5X SSC Wash Buffer for 15 min at 65°C.   
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Following the stringency washes, the membrane equilibrated in Maleic Acid Wash Buffer, 
then incubated in Blocking Solution for 1 h at room temperature.  The Blocking solution was 
replaced with Anti-DIG Antibody Solution and incubated for 1 h at room temperature.   
Unbound antibody was removed by two washes in Maleic Acid Wash Buffer for 10 min at 
room temperature.   Substrate Solution was then added and the membrane placed in the 
dark until a colour precipitate had formed. 
 
2.5 Protein Methods. 
2.5.1 Buffers and Reagents. 
2.5.1.1 2D Gel Sample Buffer. 
Urea (7 M), Thiourea (2 M), Carrier Ampholytes (1%), SB-14 (1%), Tributylphosphine 
(2 mM) made up in dH2O. 
 
2.5.1.2 2D Gel Equilibration Buffer I. 
Urea (5M), Thiourea (2M), SDS, Dithiothreitol (DTT). 
 
2.5.1.3 2D Gel Equilibration Buffer 2. 
Urea (5M), Thiourea (2M), Iodoacetamide. 
  
2.5.1.4 Ammonium Persulfate (10%). 
Ammonium Persulfate (100 mg) was dissolved in 1 mL of deionised H2O and filter 
sterilised through a 0.22 µM syringe filter.   The solution was stored at 4°C wrapped in foil for 
up to 3 months. 
 
2.5.1.5 Bradford Coomassie Reagent. 
Coomassie Brilliant Blue R-250 (0.05% w/v) dissolved in Ethanol (25 mL, 95%) and 
Phosphoric Acid (50 mL, 88%), then diluted with water to 500 mL.   Store at 4°C, filter before 
use. 
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2.5.1.6 Cell lysate buffer 
Tris-HCl (0.1 M, pH 6.8), SDS (2% w/v) and glycerol (15% v/v) were dissolved in water. 
 
2.5.1.7 Coomassie Stain. 
Coomassie Brilliant Blue R-250 (0.05% w/v) was dissolved in methanol (250 mL) and 
Acetic Acid (50 mL).  After the Coomassie Brilliant Blue had dissolved, the solution was 
diluted to 500 mL with deionised H2O (Final concentration 50% Methanol, 10% Acetic Acid). 
 
2.5.1.8 Coomassie Destaining Reagent. 
Ethanol (10% v/v) and Acetic Acid (10% v/v) was diluted in deionised H2O. 
 
2.5.1.9 GST Regeneration Buffer I. 
Boric Acid (0.1M) and NaCl (0.5M) was dissolved in deionised H2O and the pH 
adjusted to pH 8.5 with 10M NaOH. 
 
2.5.1.10 GST regeneration Buffer II. 
Sodium Acetate (0.1M) and NaCl (0.5M) was dissolved in deionised H2O and the pH 
adjusted to pH 4.5 with Glacial Acetic Acid.  
 
2.5.1.11 GST Elution Buffer. 
Tris-HCl (50mM) and reduced Glutathione (10mM) were dissolved in deionised H2O, 
pH 9.5 ± 0.1. 
 
2.5.1.12 IMAC Buffer 
NaH2PO4 (25 mM), NaCl (250 mM) and Imidazole (10 mM) dissolved in H2O. 
 
2.5.1.13 IPTG (1M). 
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IPTG (2.38g) was dissolved in 10 mL of deionised H2O and filter sterilised using a 
syringe filter. 
 
2.5.1.14 Lowry Folin Reagent 
Folin-Ciocalteau reagent was mixed with distilled water at a 1:1 ratio. 
  
2.5.1.15 Lowry Reagent A. 
Sodium Carbonate (2% w/v), Sodium Hydroxide (0.4% w/v), sodium tartrate (0.16% 
w/v) and SDS (1% w/v) dissolved is deionised H2O. 
 
2.5.1.16 Lowry Reagent B. 
Copper sulfate (4% w/v) dissolved in deionised H2O. 
 
2.5.1.17 Lowry Reagent C. 
Lowry Reagent A (50 mL) and Lowry Reagent B (0.5 mL) were mixed before use 
 
2.5.1.18 Outer membrane protein (OMP) Extraction Buffer. 
Tris base (50mM) and EDTA (10mM) was dissolved in deionised H2O, then 0.05% 
TritonX-114 was added. 
 
2.5.1.19 10X PAGE Running Buffer. 
Tris Base (3% w/v), Glycine (14.4% w/v) and SDS (1% w/v) was dissolved in deionised 
H2O, pH 8.3.   Diluted to 1X in water before use. 
  
2.5.1.20 PAGE Sample Buffer. 
Glycerol (10% v/v), Tris Base (62.5mM), SDS (2% w/v) were dissolved in water. 
 
2.5.1.21 PBS. 
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0.01 M phosphate buffer, 0.0027 M potassium chloride and 0.137 M sodium chloride, 
pH 7.4. 
 
 
2.5.1.22 SDS-PAGE Sample Buffer 
Tris-HCl (125 mM, pH 6.8), β-mercaptoethanol (5% w/v), Bromophenol blue (0.02% 
w/v) and glycerol (10% v/v) in water. 
 
2.5.1.23 Silver Stain. 
Concentrated ammonium hydroxide (2 mL) was mixed with 28 mL of NaOH (0.1 M).   
Five millilitres of freshly prepared silver nitrate (20% w/v) was then added to the solution 
while it was being stirred.   Water was added to a final volume of 150 mL. 
 
2.5.1.24 Silver Stain Developing Solution. 
Periodic acid (0.7% w/v) in ethanol (40% v/v) and acetic acid (5% v/v). 
 
2.5.1.25 Silver Stain Fixing Solution. 
Methanol (50% v/v) and Acetic Acid (10% v/v) was diluted in deionised H2O. 
 
2.5.1.26 Silver Stain Stop Solution. 
Five mL of 80% Acetic acid in 200 mL of Tris-base (5% w/v). 
 
2.5.1.27 TBS. 
Tris Base (10mM) and NaCl (500mM) was dissolved in deionised H2O, pH 7.4, then 
autoclaved at standard conditions. 
 
2.5.1.28 TBS/Tween 
Tween 20 (0.05%) was added to TBS. 
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2.5.1.29 TE Buffer. 
Tris Base (10mM) and EDTA (1mM) were diluted in deionised H2O, pH 7.5, and 
autoclaved at standard conditions. 
 
2.5.1.30 Western Blot Blocking Solution. 
Skim milk (5%) was dissolved in TBS. 
 
2.5.1.31 Western Blot Substrate Solution. 
The substrate, 4-Chloro-1-Naphthol (30 mg), was dissolved in 10 mL of Methanol.   
This solution was added to 40 mL Tris (50 mM), and 30 µL of H2O2. pH 7.0. 
 
2.5.1.32 Western Blot Transfer Buffer. 
Tris Base (25 mM) and Glycine (192 mM) was dissolved in deionised H2O, then 
Methanol was added to final concentration 20% v/v. 
 
2.5.2 Protein Extraction Methods. 
2.5.2.1  Whole Cell Lysate. 
2.5.2.1.1 Boiling Method. 
Cells were harvested by centrifugation at 5000 x g for 10 min, and the pellet 
resuspended in 900 µL of TE buffer and 100 µL of 10% SDS.   The solution was then boiled 
for 5 min at 100°C.   Intact cells and cellular debris was pelleted by centrifugation and the 
supernatant collected.   The protein concentration was determined by the Lowry assay and 
the sample stored at –20°C until use. 
 
2.5.2.1.2 Freeze/Thaw Method. 
Cells were harvested by centrifugation at 5000 x g for 10 min and the pellet 
resuspended in the appropriate solution (depending on the downstream application of the 
lysate).   Lysozyme was added to the suspension (4 mg/mL) and the suspension was frozen 
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in a dry ice/ethanol bath.   After complete freezing, the cells were thawed at 37°C, and then 
frozen in a dry ice/ethanol bath.  The freeze/thaw procedure was repeated as necessary until 
a viscous solution was obtained.   The lysate was then incubated with DNase at 37°C and 
clarified by centrifugation at 5000 x g for 20 min.   The protein concentration was determined 
by Bradford assay and the lysate was stored at –20°C if not used immediately. 
 
2.5.2.1.3 Sonication. 
Cells were harvested by centrifugation at 5000 x g for 10 min and resuspended in the 
appropriate buffer (depending on the downstream application for the lysate).   The cell 
suspension was then sonicated in an ice bath for 6 cycles of 30 s on and 30 s off.    The 
lysate was clarified by centrifugation at 5000 x g for 10 min to remove cellular debris, and the 
supernatant collected. The protein concentration was determined by the Bradford assay and 
the lysate was stored at –20°C if not used immediately. 
 
2.5.2.2  Outer Membrane Preparation. 
Outer membrane proteins were extracted using the triton X-114 method.   Cells that 
had been growing for 3 days were harvested from SBA plates, resuspended in 10 mL OMP 
extraction buffer and incubated at 4°C shaking overnight.   The following day, intact cells 
were removed by centrifugation and the supernatant was incubated at 37°C for 15 min to 
induce phase separation.   Following centrifugation at 5000 x g at RT, the detergent phase 
was collected and diluted with 10 mL of extraction buffer and the 4°C incubation was 
repeated.   The following day the 37°C phase seperation was repeated and the sample 
returned to 4°C overnight.   The following day the phase seperation was repeated, and 10 
mL of acetone was added to the detergent phase.    Following incubation at 4°C, the 
precipitated proteins were harvested by centrifugation at 5000 x g at 4°C.   The protein pellet 
was either resuspended in water, or 2D gel sample buffer. 
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2.5.3 Determination of Protein Concentration. 
2.5.3.1  Lowry Assay. 
A Lowry assay was used when levels of SDS prevented the use of a Bradford assay. A 
standard curve was set up from a 1 mg/mL BSA stock at 50, 100, 150, 200, 250, 350 and 
500 µg/mL in a total volume of 200 µL in H2O.   Test samples were diluted 1:20 in a total 
volume of 190 µL in H2O.   Lowry Reagent C (0.6 mL) was added to each tube and incubated 
for 20 min at RT.   Lowry Folin Reagent (0.06 mL) was added to each tube and incubated for 
30 min at RT.   An aliquot (200 µL) of each sample was added to a 96 well plates and 
absorbances read at 600 nm. 
 
2.5.3.2  Bradford Assay. 
A standard curve was set up from a 1 mg/mL BSA stock  at 30, 60, 90, 120, 150, 180 
and 210 µg/mL in 0.15 M NaCl.   Test samples were diluted 1/10 with 0.15 M NaCl in a total 
volume of 100 µL. Bradford reagent (1 mL) was added to each standard and test solution 
and incubated at room temperature for 2 min.   Samples (200 µL) were loaded in duplicate 
into 96 well plates, and absorbances read at 600 nm. 
 
2.5.4 Recombinant Protein Expression. 
2.5.4.1  His-Tagged protein. 
2.5.4.1.1 Optimisation of protein expression. 
A 10 mL LB Broth (50 µg/mL ampicillin) was inoculated with E. coli BL21 containing the 
recombinant gene and incubated overnight at 37°C.  The following day, a 100 mL broth (50 
µg/mL ampicillin) was inoculated with 1 mL of the overnight culture.   The 100 mL broth was 
incubated at 37°C for 2 h, then a 1 mL sample was taken to serve as a 0-h sample and IPTG 
was added at a final concentration of 1 mM.    Every hour after that for 5 h, 1 mL samples 
were obtained.   Cells samples were centrifuged and lysed using the Whole Cell Lysate 
Method.  Protein concentration was determined using a Bradford assay, and 20 µg of protein 
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was electrophoresed on a SDS-PAGE gel.   Samples were compared to determine the 
optimum growth time for expression of recombinant protein. 
 
 
 
2.5.4.1.2 Expression of protein. 
His-Tagged proteins were purified by Immobilised Metal Affinity Chromatography 
(IMAC).    Briefly, 200 mL cultures containing 50 µg/mL Ampicillin were inoculated with 2 mL 
of an overnight culture of the recombinant E. coli.  Cultures were grown for 2 h before IPTG 
was added to a concentration of 1 mM.   Cultures were grown for another 3 h to allow the 
production of recombinant protein.   Cells were harvested by centrifugation at 5000 x g for 5 
min at 4°C.   Cells were lysed by the freeze/thaw Method, and the supernatant was 
recovered and added to the IMAC column. 
 
2.5.4.1.3 Preparation of IMAC column. 
Chromatography columns were wet with water prior to the addition of 1 mL of 
sepharose.   The solid phase was allowed to settle, before 10 column volumes of water were 
allowed to pass through the column.   Nickel sulfate solution was added to the column.   10 
more column volumes of water were passed through the column.  The column was then 
equilibrated in 5 volumes of 1x Start Buffer. 
 
2.5.4.1.4 Optimisation of Imidazole concentration. 
To determine the optimal Imidazole concentration for elution of the his-tagged protein, 
the bound protein was eluted with 250 mM Imidazole and 500 mM Imidazole.   Depending on 
where the recombinant protein was found in the eluates, the imidazole concentration was 
lowered or raised accordingly.  This procedure was performed until the optimal concentration 
for elution was reached. 
 
2.5.4.1.5 Purification of recombinant Haemolysin. 
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Cell lysate was filter sterilised through a 0.45 µM filter before 20 mg was added to the 
IMAC resin.   The column was then rotated end over end for 30 min at room temperature.   
The IMAC column was then washed with 4 column volumes of IMAC Wash Buffer.   Elution 
of bound protein was achieved by increasing the imidazole concentration in the IMAC Start 
Buffer.   1 mL fractions were taken at each elution concentration to a total of 10 mL.   Eluates 
were analysed for the presence of the recombinant protein by SDS-PAGE analysis. 
 
2.5.4.2  GST Fusion Protein. 
2.5.4.2.1 Expression of Protein. 
Escherichia coli BL21 containing plasmid encoding for GST-fusion protein was grown 
overnight in a 10 mL LB broth.   A 1 litre LB Broth was then inoculated with 10 mL of the 
overnight culture and grown at 28°C overnight in the presence of 10mM IPTG.   The 
following day, cells were harvested and resuspended in 20 mL of PBS containing 4 mg/mL 
Lysozyme.   Cells were fractured by 5 freeze/thaw cycles in dry ice/ethanol and 37°C water 
baths.    The lysate was DNase treated for 30 min at 37°C and then TritonX-100 (1%) was 
added.  The lysate was clarified by centrifugation at 5000 x g for 10 min followed by filtration 
through a 0.2 µM syringe filter.  Lysate was then loaded onto the column. 
 
2.5.4.2.2 Preparation and regeneration of Glutathione agarose beads. 
Glutathione-Agarose beads were re-hydrated in 10 volumes of dH2O for 2 h.   The gel 
was then washed in 30 volumes of dH2O to remove any sucrose.   The gel was then washed 
in 5 volumes of PBS to prepare the gel for binding of protein.   To regenerate the column 
after the protein has been eluted, the gel was washed in 5 column volumes of GST 
regeneration buffer I, followed by 5 volumes of PBS, 5 volumes of GST regeneration buffer II, 
and finally stored in 2 M NaCl.  Prior to re-use the gel was washed in 5 volumes of PBS to 
wash out any NaCl. 
 
2.5.4.2.3 Purification of GST-fusion protein. 
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The cell lysate was loaded onto the column and the flow through collected.   The flow 
through was then re-loaded onto the column and the procedure repeated 3 times.   The 
bound protein was washed with at least 20 volumes of PBS-T and then 5 volumes of PBS.   
Elution of bound protein was accomplished by washing the gel in GST Elution Buffer 
2.5.5 Polyacrylamide Gel Electrophoresis. 
2.5.5.1  SDS-PAGE. 
Polyacrylamide mini-gels were prepared according to the following formula: 
 
12.5% Resolving gel. 
Water................................................... 4.22 mL 
1.5 M Tris (pH 8.8) ................................ 2.5 mL 
10% SDS............................................... 0.1 mL 
Bis-Acrylamide (40%)........................ 3.135 mL 
10% Ammonium persulfate ................. 0.05 mL 
TEMED................................................ 0.01 mL 
Total ....................................................... 10 mL 
 
4.5% Stacking Gel 
Water..................................................... 2.2 mL 
0.5 M Tris (pH 6.8) ................................ 2.5 mL 
10% SDS............................................... 0.1 mL 
Bis-Acrylamide (40%)........................ 3.135 mL 
10% Ammonium persulfate ................. 0.05 mL 
TEMED................................................ 0.01 mL 
Total ......................................................... 5 mL 
 
SDS-PAGE loading buffer was added to samples to be analysed in a 4:1 sample to 
buffer ratio.   Prepared samples were then heated to 100°C for 10 min in a heat block.   SDS-
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PAGE gel wells were loaded with 20 mL of sample using a syringe.   SDS-PAGE was 
performed at 60 V for 40 min then 180 V for 30 min.    Maxigels were electrophoresed for 30 
min at 60 V, then for ~3 h at 180 V. 
 
2.5.5.2  Visualisation of Proteins. 
2.5.5.2.1 Coomassie Staining. 
The gel was stained in Coomassie Blue Stain for at least 1 h with gentle agitation, and 
then destained in Destaining solution, with several solution changes, until protein bands were 
clearly visible. 
 
2.5.5.2.2 Silver Staining. 
Acrylamide gels were fixed overnight in Silver Stain Fixing solution.   Gels were 
transferred into a clean glass bowl and washed in de-ionised water 3 times for 15 min each.  
Gels were incubated in the Silver Stain Staining Solution for 15 min.   The gels were washed 
in de-ionised water 3 times for 10 min each.   Protein bands was developed in Silver Stain 
Developing Solution for 2-10 min before being transferred into de-ionised water.   Rinsing the 
gels in Silver Stain Stop Solution stopped development of the colour.   Polyacrylamide gels 
were stored in de-ionised water. 
 
2.5.5.3  Western Blot. 
2.5.5.3.1 Transfer of Protein to Nitrocellulose Membrane. 
Following PAGE, the gel and two scotch-brite pads were soaked in Western Blot 
Transfer Buffer.   A piece of Nitrocellulose membrane and 4 pieces of Whatman paper were 
cut slightly larger than the gel and soaked in Western Blot Transfer Buffer.   To assemble the 
Western Blot, a pad was placed on the apparatus, followed by the gel, the membrane, the 
Whatman paper, and another pad.   The apparatus was assembled according to the 
manufacturer’s instructions, and the Western Blot was performed at 70 V for at least 1 h. 
 
2.5.5.3.2 Development of Western Blot. 
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The nitrocellulose membrane was incubated shaking for 1 h in TBS/Skim milk (5% v/v) 
at room temperature.   The blocking solution was discarded and the membrane was washed 
3 times in TBS/Tween (0.05% v/v).  The Primary Antibody was diluted in TBS/Skim Milk (1% 
v/v), added to the membrane and incubated for at least 1 h at room temperature or overnight 
at 4°C.   The Primary Antibody Solution was discarded and the membrane washed twice for 
5 min in TBS/Tween (0.05% v/v).  The Detection Antibody was diluted in TBS/Skim Milk (1% 
v/v), added to the membrane and incubated for 1 h shaking at room temperature.   The 
membrane was washed twice in TBS/Tween (0.05% v/v), once in TBS, then equilibrated in 
TE Buffer.   The membrane was developed by the addition of Western Blot Substrate 
Solution and incubated in the dark until colour developed. 
 
2.5.6 2D Gel Electrophoresis. 
Outer membrane extracts were resuspended in 150 µl of 2D-gel Sample Buffer, then 
added to the IPG strip and was allowed to re-hydrate overnight to absorb the sample.   
Isoelectric focusing was performed using a step-wise protocol with a final voltage of 6000 V 
equalling a total of 75 kV h.   Following isoelectric focusing, the IPG strips were equilibrated 
in 2D-gel Equilibration Buffer I twice for 30 min, then 2D-gel Equilibration Buffer II twice for 
30 min.   The IPG strips were then transferred to the wells of pre-cast 8-20% Criterion gels, 
and overlayed with 1% molten agarose in TAE.   Electrophoresis was then performed for 1 h 
at 200 V, or until the dye front reached the end of the gel.   Visualisation was performed 
using Coomassie staining or Silver Staining. 
 
2.5.7 Haemolysin Assay. 
For the haemolysin assay, native haemolysin was prepared by freeze/thawing B. 
hyodysenteriae cells in PBS.   Sheep RBC (SRBC) were washed 3X in PBS after 
centrifugation at 2000 x g for 5 min, and 100 µL of packed, washed SRBC were resuspended 
in 10 mL of PBS.   Control SRBC for reference were prepared by resuspending 100 µL of 
packed SRBC in 10 mL of sterile, deionised H2O.   For the assay, 90 µL of SRBC were 
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added to 96 well plates, followed by 10 µL of the test sample, with the additional of 
calcium/magnesium chloride where appropriate.   The SRBC in H2O served as the positive 
control, and the negative control was SRBC in PBS.   After incubation at 37°C for 1 h, the 96 
well plates were read on an ELISA plate reader at 600 nm, with the SRBC in PBS serving as 
the blank.   The results were expressed as a percentage of the positive control SRBC 
haemolysis. 
2.6 Animal Experimentation Methods. 
All experiments involving animals were carried out with the approval of the RMIT 
AEEC. 
 
2.6.1 Buffers and Reagents. 
2.6.1.1 ACK Lysing Buffer 
NH4Cl (0.15 M), KHCO3 (10 mM) and Na2EDTA (0.1 mM) dissolved in H2O, pH to 7.3 
with 1N HCl, and filter sterilised through a 0.2 µM filter. 
 
2.6.1.2 Carbonate Buffer 1 
NaHCO3 (8.4 g) was added to 100 mL of H2O.  Stored at 4°C. 
 
2.6.1.3 Carbonate Buffer 2 
Na2CO3 (10.6 g) was added to 100 mL of H2O. Stored at 4°C. 
 
2.6.1.4 Complete Dulbecco’s modified eagle’s medium (DMEM) 
5X DMEM ...................................................... 100 mL 
HEPES Buffer (1 M) ........................................ 10 mL 
Sodium bicarbonate (7.5 %)......................... 13.5 mL 
L-Glutamine (200 nM) .................................... 4.5 mL 
Milli-Q H2O..................................................... 372 mL 
NCS....................................................................10% 
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2.6.1.5 ELISA Substrate Solution. 
For 1 plate, immediately before use, 5 mL of TMB substrate reagent A was mixed with 
5 mL of TMB substrate reagent B, and stored in the dark until use. 
 
 
2.6.1.6 ELISPOT Blocking Buffer. 
NCS (5% v/v) was filter sterilised into sterile PBS.   Made fresh as required. 
 
2.6.1.7 ELISPOT Coating Buffer. 
Carbonate buffer 1 (4.53 mL) was added to Carbonate buffer 2 (1.82 mL) and diluted to 
100 mL with H2O.   The pH was adjusted to 9.6 with either Carbonate buffer 1 or 2. Made 
fresh as required. 
 
 
2.6.1.8 ELISPOT Detection Solution. 
BCIP/NBT solution, prepared according to the manufacturers instructions.   BCIP (100 
µL) and NBT (100 µL) was added to 10 mL of BCIP/NBT Buffer. 
 
2.6.1.9 PBS. 
Phosphate buffer (0.01 M), 0.0027 M potassium chloride and 0.137 M sodium chloride, 
pH 7.4. 
 
2.6.1.10 PBS/T 
Phosphate buffer (0.01 M), 0.0027 M potassium chloride and 0.137 M sodium chloride, 
pH 7.4, autoclaved at standard conditions.   Tween 20® (0.05% v/v) was then added. 
 
2.6.1.11 RPMI/NCS. 
New Calf Serum (5% v/v) was filter sterilised, added to RPMI and stored at 4°C. 
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2.6.1.12 RPMI/NCS/Abs. 
New Calf Serum (5% v/v) was filter sterilised and added to RPMI.   
Penicillin/Streptomycin (0.1% v/v) was then added to the RPMI and stored at 4°C. 
 
2.6.2 Plasmid Stability Studies. 
STM-1 vaccines containing expression vectors was grown overnight in the presence of 
the selective antibiotic (kanamycin or ampicillin).   The number of viable cells in this initial 
culture was enumerated and a 10-3 dilution was inoculated into 10 mL of LB broth without 
antibiotics.    
 
After incubation overnight at 37°C, viable cell counts were performed in triplicate on the 
second culture, plating the dilutions onto both LB agar and LB/Antibiotics agar.   A 10-3 
dilution of the second culture was inoculated into a third LB broth without antibiotics and 
grown overnight at 37°C.   This process was repeated for 5 days, or until the number of 
viable cells on the plates with antibiotics was 1% of the total viable cells. 
 
2.6.3 Macrophage Survival Experiment. 
The mouse macrophage cell line J774 was seeded at 1 x 105 per well in 24 well plates 
and allowed to adhere overnight.   The following day, the J774 cells were exposed to 1 x 106 
colony forming units (cfu) of the S. typhimurium vaccine strains and invasion was allowed to 
occur for 1 hour.   Following the invasion incubation, the cells were washed 3 times in PBS, 
before DMEM/Gentamycin was added to kill any extracellular bacteria.    
 
At 0, 2, 8 and 24 hours, the appropriate wells were washed 3X in PBS to remove any 
residual gentamycin, and the macrophages were lysed in PBS with 0.5% v/v Triton X-100.   
The lysate was recovered and plated onto LB agar at several dilutions. 
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2.6.4 Vaccination with STM-1. 
Cultures of STM-1 were grown for vaccination using the following method.   A 10 mL 
LB broth containing the appropriate antibiotic was inoculated from a –70°C Stock of STM-1 
and grown overnight at 37°C.   The following day, a 100 mL LB broth containing the 
appropriate antibiotic was inoculated with 1 mL of the overnight culture.  This culture was 
incubated for 3-5 h at 37°C, until STM-1 reached an O.D.600 of about 0.6.   The STM-1 were 
recovered by centrifugation at 5000 x g for 10 min at 4°C.  The cell pellet was washed twice 
in 10 mL of PBS, before being resuspended at a concentration of 2 x 1010 cells/mL.   Mice 
were vaccinated with 109 cells/50 mL of STM-1 via gastric intubation. 
 
2.6.5 Vaccination with Recombinant Protein 
For the initial vaccination, recombinant protein (50 µg) was combined with an equal 
volume of complete Freund’s adjuvant.    Mice were vaccinated I.P. with 50 µL of the 
protein/Freund’s solution.   Three and six weeks post-vaccination, 50 mg of recombinant 
protein was mixed with and equal volume of incomplete Freund’s adjuvant, and mice were 
vaccinated I.P. with 50mL of the protein/Freund’s mixture. 
 
2.6.6 Vaccination with DNA vaccine. 
DNA from the Plasmid Maxipreps was diluted to a final concentration of 1 mg/mL DNA 
in 0.9% NaCl.   Mice were vaccinated with the DNA vaccine by injecting 50 µL of the DNA 
Vaccine Preparation into each thigh muscle 3 times, 3 weeks apart. 
 
2.6.7 Challenge with Brachyspira hyodysenteriae. 
B. hyodysenteriae were grown in Kent media for 3-5 days until motility was observed 
under dark field microscopy, indicating mid-log phase of growth.   Cells were recovered by 
centrifugation and washed twice in PBS.   Cells were resuspended in PBS at 109 cells/mL.  
The challenge was administered at 108 cells per mouse via gastric intubation. 
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2.6.8 Recovery of Brachyspira hyodysenteriae. 
Four weeks post challenge, mice were sacrificed and their caecum removed, weighed 
and photographed.   Caecum contents were homogenised in PBS.   Caecal homogenate was 
added to 20 mL of molten TSA (50°C, to which 5% sheep blood and spectinomycin was 
added) and poured into Petri dishes at 10-2, 10-3 and 10-4 dilutions.   The plates were 
incubated under anaerobic conditions for 3-5 days, then haemolytic colonies were 
enumerated. 
 
A loop of the caecal homogenate was also streaked onto SBA parallel to slices cut into 
the surface of the agar, according to the method of Calderaro et al.   The colonisation of B. 
hyodysenteriae was then scored according to the amount of haemolysis observed throughout 
the agar slices. 
 
2.6.9 Blood collection. 
Mice were bled by retino-orbital puncture, and the red blood cells pelleted by 
centrifugation at 1000 x g for 10 min.   Typically 100-300 µL of blood was collected.   The 
serum was aspirated and stored at –20°C. 
 
2.6.10 ELISA for serum antibody levels. 
Purified antigen was diluted to 1 mg/mL in Carbonate Coating Buffer and 100 µL was 
added to 96 well plates and allowed to incubate overnight at 4°C.   Plates were washed in 
PBS 3 times and then blocked for 1 h at room temperature in PBS/Skim milk (5% v/v).   
Serum was diluted in PBS/Skim milk (1% v/v) at the appropriate concentration and 100 µL 
was added to each well in duplicate.   Serum was incubated for 2 h at 37°C.   Plates were 
washed 3 times in PBS/T, and any remaining liquid was removed by tapping the plates on 
paper towels.   Detection antibody (anti-IgG (H+L)) was then diluted 1:3000 in PBS/T and 
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100 µL was added to each well.   The detection antibody was incubated for 1 h at room 
temperature.   Plates were then washed 3 times in PBS/T and twice in PBS.   Any remaining 
liquid was removed from the wells by patting the plates on absorbent paper towels.   The 
substrate was added, 100 µL to each well and allowed to develop for 30 min.   The reaction 
was then stopped by the addition of 50 µL of 0.2 N H2SO4.   Plates were then read on and 
ELISA plate reader at 600 nm. 
 
2.6.11 ELISPOT assay for cytokine producing cells. 
2.6.11.1  Collection of Spleen Cells. 
Mice were sacrificed and their spleens collected in sterile RPMI/NCS/Abs.   Spleens 
were placed in petri dishes, crushed with the end of a 3 mL syringe and resuspended in 5 mL 
of RPMI/NCS and filtered through a cell strainer.   The cells were recovered by centrifugation 
at 1600 x g for 5 min at 4°C and resuspended in 5 mL of ACK Lysing Buffer.  After 5 min, 5 
mL of RPMI/NCS was added and the cells recovered by centrifugation at 1600 x g for 5 min 
at 4°C.   The lymphocytes were washed in RPMI/NCS 3 times, and resuspended in 1 mL of 
RPMI/NCS.   Recovered lymphocytes were counted by diluting 10 µL of the cell suspension 
in 90 µL of PBS.   The solution to be counted was prepared by adding 10 µL of Trypan Blue 
reagent, 80 µL of PBS and 10 µL of the diluted lymphocyte preparation.   After 5 min, 10 µL 
of the stained cells was loaded onto a haemocytometer, and the number of viable cells 
counted under an inverted microscope. 
 
2.6.11.2  ELISPOT assay. 
The ELISPOT plate was prepared by wetting the membrane with 100% Methanol for 5 
min, followed by three washes in sterile PBS.   Capture antibody (100 µL) was diluted in 
ELISPOT Coating Buffer and added to the wells (1 µg/mL IL-4, 0.5 µg/mL IFN-γ) and 
incubated overnight at 4°C.   The capture antibody was discarded and the wells washed 3 
times with 200 µL of PBS/T.   The wells were blocked with 100 µL of ELISTPOT Blocking 
Buffer and incubated at room temperature for 3 h.    
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The wells were washed three times with 200 µL of PBS/T, then 100 µL of RPMI/NCS 
(5%v/v) was added and the plates were incubated for 10 min at 37°C and 5% CO2.   The 
RPMI was discarded and the cells were seeded in triplicate with 1x106 cells in 90 µL per well.   
Antigen (Recombinant SmpA or Recombinant HylA) was added at 25 µg/mL, and Concavalin 
A was added to the positive control wells at a concentration of 1 µg/mL.   The negative 
control was unstimulated spleen cells.   The spleen cells were incubated with the mitogen for 
20 h at 37°C and 5% CO2. 
 
The following day, the spleen cells were discarded and the plates washed 5 times in 
PBS/T, and any remaining wash solution removed by tapping the plates on absorbent paper.   
The Biotin labelled detection antibody was then diluted 1:5000 in PBS/NCS (5% v/v), and 
100 µL was added to the wells and incubated at room temperature.   After 2 h of incubation, 
the wells were washed in PBS/T 5 times and the remaining wash solution removed by 
tapping the plates on absorbent paper towel.   After washing, 100 µL of Alkaline phosphatase 
labelled streptavidin was added to the wells, and incubated at room temperature for 2 h.   
The streptavidin solution was discarded and the plates were washed 7 times in PBS/T and 3 
times in PBS and any remaining liquid was removed by tapping the plates on absorbent 
paper.   The ELISPOT was developed by the addition of 50 µL of ELISPOT substrate 
solution and incubated at room temperature in the dark until blue spots developed.   The 
reaction was then stopped by washing the plates 3 times in de-ionised water.   Spots were 
enumerated under a dissecting microscope. 
 
2.6.12 Statistical analysis. 
Statistical analysis was performed using the student’s TTEST function of Microsoft 
Excel.   The critical value below which the hypothesis was rejected was 5% (P = 0.05). The 
error bars on histograms represents standard deviations. 
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Primer Name Sequence (5’ ? 3’) Tm
BlpAEFG1 AGT GTT ATG AAA AAG AAT TA 49 
BlpAEFG2 TTA GAG CCT TCT TTA GAT GA 54 
HlyAORF1 AGC TGG ATC CGA TGA AAT TAA AGA TGT TGT 66 
HlyAORF2 ACA TGG ATC CAT TTA CGG GAA ATT TAA ATA 63 
HlyA1 AAT AGG ATC CAA CAA TAT ACA ATT TAA GGA GA 62 
HlyA2 CCG GAT CCA GAC ATA ATT CTA TTT ACG GGA 67 
HlyAClus1 AGG GTA AAT ATG GAC TTA AAT C 55 
HlyAClus2 GCC CCA TTT ATA ATT AAA TAG G 57 
SmpA1 ATG GAT CCG TTC TTA AAT AAT ACC TAA TC 61 
SmpA2 ATT AGG ATC CGC CAG TCA AAT AAT CTT TTA AT 65 
SmpBORF1 AAC GGG ATC CTA CAA TAT GTT AAT TCT TTA 62 
SmpBORF2 TCA AGG ATC CAA CAA AAA AAT TTT CAC ACT 65 
South53801 TCT CCT CCA CTC ACT ACT AC 58 
South53802 TGT ACT AGC TGG TGT AAG TC 58 
SouthB2041 AGA GGC TAC ATC TGG TTC TG 60 
SouthB2042 AGC TCC CCA ATT TTC TTT AG 62 
VspABCD1 GAT AAG CAC CAG CAG CTC CT 64 
VspABCD2 TGT TAC TGC TAT ACT TAC AC 53 
VspAB1 TAA TTA TAC CAG CCA TTC CT 55 
VspAB2 AAT ATT TCC TGC TGC TTT AG 55 
VspCD1 TTA GAT AGT ATG TTT GAA CC 48 
VspCD2 AGG ACG ATC TGG ATA ATA AT 54 
VspEFGH1 TTA TCA GTC AGC ATT TCA TT 54 
VspEFGH2 ATT TCA TAG TCA AGC ATT CT 54 
Table 2.1 : List of Primers used in this study 
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Chapter 3 –Characterisation of smpB. 
3.1 Introduction. 
Two different B. hyodysenteriae antigens were chosen for examination in this study, 
based on review of the literature.   Outer membrane proteins are often utilised for vaccination 
purposes, as they are generally available to the host immune system early in the infection.   
The SmpA lipoprotein was chosen as it was the only outer membrane protein known that is 
not encoded by a multi-gene cluster.   A second antigen HlyA was chosen, as toxins are 
often good targets for vaccination.   The HlyA haemolysin will be discussed in following 
chapters. 
 
Previous characterisation of protein components of the outer membrane of B. 
hyodysenteriae revealed the existence of a 16 kDa immunodominant lipoprotein, SmpA 
(Sellwood et al., 1995; Thomas et al., 1992; Thomas & Sellwood, 1993).   Immunogold 
labelling revealed that SmpA is a membrane-associated lipoprotein that localises to the outer 
surface of the spirochete, and studies have demonstrated that SmpA is availably to 
antibodies on the surface of the cell (Thomas & Sellwood, 1992).   However, expression of 
the smpA gene is environmentally regulated, with decreased expression observed in swine 
post infection (Sellwood et al., 1995).   As SmpA expression is not decreased until late in the 
disease, it may still have the ability to induce immune responses that prevent establishment 
of the disease.   Monoclonal antibodies generated against the SmpA protein prevent the 
growth of B. hyodysenteriae in vitro (Thomas & Sellwood, 1992).   Although the function of 
SmpA remains unknown, antibodies directed against SmpA have the potential to inhibit the 
growth of B. hyodysenteriae.   SmpA has potential as a vaccine although as yet no 
investigation of this potential has been made. 
 
In initial experiments to clone smpA into expression vectors for vaccination via 
attenuated Salmonella typhimurium, sequence variation was observed in some strains of B. 
hyodysenteriae.   This result was unexpected and led to a further study of the sequence 
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variation of SmpA amongst B. hyodysenteriae strains.   Variation at the smpA locus has been 
observed in smpA before, although at the time no characterisation of the variation was made 
beyond DNA-DNA hybridisation (Turner et al., 1995).   The intensity of the hybridisation 
signal varied in several strains, and upon digestion with HindIII, some strains generated two 
reactive DNA fragments (Turner et al., 1995).   At the time the difference in the smpA locus 
was attributed both to sequence variation and the presence of a multiple smpA homologues 
in several strains (Turner et al., 1995). 
 
With this background, the aims of this chapter were: 
 
1) To determine the sequence at the smpA locus in B. hyodysenteriae 5380 and 
characterise the newly identified smpB; 
2) To investigate the distribution of smpB and smpA via DNA-DNA hybridisation; 
3) To determine the function of SmpB by knock-out mutagenesis; 
4) To investigate the relationship between the electrophoretic type (ET) and the presence of 
smpB. 
 
The results depicted in this chapter were published in Veterinary Microbiology (Holden 
et al., 2006).    
 
The newly identified smpB sequence was submitted to Genbank (Accession number: 
DQ223651) 
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3.2 Results. 
3.2.1 Discovery of smpB in Brachyspira hyodysenteriae 5380. 
PCR primers SmpA1 and SmpA2 were designed in the intergenic regions surrounding 
smpA from the reported sequence of B. hyodysenteriae B204 (Genbank accession X68401) 
(Figure 3.2).   The amplification conditions for the PCR were 92°C for 2 min followed by 35 
cycles of 92°C for 30 s, 50°C for 30 s, and 72°C for 1 min, then a final elongation at 72°C for 
7 min.   Amplification of smpA by PCR of B. hyodysenteriae B204 DNA generated a 750 bp 
product.   The same PCR in B. hyodysenteriae 5380 generated a 796 bp product (Figure 
3.1).   Analysis of the PCR products by RFLP revealed that the B. hyodysenteriae 5380 
smpA contains a unique HindIII site, cleaving the 796 bp product into ~450 bp and 300 bp 
fragments. 
 
The partial nucleotide sequence of five of the PCR products and full nucleotide 
sequence of two (covering both PCR product sizes) was determined to identify differences in 
the smpA gene.  Surprisingly, there were two classes of sequence. The first (from the smaller 
PCR product) was almost identical to that previously identified as smpA (Thomas and 
Sellwood (1993).   Analysis of the larger PCR product showed that the sequence of the DNA 
at the 5’ and 3’ ends of the PCR product was identical to the smpA sequence (this might be 
expected as the primer binding sites must be present).   However, the DNA sequence in the 
central regions of the PCR product was highly divergent, as is shown in Figure 3.2.  
Therefore, in some strains of B. hyodysenteriae there is an alternative to smpA, named 
smpB.   The GC content of smpB is ~32% compared to 25% for smpA. 
 
Pairwise alignment analysis of the entire ORF, including the signal sequence, revealed 
some sequence identity with smpA from B. hyodysenteriae (Figure 3.3).   The area of 
similarity is confined to the nucleotides encoding the N-terminal signal sequence, not the 
region encoding the mature protein.    
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GGATCCGTTCTTAAATAATACCATAATCAAAAAATATAAATGTTTCTAAAACAATTTTTCAAATAAGC
ATTAGAAATAATGTTTATTATAAATTTCATTTAAAGGAGTTCAAAATATGAACAAAAAAATTTTCACA
CTATTTTTAGTAGTTGCCGCATCTGCAATATTTGCAGTAAGCTGTAACAACAAAACAACAAATCCTAC
TTCCTCATCTGCTAATCTACCAGCTGTTGAAGTAAAAGCTCAAGATGTTGCAAAAGCATTAAAATCTA
TAGGTTCTTACAAAAATGGATCTCAAACTTGGGAATTTGGAGGAAAATTTGATTCTTTAAAAGCTTCT
GAAGATATAACAGGAACAGGAGATGATGGAGCAACTTCTGCTACAACTAAATCTGAAGTTAAAGCAAA
AATAGAATCAGCATTAAAGGCTATACGTGTTAATCCTACTGTAGTAGTGAGTGGAGGAGATAAAGGTG
GAGAAACTAAGATGACATTCAAAATAACTATAGAACCAGCAGATTCAAAAGTTACTTTTAATAATGAT
TTAAATGAATATAAGACTGATAAAGCAGGATGTACAATAGGACTTACACCAGCTAGTACAAAAAACTG
GAAATAAATAAAGAATTAACATATTGTAAAATATGCTTGTCATACAAAAAATTGAATTAAAAAACGGT
GTGAATATATATAATTATAATTGCACCAAAAACACAAACTATATATAACTATTATTCAAAAAATATTT
TATTTATCTTTCTAATTAAAAGATTATTTGACTGGCGGATCC 
 
Figure 3.2: Sequence of smpB of Brachyspira hyodysenteriae 5380.  
The 504 bp smpB ORF is underlined.   Primers used to amplify PCR products depicted in Figure 3.1 
are shown in green.   Primers used to amplify a PCR product suitable for cloning into pRSET-A with 
subsequent recombinant protein expression (Chapter 4) are shown in blue.   Primers used to 
distinguish smpA and smpB by PCR and DNA-DNA hybridisation are shown in purple.   The unique 
HindIII site is shown in red. 
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            1         11        21        31        41        51         
SmpA_B204     ATGAACAAAAAAATTTTCACACTATTTTTAGTAGTTGCCGCATCTGCAATATTTGCAGTA 
SmpA_B8044    ATGAACAAAAAAATTTTCACACTATTTTTAGTAGTTGCCGCATCTGCAATATTTGCAGTA 
SmpB          ATGAACAAAAAAATTTTCACACTATTTTTAGTAGTTGCCGCATCTGCAATATTTGCAGTA 
 
              61        71        81        91        101       111        
SmpA_B204     AGCTGTAACAACAAAACAACAAATCCTACTTCA--AACAGCTCAGAAAAAAAGA-TTGTT 
SmpA_B8044    AGCTGTAACAACAAAACAACAAATCCTACTTCA--AACAGCTCAGAAAAAAAGA-TTGTT 
SmpB          AGCTGTAACAACAAAACAACAAATCCTACTTCCTCATCTGCTAATCTACCAGCTGTTGAA 
 
              121       131       141       151       161       171        
SmpA_B204     ACAAAAG---AAGATTTTAAAAATGCTATAGAAGGTTTAA---CTTACAAAA-------- 
SmpA_B8044    ACAGAAG---AAGATTTTAAAAATGCTATAGAAGGTTTAA---CTTACAAAA-------- 
SmpB          GTAAAAGCTCAAGATGTTGCAAAAGCATTAAAATCTATAGGTTCTTACAAAAATGGATCT 
 
              181       191       201       211       221       231        
SmpA_B204     ----CTTGGGCATTTACTGGAAAAGGAAAATCATTTAAT--TTCGGAAGTCCTAT----A 
SmpA_B8044    ----CTTGGGCATTTACTGGAAAAGGAAAATCATTTAAT--TTCGGAAGTCCTAT----A 
SmpB          CAAACTTGGGAATTTGGAGGAAAATTTGATTCTTTAAAAGCTTCTGAAGATATAACAGGA 
 
              241       251       261       271       281       291        
SmpA_B204     ACTGTAGAGGCTACATCTGGTTCTGATTCATTAGCAGGGGTAGAAAAGGGATTTGGAAAT 
SmpA_B8044    ACTGTAGAGGCTACATCTGGTTCTGATTCATTAGCAGGTGTAGAAAAGGGATTTGGAAAT 
SmpB          ACAGGAGATGATGGAGCAACTTCTGCTACAACTAAATCTGAAGTTAAAGCA------AA- 
 
              301       311       321       331       341       351        
SmpA_B204     GCATTAAAATCAGCTTTAGCAGCTAAAGGAATTGAT---ACTGGAAATATAACTTTTG-- 
SmpA_B8044    GCATTAAAATCAGCTTTAGCAGCTAAAGGAATTGAT---ACTGGAAATATAACTTTTG-- 
SmpB          --AATAGAATCAGCATTAAAGGCTATACGTGTTAATCCTACTGTAGTAGTGAGTGGAGGA 
 
              361       371       381       391       401       411        
SmpA_B204     -ATAAAGGGGGAGCAAGTTCT-TCAGATAAAACATCTGTATCTTTCAAATTTACTCCTAA 
SmpA_B8044    -ATAAAGGTGGAGCAAGTTCT-TCAGATAAAACATCTGTATCTTTCAAATTTACTCCTAA 
SmpB          GATAAAGGTGGAGAAACTAAGATGACATTCAAAATAACTATAGAACCAGCAGATTCAAAA 
 
              421       431       441       451       461       471        
SmpA_B204     AGCTCTTGGAACATCAAATTTTGAAGAAAAATTAAAATCTT----CTGTAAAAGAAGTAG 
SmpA_B8044    AGCTCTTGGAACATCAAATTTTGAAGAAAAATTAAAATCTT----CTGTAAAAGAAGTAG 
SmpB          GTTACTTTTAATA--ATGATTTAAATGAATATAAGACTGATAAAGCAGGATGTACAATAG 
 
              481       491       501       511        
SmpA_B204     AAATAAAATTAACTCCTAAAGAAAATTGGGGAGCTTAA 
SmpA_B8044    AAATAAAATTAACTCCTAAAGAAAATTGGGGAGCTTAA 
SmpB          GACTTACACCAGCTAGTACAAAAAACTGGAAA---TAA 
 
Figure 3.3: Pairwise Alignment of Brachyspira hyodysenteriae smpA and smpB. 
A pairwise alignment of smpA from B. hyodysenteriae B204 and B8044 and smpB from B. 
hyodysenteriae 5380.   The first 92 bp (including the start codon) is identical in B. hyodysenteriae 
5380 and B204.   However, the region encoding the mature protein has very low identity. 
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SmpA  MNKKIFTLFLVVAASAIFAVSCNNKTTNPT------------------SNSS--EKKIVT 40 
SmpB  MNKKIFTLFLVVAASAIFAVSCNNKTTNPT------------------SSSVNLPAVEVK 42 
BmpC  MNKKILSIFVMVMALSLLSISCNNKKTTGTGDIGGGTTENTGTTEDTGNKEPEETRTILK 60 
      *****:::*::* *:::::*****.*. *                  ...      :. 
 
SmpA  KEDFKNAIEGLT-----YKTWAFTGKGKSFNFGSPITVEATSGSDSLAGVEKGFGNALKS 95 
SmpB  AQDVAKALKSIGSYKNGSQTWEFGGKFDSLKASEDITGTGDDGATSAT-TKSEVKAKIES 101 
BmpC  ASDLEAWLKNIPETSPVNNAIFTFSSGNFSGDTLSVESTGASSKVSADNVKTEVLNSLKS 120 
       .*.  ::.:      ::    .. .      :   . ..  *   .:. .  ::* 
 
SmpA  ALAA-KGIDTGNITFDKGGASSSDKTSVSFKFTPKALG----TSNFEEKLKSSVKEVEIK 150 
SmpB  VLKA-IRVNP---TVVVSGGDKGGETKMTFKITIEPADSKVTFNNDLNEYKTGKAGCTIG 157 
BmpC  LDKSKFKIKTTIGRSIFTGGNASGNSPLVATFEIEPANDSYVFDSNVEAIKS---KIKLS 177 
        :  :..        *.. ..:::  .: :. .     .. :  *:     :  
 
SmpA  LTPK--ENWGA 159 
SmpB  LTPASTKNWK- 167 
BmpC  LTVNDNYIWQ- 187 
      ** 
 
 
Figure 3.4: Multiple Sequence Alignment of SmpA, SmpB and BmpC. 
Analysis of SmpA, SmpB and BmpC from B. pilosicoli.   The first 31 AA of SmpA and SmpB are 
identical, with the AVSC peptidase site beginning at AA 19.   The remainder of the proteins show very 
little similarity.   BmpC from B. pilosicoli is a 16 kDa outer membrane protein that displays sequence 
similarity with SmpB, restricted to the signal peptide.    The gaps in the amino acid sequence 
represent deletions in the DNA.   Identical residues are represented by a *, highly conserved residues 
by a :, conserved residues by a ., and a gap by a -. 
  
 
Figure 3.5: Hydropathy Plot for SmpA and SmpB. 
The SmpB and SmpA proteins both contain an identical hydrophobic signal sequence in the first ~30 
amino acids.   The remainder of the proteins are predicted to be mostly hydrophilic. 
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Figure 3.6: pCRsmpBP Expression Vector. 
Figure 3.6a: In order to express smpB in E. coli, the entire smpB region including the promoter 
depicted in Figure 3.1a was cloned into pCR2.1. Figure 3.6b: Insertion of smpB into pCR2.1.   The 
insert was confirmed to be in the reverse orientation by DNA sequence characterisation, however this 
did not effect the expression of the protein (Figure 3.7). 
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gure 3.7: Immunoblot of Recombinant SmpA and SmpB in E. coli. 
 coli lysates (10mg) expressing recombinant SmpA or SmpB was subjected to SDS-PAGE and 
estern blot analysis.   The anti-5380 antisera only reacts with E. coli expressing recombinant SmpB 
ft panel).   The anti-B204 antisera only reacts with E. coli expressing recombinant SmpA (right 
nel).   Lane 1, E. coli expressing recombinant SmpA; Lane 2, E. coli expressing recombinant SmpB; 
ne 3, E. coli expressing recombinant GST-SmpB; Lane 4 and 5, MW Marker; Lane 6, E. coli 
pressing recombinant SmpA; Lane 5, E. coli expressing recombinant SmpB. 
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3.2.2 Analysis of the Predicted SmpB Protein. 
The predicted amino acid sequences, shown in alignment format in Figure 3.4, 
concurred with the DNA sequence, demonstrating that the majority of the predicted SmpA 
and SmpB protein sequence is different (38% identity with the signal sequence, 26% 
without). However, the amino acid sequence of the first 31 amino acids, which comprise the 
signal peptide and the first 9 amino acids of the mature protein, are identical.  As previously 
described (Thomas & Sellwood, 1993) smpA encodes a 159 amino acid protein with a 
predicted molecular mass of 16.8 kDa.  The smpB sequence encodes a larger protein of 167 
amino acids with a predicted molecular mass of 17.6 kDa. 
 
The N-terminus of SmpB resembles a lipoprotein signal sequence, which is present in 
both SmpA and SmpB and cleaved to generate the mature protein.   The peptidase cleavage 
site AVSC at residues 19-22 is conserved in both predicted proteins and the lipid is predicted 
to be attached to the post-cleavage N-terminal cysteine.   The 9 amino acids following the 
cleavage site comprise an identical hydrophilic region; however that is the extent of the 
similarity.   The signal sequence is hydrophobic and consistent with its role to anchor the 
protein in the membrane prior to acylation (Figure 3.5).   SmpA contains a GTP-binding motif, 
however SmpB does not contain the GTP-binding motif indicating that the function of SmpB 
may be different from SmpA.   However, as BLAST analysis returns no significant matches to 
known proteins, the function of SmpB, like SmpA, remains unknown. 
 
The gene encoding SmpB was amplified by PCR and cloned into the TA cloning vector 
pCR2.1 (Figure 3.6).   This enabled the gene products to be expressed after transformation 
of E. coli Top10F.   E. coli expressing recombinant SmpA was supplied by George Moutafis.   
Western blot analysis showed that the recombinant proteins that were expressed in E. coli 
only reacted with polyclonal antisera raised against that particular strain (Figure 3.7).  
Recombinant SmpA from B. hyodysenteriae P18A only reacted with polyclonal sera raised in 
rabbits against B. hyodysenteriae P18A.  Similarly, the SmpB recombinant protein from B. 
hyodysenteriae 5380 only reacted with polyclonal sera raised in rabbits against B. 
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hyodysenteriae 5380.  The mature SmpB protein is unique among known protein sequences. 
Using the predicted protein sequence of SmpB in a BLAST search (Altschul et al., 2005) of 
the NR SwissProt/TrEMBL database reveals significant similarity with only BmpC of B. 
pilosicoli (Figure 3.4).   The sequence similarity between BmpC and SmpB is largely confined 
to the amino acids comprising the signal sequence.   When only the mature peptide (signal 
sequence removed) was used in a BLAST search, there was no significant matching protein. 
 
3.2.3 Distribution of smpB Analysed by PCR. 
To determine the distribution of the smpB gene amongst B. hyodysenteriae strains a 
PCR was developed to differentiate between smpA and smpB.   The primers South53801, 
South53802, SouthB2041 and SouthB2042 were designed from the unique regions of DNA 
sequence (Figure 3.2), and the multiplex PCR was optimised.   The conditions of the 
multiplex PCR were 92°C for 2 min followed by 35 cycles of 92°C for 30 s, 50°C for 30 s, and 
72°C for 1 min, then a final elongation at 72°C for 7 min.   All strains tested generated either 
a 320 bp product (smpA) or a 260 bp product (smpB) (Figure 3.8).   No strain produced both 
products, indicating that no strain contains both smpA and smpB. 
 
3.2.4 Distribution of smpB Analysed by DNA-DNA Hybridisation. 
This investigation has revealed some polymorphisms at the smp locus (Figure 3.8).  It 
is assumed that the variation does occur at a single locus, although the PCR analysis cannot 
preclude that some strains may contain both the smpA and smpB genes with slight variations 
in the primer sequences.   DNA-DNA hybridisation was initially performed with the entire 
smpA region, including the flanking DNA, with HindIII digested genomic DNA as the template 
(Figure 3.9).   All strains with the exception of B8044 hybridised with the probe and the 
strains containing smpB displayed a larger band indicative of a double band produced by the 
presence of the novel HindIII site in smpB (Figure 3.2).   With the exception of B8044, this 
result is as expected based on the results of Turner et al. (1995), where a HindIII 
polymorphism was identified. 
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Figure 3.8: Multiplex PCR of smpA and smpB.   
Multplex PCR with primers to amplify both smpA and smpB.   B. hyodysenteriae strains containing 
smpA only amplify smpA, and those containing smpB only amplify smpB.  Lane 1, MW marker; Lane 
2, 5380; lane 3 , P18A; Lane 4, B204; Lane 5, 8044; Lane 6, G131; Lane 7, FMV-89; Lane 8, A1; Lane 
9, R7273; Lane 10, 8930; Lane 11, Y32; Lane 12, T70A; Lane 13, Williams B; Lane 14, B78T; Lane 
15, Vld; Lane 16, B169 
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Figure 3.9: DNA-DNA hybridisation of the entire smpA. 
DNA-DNA hybridisation was performed with the entire smpA region as in Turner et. al (1995), after 
digestion of genomic B. hyodysenteriae DNA with HindIII.   All strains with the exception of B8044 
reacted with the probe from B. hyodysenteriae B204.   Lane 1, B204; Lane 2, P18A; Lane 3, B8044; 
Lane 4, B78T; Lane 5, Vld; Lane 6, WAA1; Lane 7, A1; Lane 8, 5380; Lane 9, 8930; Lane 10, R7273; 
Lane 11, T70A; Lane 12, G131. 
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Figure 3.10: DNA-DNA hybridisation of Brachyspira hyodysenteriae smpA.  
Figure 3.10a: Hybridisation of HindIII digested DNA with B. hyodysenteriae B204 smpA probe, 
synthesised from the PCR product in Figure 3.8.   Only strains that generated the smaller DNA 
fragment in Figure 3.1 reacted with this probe.   The B8044 strain did not react with the entire smpA 
probe from B204 (Figure 3.9), or the smpB probe from 5380 (Figure 3.11), indicating a potentially 
different sequence.   Figure 3.10b: B. hyodysenteriae 8044 smpA probe.   Lane 1, B204; Lane 2, 
P18A; Lane 3, B8044; Lane 4, B78T; Lane 5, Vld; Lane 6, WAA1; Lane 7, A1; Lane 8, 5380; Lane 9, 
8930; Lane 10, R7273; Lane 11, T70A; Lane 12, G131. 
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Figure 3.11: DNA-DNA hybridisation of Brachyspira hyodysenteriae smpB.  
Hybridisation of HindIII digested DNA with B. hyodysenteriae 5380 smpA probe, synthesised from the 
PCR product in Figure 3.8.   Only strains containing smpB reacted with the 5380 probe.   Lane 1, 
B204; Lane 2, P18A; Lane 3, B8044; Lane 4, B78T; Lane 5, Vld; Lane 6, WAA1; Lane 7, A1; Lane 8, 
5380; Lane 9, 8930; Lane 10, R7273; Lane 11, T70A; Lane 12, G131. 
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Figure 3.12: DNA-DNA hybridisation of Brachyspira hyodysenteriae flaA. 
In order to analyse the lack of hybridisation with B8044 chromosomal DNA with either the smpA or 
smpB probes, a southern blot was performed using flaA as a control.    The lower band corresponds to 
the flaA sequence.   The B8044 DNA did react with the FlaA probe, indicating that the DNA is 
available for binding of the probe.   The upper band is the same band in Figure 3.9.  The gel was 
unable to be destained completely before the next blot.   Lane 1, B204; Lane 2, P18A; Lane 3, B8044; 
Lane 4, B78T; Lane 5, Vld; Lane 6, WAA1; Lane 7, A1; Lane 8, 5380; Lane 9, 8930; Lane 10, R7273; 
Lane 11, T70A; Lane 12, G131. 
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Figure 3.13: Attempted Knock-out mutagenesis of smpB. 
Figure 3.13a: Knock-out plasmid constructed with smpB, and the kanamycin cassette 
inserted into the HindIII site.   Figure 3.13b: Confirmation of the presence and orientation of 
the kanamycin cassette.   Lane 1, Lambda PstI marker; Lane 2, pBSmpBKan digested with 
EcoRI.   Figure 3.13c: Isolated kanamycin resistant colonies. Lane 1, Lambda PstI marker; 
Lane 2, Negative control; Lane 3, B. hyodysenteriae 5380 smpB PCR; Lanes 4-9 smpB PCR 
of isolated colonies.
 115
 116
To further investigate the distribution of the novel regions of DNA contained in smpA and 
smpB, the 320bp smpA and 260bp smpB PCR products from Figure 3.8 were labelled with 
DIG-dNTP.   DNA-DNA hybridisation confirmed that strains contained either smpA or smpB, 
but not both.   Probes synthesised from smpA hybridised with strains that generated the 
smpA PCR product, with the exception of B8044 (Figure 3.10).   Probes synthesised from 
smpB hybridised with strains that generated the smpB PCR product (Figure 3.11).   There 
was no cross reactivity between the smpA probe and smpB, nor between the smpB probe 
and smpA.   This evidence, coupled with the PCR analysis, strongly indicates that the 
variability occurs at a single locus and that B. hyodysenteriae contains a gene encoding 
either the SmpA or SmpB protein, but not both. 
 
B. hyodysenteriae B8044, although producing the smpA PCR product, did not react 
with the smpA probe from strain B204 (Figure 3.9a).   The B8044 smpA product was 
characterised by DNA sequence analysis and found to contain 2 single base substitutions 
relative to B204 (Figure 3.3).   However, these mutations should not be enough to effect the 
binding of the probe.   The B8044 smpA product from Figure 3.8 was DIG-labelled and DNA-
DNA hybridisation was performed (Figure 3.10b).   Only the B8044 DNA reacted with the 
probe, indicating that the B8044 smpA probe can react, but not with a probe created from 
other strains.   A control probe was used to confirm that the DNA of strain B8044 was in fact 
able to react with B. hyodysenteriae DNA.   A labelled probe was synthesised from flaA of 
strain B204, which is conserved across several species of Brachyspira.    All strains of B. 
hyodysenteriae reacted with this probe (Figure 3.12), indicating that the lack of hybridisation 
of B8044 was not due to problems with the DNA preparation or hybridisation procedure.   
The lack of hybridisation of B8044 smpA with probes generated from other strains is 
unexplainable at this time. 
 
3.2.5 Attempted Knock-out Mutagenesis of smpB. 
Attempts were made to knock-out smpB of B. hyodysenteriae 5380 by inserting a 
Kanamycin resistance cassette into the unique smpB HindIII site.   pBluescript was digested 
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with SpeI and XhoI and self-ligated to remove the HindIII site.   To obtain smpB, pCRsmpB1 
(Figure 3.13) was digested with BamHI, and then ligated into the BamHI sites of the 
aforementioned modified pBluescript to form pBsmpB.   To obtain the Kanr cassette, pMW2 
was digested with HindIII.   The pMW2 Kanr cassette was then ligated into the HindIII 
digested pBsmpB to form pBsmpBKan (Figure 3.13a).   The kanamycin resistance cassette 
was inserted in the reverse orientation (Figure 3.13b).   Despite numerous attempts using 
different transformation methods including electroporation and natural transformation, no 
smpB knock-out mutants were isolated.   Kanamycin resistant colonies were isolated from 
the natural transformation, however none contained the Kanamycin cassette as determined 
by PCR amplification of smpB (Figure 3.13c). 
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3.3 Discussion. 
In this study an 18 kDa putative lipoprotein of B. hyodysenteriae was identified.   The 
characterised 503 bp ORF was named smpB due to the similarities to smpA.   The previous 
designation of B. hyodysenteriae was Serpulina hyodysenteriae, therefore the SmpA 
nomenclature was adopted when the lipoprotein was characterised by Thomas and Sellwood 
(1993).  Since the genus name change to Brachyspira, Lee et al (2000) proposed a name 
change for SmpA to BmpA, when the 30 kDA lipoprotein BmpB was characterised.  As this 
nomenclature has not been formally adopted to date, and the gene encoding the 18 kDa 
lipoprotein identified in this investigation is hypothesised to share the same chromosomal 
location on the Brachyspira genome as smpA, it is proposed that this protein be named 
SmpB, until any gene name amendments are formalised.   Sequence analysis revealed that 
the flanking regions of DNA are homologous and DNA-DNA hybridisation revealed that no 
strain contains both genes. 
 
Motif analysis of the predicted amino acid sequence of SmpB supports the hypothesis 
that smpB encodes a lipoprotein.  Lipoproteins usually contain a short hydrophobic signal 
peptide including a 4 AA signal peptidase site that anchors the protein to the outer 
membrane prior to acylation.   The predicted signal sequence of SmpB, which suggests 
acylation of the mature protein, is identical to that of SmpA.   The AVSC peptidase site 
(Haake, 2000) is conserved in the two proteins, however the mature proteins are 
considerably different.   Immediately adjacent to the predicted lipid attachment site is a 
hydrophilic N-terminus, consistent with other bacterial lipoproteins (Cullen et al., 2004; 
Haake, 2000).   Further experiments such as immunogold labelling of anti-SmpB antibodies 
and visualisation by Transmission Electron Microscopy are required to confirm that SmpB is 
indeed an outer membrane protein, however the signal peptide and the similarities to SmpA 
suggest that SmpB is indeed a outer membrane lipoprotein. 
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Recombinant SmpA and SmpB expressed in E. coli under the control of their own 
native promoters could only react with polyclonal antisera raised in rabbits immunised with a 
B. hyodysenteriae strain harbouring the identical protein.   SmpA and SmpB are therefore 
immunologically distinct proteins.   This lack of cross-reactivity (which is expected as the 
predicted protein sequences are not similar) presumably means that antibodies that 
specifically target B. hyodysenteriae SmpA (Sellwood et al., 1989) would not inhibit the 
growth of strains that encode SmpB.   This has not been tested.   Variation in the 
complement of surface proteins expressed to evade the host immune response is common 
amongst spirochaetes, enabling the establishment of persistent infections (Haake, 2000).   
The variable surface protein genes are thought to be involved in antigenic variation in B. 
hyodysenteriae (Gabe et al., 1998; McCaman et al., 1999; McCaman et al., 2003).   A high 
degree of lateral transfer occurs between bacteria, contributing greatly to bacterial evolution 
(Arber, 2000; Kurland et al., 2003; Lan & Reeves, 1996).   Whether the presence of 
alternative proteins encoded from the smpA locus has any in vivo significance in terms of 
immune evasion remains to be confirmed.   However, the data here suggests that the 
variation at this locus is not a mechanism of immune evasion. 
 
Previous studies on smpA utilised DNA-DNA hybridisation to show that all strains of B. 
hyodysenteriae contained the smpA gene (Turner et al., 1995).   When digested with Sau3AI 
the ~900 bp smpA probe reacted with a single band in each strain.   The probe reacted with 
either a 1.4 kb band or a 1.0 kb band and combined with the difference in observed 
hybridisation intensity some sequence variation was inferred.   Moreover, when digested with 
HindIII, the probe reacted with two bands in some strains of B. hyodysenteriae – this was 
attributed to the presence of a second gene similar to smpA in these strains (Turner et al., 
1995). 
 
This study demonstrates that the observed two bands upon HindIII digest in of B. 
hyodysenteriae are a result of sequence variation within the single smpA locus, not the 
presence of a second locus as was previously thought.   The presence of a unique HindIII 
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site in the smpB gene combined with the affinity of the 900 bp probe used by Turner et al. for 
the identical flanking DNA ensured hybridisation with both fragments of the HindIII digest in 
smpB.   The greater specificity of the smaller probes used in this investigation allowed a 
clearer understanding of the distribution of smpA and smpB amongst B. hyodysenteriae 
strains. 
 
B. hyodysenteriae B8044 did not react with either the smpA or smpB probes, despite 
sequence confirmation as smpA.   The lack of reactivity in B8044 is unusual.   The sequence 
of 8044 smpA is essentially identical to the sequence of B204 smpA gene product.   The 
nucleotide mismatches observed between the B204 smpA and the B8044 smpA is not 
enough to prevent binding of the probe.   However, problems with the template DNA used for 
DNA-DNA hybridisation were eliminated as a possible cause of non-reactivity by 
hybridisation with a DNA probe specific for B8044 smpA and flaA, a gene encoding a flagella 
constituent.   It is possible that these non-reactive genes possess some secondary structure 
that is preventing binding of the probes at specific locations, however the denaturation step 
should remove any such structures.   B. hyodysenteriae B8044 also did not react with the 
vspABCD or vspEFGH probes (See Chapter 6), indicating that there are some fundamental 
differences between B. hyodysenteriae B8044 and other strains. 
 
The knock-out mutagenesis studies were performed with a view towards identifying the 
function of SmpB.   Several methods were utilised in order to obtain the required mutant 
including electroporation and natural transformation.   Some kanamycin resistant colonies 
were isolated from the natural transformation, indicating the kanamycin gene was integrated 
into the chromosome, however this was not at the smpB locus as determined by PCR 
analysis.   Considering the lack of growth observed after treatment with anti-smpA antibodies 
(Thomas & Sellwood, 1992), it is not suprising that no knock-outs were isolated.   If the 
function of SmpA is essential for growth and SmpB replaces SmpA in some strains, smpB 
knockout may be lethal, and requires further study. 
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The BLAST analysis of SmpB showed sequence similarity with the signal sequence of 
SmpA from B. hyodysenteriae and BmpC from B. pilosicoli.  When only the mature peptide 
(signal sequence removed) was used in a BLASTP search, there was no significant matching 
protein found in the database.   SmpB, like SmpA, is a protein unique to B. hyodysenteriae.   
It has been suggested that approximately 25-30% of all genes share no sequence similarity 
with genes from any other genera and are referred to as ‘orphan’ genes (Mira et al., 2002).   
These unique ‘orphan’ genes are usually responsible for species-specific metabolic diversity 
or host-specificity and pathogenicity.   The average size of ‘orphan’ genes is 674 bp, as 
compared to 1040 bp for genes with known functions or conserved between genera (Mira et 
al., 2002).   The 503 bp smpB and 476 bp smpA are much closer to the average size of 
‘orphan’ genes than that of functional, widely distributed genes.   It is possible that smpA and 
smpB represent ‘orphan’ genes of B. hyodysenteriae. 
 
SmpB and SmpA either evolved to alter the function of the protein or to assist the 
bacteria in evading the immune system (antigenic variation).   Proteins that are involved in 
antigenic variation frequently contain regions of hydrophilic variability and regions of 
hydrophobic conservation.   This pattern is to retain the function of the protein (conserved) 
while altering the antigenic epitopes (variable) (McCaman et al., 2003).   The lack of 
conserved regions in the mature SmpA and SmpB, as shown in the protein sequence 
alignment, suggests that the variation resulting in SmpB is not a result of antigenic variation.    
 
Furthermore, common methods of antigenic variation utilise multiple copies of 
unexpressed “pseudogenes” that are inserted into a single expressed locus to generate 
variability (Arber, 2000; van der Woude & Baumler, 2004; Zhang et al., 1997).   This often 
results in the presence of multiple bands during DNA-DNA hybridisation due to the 
conservation of sequence (McCaman et al., 2003).   The presence of single bands during 
DNA-DNA hybridisation with smpA or smpB probes supports the hypothesis that antigenic 
variation is not the reason for the presence of smpA and smpB. 
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The elimination of antigenic variation as the reason for the sequence divergence 
resulting in smpA and smpB leaves alteration of function as the possible reason.   Variability 
of protein sequence resulting in altered function has been observed in the bit operon of B. 
hyodysenteriae, with three paralogous proteins thought to be involved in chelating iron from 
different sources (Dougard et al., 1999).    The prevention of growth of B. hyodysenteriae by 
anti-SmpA antibodies suggests that SmpA may be essential for the in vitro growth of B. 
hyodysenteriae (Thomas & Sellwood, 1992).   Despite the sequence variation between 
SmpA and SmpB, SmpB can functionally substitute for the absence of SmpA. 
 
The mechanism resulting in the alternate sequence at the smpA locus is unknown.   If 
intra-chromosomal crossover were the mechanism by which smpA and smpB arose, a highly 
similar region of the chromosome would be present that would react with the smpA or smpB 
probe during DNA-DNA hybridisation.   The presence of a single band in Figure 3.10 and 
Figure 3.11 largely eliminates intra-chromosomal recombination as a source of the variation 
in smpA and smpB, leaving foreign DNA acquisition or horizontal gene transfer (Kurland et 
al., 2003) from another organism as the probable source of variation.   The lack of any 
homologous sequences identified by BLAST analysis does not preclude the generation of 
smpB from horizontal gene transfer.   Considering the limited amount of DNA sequence 
characterised from different Brachyspira spp., the homologous sequence of DNA may not 
have been identified as yet and smpA/B may not be an ‘orphan’ gene. 
 
There are many mechanisms utilised for the horizontal transfer of genes between 
organisms (Arber, 2000; Daubin et al., 2003; Kurland et al., 2003).   Brachyspira species do 
contain VSH-1, a defective bacteriophage which may contribute to horizontal gene transfer 
(Humphrey et al., 1995; Humphrey et al., 1997; Stanton et al., 2003). It was demonstrated 
that VSH-1 packages ~7 kb fragments of Brachyspira spp. chromosomal DNA for 
generalised transduction (Humphrey et al., 1997).   Genes encoding VSH-1 have been 
detected in B. hyodysenteriae, B. pilosicoli, B. innocens, B. murdochii, B. intermedia and B. 
alvinipulli, therefore VSH-1 may be a mechanism by which genes are transferred between 
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Brachyspira spp. (Calderaro et al., 1998; Humphrey et al., 1995; Stanton et al., 2003).   The 
wide distribution of VSH-1 genes and the packaging of chromosomal DNA fragments 
suggest that VSH-1 phages perform an important role in genetic evolution in Brachyspira 
species. 
 
Also present in B. hyodysenteriae are ~6.5kb extracellular DNA fragments (Turner & 
Sellwood, 1997).   The smpA gene has been detected in these fragments of DNA, and these 
may be sources of homologous recombination in B. hyodysenteriae.   Both the VSH-1 
bacteriophage and the 6 kb extra-cellular DNA fragment are possible sources of foreign DNA 
in homologous recombination.   Niesseria gonorrhoeae has been demonstrated to produce 
membrane vesicles called ‘blebs’ (Dorward & Garon, 1989; Dorward et al., 1989), that 
display similar characteristics to the vesicles observed in B. hyodysenteriae (Turner & 
Sellwood, 1997).   The mechanism by which these ‘blebs’ transfer DNA is not known in N. 
gonorrhoeae or B. hyodysenteriae.   The 6.5 kb fragments detected in extracellular vesicles 
may be the same random fragments packaged into the VSH-1 generalised transducing 
phage (Matson et al., 2005).   However, the presence of extra-chromosomal DNA in other 
organisms gives ‘blebs’ credibility as a unique method of DNA transfer. 
 
The lateral transfer of genes is dependent on many factors.   The availability and 
uptake of foreign DNA, the propensity for integration into the chromosome and the 
advantage (if any) conferred upon the recombinant organism by integration of the 
heterologous gene all influence the rate of horizontal gene transfer (Lawrence, 2002).     
Thus the rate of horizontal transfer depends on the avaliability of recombination sites and 
exposure to phages such as VSH-1.   It is unknown how these factors influence 
recombination events in B. hyodysenteriae.   However, the high number of recombinant 
events in the B. hyodysenteriae genome and the disposition towards chromosomal 
rearrangements (Trott et al., 1997) suggests that such events are important in evolution the 
of B. hyodysenteriae.  
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Considering the highly recombinant genome of B. hyodysenteriae (Trott et al., 1997), it 
is not suprising to observe genetic variation, particularly in those genes that encode proteins 
that are exposed to environmental selective pressure.   Characterisation of the function of 
SmpB and SmpA would allow conclusions to be drawn about why the replacement occurred, 
and how SmpB functionally replaces SmpA, a protein that was previously thought to be 
essential by growth inhibition studies (Thomas & Sellwood, 1992).   The inability to isolate 
smpB knockout mutants in this study may reflect the essential nature of SmpB, and further 
investigations into the function, localisation and similarities to SmpA and SmpB need to  be 
performed. 
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Chapter 4 – An Evaluation of the Immunogenicity and 
Protective Responses to Recombinant SmpB 
Vaccination 
 
4.1 Introduction 
The newly discovered protein SmpB was tested for its ability to induce an immune 
response and protect mice against challenge with virulent B. hyodysenteriae.   The function 
of SmpB, like SmpA, is unknown at this time.   It is thought that SmpB replaces SmpA in 
some strains of B. hyodysenteriae (See Chapter 3) and therefore should share some 
functional similarities.   The presence of anti-SmpA antibodies in convalescent swine sera 
combined with their ability to inhibit the growth of B. hyodysenteriae also suggests that these 
antibodies may contribute to recovery from infection (Joens & Marquez, 1986; Joens et al., 
1993; Thomas & Sellwood, 1992).    
 
However, the inability to detect SmpA late in infection has lead to a cessation of 
research into its potential uses (Sellwood et al., 1995).   While it is unknown whether SmpB 
is environmentally regulated in a similar method to SmpA, the conservation of the SmpA 
promoter and regulatory elements in those strains containing SmpB suggests that the 
regulation of SmpA and SmpB should be identical.  The presence of high titres of anti-SmpA 
antibodies means that the host immune system has access to the SmpA/SmpB for a 
significant level of time (Chatfield et al., 1988; Sellwood et al., 1989; Thomas et al., 1992), 
and despite the in vivo repression (Sellwood et al., 1995) an immune response directed 
against SmpA (and possibly SmpB) may still protect against SD.   As yet no investigations 
into the potential of SmpA nor SmpB to protect against SD have been performed. 
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Infection of mice with B. hyodysenteriae is the most common non-swine animal model 
for the study of SD (Davis et al., 2005; Hutto & Wannemuehler, 1999; Kennedy et al., 1997a; 
Lee et al., 2000; Nibbelink & Wannemuehler, 1992; Rosey et al., 1996; Zhang et al., 2001).   
Various host responses to B. hyodysenteriae infection have been investigated, including 
lesion development and colonisation of the caecum (Davis et al., 2005; Nibbelink & 
Wannemuehler, 1991; Nibbelink & Wannemuehler, 1992).   Two types of mouse, C3H/HeN 
and C3H/HeJ, were found to be the most responsive to B. hyodysenteriae infection, 
developing lesions in the caecum and large intestine with concomitant swelling and oedema 
approximately 2 weeks post infection (Nibbelink & Wannemuehler, 1991). 
 
Attenuated strains of Salmonella enterica serovar typhimurium (S. typhimurium) have 
been widely used for the delivery of heterologous antigens from various sources (Bachtiar et 
al., 2003; Gentschev et al., 2000; Husseiny & Hensel, 2005b; Kang et al., 2002; Roland et 
al., 2005; Wu et al., 1997; Wu et al., 2000).   S. typhimurium are well suited for the delivery of 
antigens sourced from mucosal pathogens, as the natural route of infection results in the 
induction of a robust mucosal immune response (Jackson et al., 1996; Michetti et al., 1992; 
Michetti et al., 1994; VanCott et al., 1996; Wu et al., 1997).   The pathogenesis of S. 
typhimurium ensures that the vaccine is exposed to a large array of immune cells, including 
macrophages, dendritic cells, B lymphocytes and T lymphocytes (Finlay & Brumell, 2000a; 
Kalupahana et al., 2005a).   The type of immune response elicited by the heterologous 
antigen is the same as would be directed against the vector.   The immune response against 
S. typhimurium consists mainly of a cell-mediated immune response, with induction of CD4+ 
and CD8+ T lymphocytes, however high titres of antibodies can also be elicited (Kirby et al., 
2004; Mittrucker et al., 2002; Wijburg et al., 2002; Yrlid et al., 2001a). 
 
Several expression vectors were chosen for the expression of smpB by STM-1 and 
host cells.   SmpB was expressed in STM-1 by inserting smpB into pCR2.1, under the control 
of its own promoter.   The DNA vaccines chosen were pVR1020 and pVRMCP3.   Plasmids 
pVR1020 and pVRMCP3 contain eukaryotic origins of replication and CMV promoter 
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sequences allowing expression inside eukaryotic host cells.   An N-terminal signal sequence 
in pVR1020 causes the recombinant protein to be exported outside the cell, included in order 
to increase the antibody response.   The fusion protein of Monocyte Chemotactic Protein-3 
(MCP-3) and smpB in pVRMCP3 derived vectors allows targeting of the recombinant SmpB 
to host immune cells (Menten et al., 2001).    Recombinant, purified SmpB (rSmpB) was also 
injected as a subunit vaccine to test the immunogenicity of the protein itself. 
 
Little is known about the immune response required for resolution of B. hyodysenteriae 
infection.   However, it is known that certain subsets of T lymphocytes, particularly those 
displaying CD4+, CD8+ and γδ determinants, as well as a secretory IgA response are 
important (Hontecillas et al., 2005; Waters et al., 1999a; Waters et al., 1999b; Waters et al., 
2000b).   The ability of S. typhimurium to induce a mucosal antibody response combined with 
a CD8+ and CD4+ T lymphocyte response against the heterologous antigen makes them 
ideal for the delivery of B. hyodysenteriae antigens (Kirby et al., 2004; Mittrucker et al., 2002; 
Wijburg et al., 2002; Yrlid et al., 2001a). 
 
 
The aims of the studies described here  were: 
 
1) To determine the ability of B. hyodysenteriae 5380 to induce disease in mice. 
2) To clone smpB into various expression vectors, 
3) To compare several vaccination methods for the induction of immune responses: 
a) Recombinant SmpB vaccination, 
b) DNA vaccination with expression vectors encoding SmpB, 
c) Delivery of recombinant SmpB by STM-1. 
d) Delivery of DNA vaccines encoding SmpB by STM-1. 
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4.2 Results 
4.2.1 Validation of the Murine Model of Swine Dysentery. 
The ability of B. hyodysenteriae 5380 to establish an infection in mice was determined 
by inoculating five groups of five mice each with varying doses of B. hyodysenteriae 5380 
ranging from 1x106 to 1x109 cfu by gastric intubation.   Mice were sacrificed 2 weeks post-
infection and the caeca were weighed, the pathological effects was scored and the caecum 
contents were analysed for haemolytic activity.   Examples of these measures are given in 
Figure 4.1 and Figure 4.2. 
 
4.2.1.1  Pathological effects observed in the Caecum. 
There was a dose dependent increase in the weight of caeca of mice infected with B. 
hyodysenteriae 5380 (Figure 4.3a).   All the caeca of mice treated with B. hyodysenteriae 
were significantly different from the control mice (Table 4.1a).   The caecum was also scored 
for the gross pathology as described in Figure 4.1, which also increased significantly in a 
dose dependent manner in response to B. hyodysenteriae infection (Figure 4.3b and Table 
4.1b).   The increase in pathological effects was consistent with the caecal weight increase 
observed for each treatment group (Figure 4.3).   As the weights of the caecum were the only 
objective and quantitative data, it was given more credence when determining the dosage for 
challenge experiments. 
 
4.2.1.2  Haemolysis. 
In addition to being weighed, the caecum content was homogenised in PBS and 100µL 
was added to cooled, molten Sheep Blood Agar (SBA) with Spectinomycin. The inoculated 
agar was poured and allowed to set before incubation.   The caecum contents were also 
inoculated onto sliced SBA by inoculating the caecum homogenates perpendicular to four 
parallel slices across the surface of SBA (Calderaro et al., 2001).   
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 The B. hyodysenteriae grew inconsistently on the pour plates, however the sliced SBA 
gave consistent results.   The haemolytic activity of the caecum contents on sliced agar 
medium was scored as described in Figure 4.2.   While all the mice infected with B. 
hyodysenteriae 5380 displayed significantly more haemolysis than the control group, there 
did not appear to be any correlation between the dose and the haemolysis observed (Figure 
4.3c and Table 4.1c).   Faecal samples were also taken daily over the course of the infection.   
Faeces were collected from the cages and directly from the mouse, and homogenised in 
PBS.   Despite the different points of collection, no haemolysis was observed after streaking 
faecal homogenates onto sliced agar medium. 
 
4.2.1.3  Conclusion from SD Mouse Model Validation. 
Following inoculation of mice, it was determined that B. hyodysenteriae 5380 can 
induce disease in C3H/HeJ mice, and that the clinical signs are measurable by determining 
the weight of the caeca.   The caecum pathological effects were less consistent than the 
caecal weight for measuring the effect of B. hyodysenteriae on the mouse.   The haemolysis 
induced when the caecum contents were streaked onto SBA, while not corresponding to the 
pathological effects or caecal weight, confirmed that B. hyodysenteriae could infect mice, as 
a bacteria with morphology similar to B. hyodysenteriae could be observed after dark-field 
microscopy of caecum culture.   The optimum dosage for infection with B. hyodysenteriae 
was 1 x 108cfu of cells per mouse. 
 
4.2.2 Construction of STM-1 Vaccines. 
Two PCR primers (SmpORF1 and SmpORF2) were designed to exclude the smpB 
ATG start codon and contain a BamHI site to facilitate cloning smpB in frame with the start 
codon of pVR1020 and pMCP3.   The conditions for this PCR were 92°C for 2 min followed 
by 35 cycles of 92°C for 30 s, 50°C for 30 s, and 72°C for 1 min, with a final elongation at 
72°C of 7 min. 
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a) Group Dose Caecum/Bodyweight SD P value 
1 0 1.13 0.11 - 
2 1x106 1.29 0.08 0.048 
3 1x107 1.27 0.07 0.014 
4 1x108 1.33 0.06 0.020 
5 1x109 1.49 0.21 0.020 
 
b) Group Dose Average Pathology SD P value 
1 0 0 0.12 - 
2 1x105 1.33 0.52 0.001 
3 1x106 1 0.89 0.04 
4 1x107 1.83 0.75 0.002 
5 1x108 2.33 0.82 0.001 
 
Group Dose Average Haemolysis SD P value 
1 0 0.33 0.51 - 
2 1x105 2 1.55 0.042 
3 1x106 2.833 1.17 0.002 
4 1x107 1.333 0.82 0.04 
5 1x108 1.833 1.47 0.03 
c) 
 
Table 4.1 : Analysis of Caecal Characteristics of mice Infected with B. hyodysenteriae. 
Statistical analysis of the caecal pathological effects of mice infected with B. hyodysenteriae. Table 
4.1a: Every group inoculated with B. hyodysenteriae had significantly different caeca weights 
compared to the negative control. Table 4.1b: Every group inoculated with B. hyodysenteriae had 
significantly different caecum pathological effects compared to the negative control. Table 4.1c: Every 
group inoculated with B. hyodysenteriae had significantly different haemolysis scores compared to the 
negative control. SD represents the standard deviation. 
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The SmpORF PCR product was directly cloned into pCR2.1 (Figure 4.4) according to 
the manufacturers instructions.   The integrity of the smpB ORF was confirmed in pCRsmpB 
by DNA sequence characterisation.   To sub-clone the smpB insert from pCRsmpB into 
pVR1020 and pVRMCP3, pCRsmpB was digested with BamHI and the smpB insert was 
excised and purified from an agarose gel after electrophoresis.   The smpB insert was then 
cloned into BamHI digested pVR1020 and pVRMCP3 to give pVRsmpB (Figure 4.5a) and 
pMCsmpB (Figure 4.6a). 
 
The orientation of the inserted smpB in the expression plasmids was confirmed by 
PCR, using the primers SmpORF2 and VR1020-1.   After PCR amplification, only plasmids 
with smpB inserted in the correct orientation would produce a product (Figure 4.5b and 
Figure 4.6b).   The orientation and integrity of the insert in the isolated recombinant clones 
was confirmed by DNA sequence characterisation using the primers SmpORF2 and 
VR1020-1. 
 
Before the expression vectors containing smpB could be used in immunisation 
experiments, the vectors constructed in this chapter (pVRsmpB and pMCsmpB) and in 
Chapter 3 (pCRsmpBP) were passaged through S. typhimurium LT2 to stabilise the plasmids 
by DNA methylation.   The plasmids were then re-isolated and transformed into S. 
typhimurium STM-1 prior to evaluation and vaccination (Figure 4.7). 
 
4.2.3 Maintenance of SmpB Vaccines in STM-1. 
The maintenance of the expression plasmids in S. typhimurium STM-1 was determined 
by plasmid stability studies.   After performing the trials in triplicate, the three plasmids 
containing smpB were shown to be less stable than empty vectors.   Following 4-5 days of 
repeated passaging, the smpB expression vectors were present in <10% of STM-1, whereas 
the control plasmids were still present in ~50% of S. typhimurium STM-1 (Figure 4.8). 
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Figure 4.4: Plasmid pCRsmpB. 
Figure 4.4a: Map of pCRsmpB.   The inserted smpB is missing the ATG start codon, and is in frame 
with the coding region after subsequent cloning into pVR1020 and pVRMCP3.   Figure 4.4b: Gel of 
pCRsmpB digested with BamHI.  Lane1, MW Marker; Lane 2-4, empty pCR2.1; Lane 5, pCR2.1 
containing 528bp smpB insert.   The orientation of the insert is irrelevant as the encoded protein will 
not be expressed in this construct.   The black arrows represent the location of the primers used for 
cloning. 
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Figure 4.5: pVRsmpB Expression Vector. 
Figure 4.5a: Map of the pVRsmpB expression vector.   Figure 4.5b: PCR analysis of the pVRsmpB 
plasmid to confirm the orientation of the inserted smpB.   Lanes 1 & 5, clones with smpB in the correct 
orientation; Lanes 2, 3, 4, 6, 7, 8, clones with smpB in the incorrect orientation; Lane 9, MW Marker.   
The orientation of the inserted smpB was confirmed by DNA sequence characterisation. The black 
arrows represent the location of the primers used for cloning. 
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Figure 4.6: pMCPsmpB Expression vector. 
Figure 4.6a: Map of the pMCsmpB expression vector. Figure 4.6b: PCR analysis of the pMCsmpB 
plasmid to confirm the orientation of the inserted smpB. Lane 1, MW Marker; Lane 2, clone with smpB 
in the correct orientation; Lanes 3 & 4, clones with smpB in the incorrect orientation.  The orientation 
of the inserted smpB was confirmed by DNA sequence characterisation. The black arrows represent 
the location of the primers used for cloning. 
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Figure 4.7: SmpB Expression Vectors in STM-1. 
Following construction of the SmpB expression vectors, the plasmids were passaged through S. 
typhimurium LT2 and then transformed into STM-1 prior to vaccination.   The transformation of the 
correct plasmid was confirmed by digestion with BamHI.   Lane 1, pCRsmpBP; Lane 2, pVRsmpB; 
Lane 3, pMCsmpB; Lane 4, λ/pstI MW marker.   The larger smpB fragment in Lane 1 represents the 
incorporation of flanking regions of DNA that was cloned into pCRsmpBP. 
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Figure 4.8: Stability of smpB Expression Vectors in STM-1. 
The stability of the smpB expression vectors in STM-1 was lower than the control plasmids (empty 
pVR1020 or pMCP3).   After 4-5 days (~ 5000 generations) of repeated passage,  less than 10% of 
STM-1 contained the smpB expression vector.   At the same time points, the control plasmids were 
present in ~50% of the STM-1.   All stability trials were performed in triplicate.  
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Figure 4.9: Survival of STM-1 Harbouring SmpB Vaccines inside J774 Macrophages. 
Following infection of J774 macrophages with the recombinant STM-1 vaccines, the viable cell count 
increased quickly to ~1x103 cfu at 2 hours.   The viable cell count then steadily decreased to almost 0 
at 24 hours.   The survival of STM-1 inside J774 macrophages was only greatly repressed by the 
pMCsmpB plasmid (p = 0.03).   The prokaryotic expression vector, pCRsmpB also suppressed the 
growth of STM-1 inside macrophages, although not as greatly as pMCsmpB.   All survival trials were 
performed in triplicate, and the data points are mean values. 
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The effect of plasmid maintenance on S. typhimurium STM-1 was further characterised 
by performing macrophage survival studies.   The murine macrophage line J774 was infected 
in triplicate with STM-1 harbouring the plasmid, and the presence of STM-1 was determined 
at 0, 2, 8 and 24 hours (Figure 4.9).   Over the first 2 hours of infection, STM-1 was able to 
replicate inside the macrophages, increasing the viable cell count to ~1 x 103 cells.   This 
trend was observed for the control STM-1 and for STM-1 harbouring pCRsmpB and 
pVRsmpB.   The STM-1(pMCsmpB) was unable to replicate to a large viable cell count inside 
the J774 macrophages, indicating a large impact of pMCsmpB upon the growth of STM-1. 
 
4.2.4 Expression and Purification of Recombinant SmpB. 
The pGEXsmpB expression vector (See Appendix) was supplied by George Moutafis 
(RMIT).   The recombinant GST-SmpB fusion protein (rSmpB) was purified (Figure 4.10a) by 
Glutathione-Agarose Affinity Chromatography.   The results of an anti-GST Immunoblot 
confirmed the purification of the correct product (Figure 4.10c).   The antigenicity of the 
recombinant rSmpB was confirmed by Immunoblot using anti-B. hyodysenteriae 5380 
antibodies (Figure 4.10b).   The recombinant rSmpB was used in the immunisation 
experiments and for ELISA and ELISPOT assays.  
 
4.2.5 SmpB Vaccination Experiments. 
The immunogenicity and potential protection induced by SmpB vaccination was 
investigated by inoculating mice 3 times over a 6 week period with either 1x109 cfu 
recombinant STM-1, 100µg of DNA or 50µg of rSmpB/Freunds (Summarised in Table 4.2).   
Four weeks following the final vaccination, 3 mice were sacrificed, their spleens removed and 
ELISPOT assays performed to enumerate SmpB-specific cytokine producing cells.   The 
remaining mice were challenged with 1x 108 cfu of B. hyodysenteriae 5380.   Two weeks post 
challenge, the mice were sacrificed and their caeca were scored for pathological effects, 
removed, weighed and the caeca contents cultured.   Blood samples were taken prior to 
challenge to evaluate the antibody response induced by vaccination. 
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Figure 4.10: Expression of Recombinant SmpB-GST Fusion Protein. 
Figure 4.10a: SDS-PAGE analysis of Purified GST-SmpB.   Ten micrograms of protein was added to 
each lane.   Lane 1, MW Marker; Lane 2, Purified rSmpB. The ~26kDa band represents recombinant 
GST and the ~50kDa band represents the rSmpB fusion protein.   There is some spontaneous 
cleavage during the purification of the recombinant SmpB, resulting in a smaller product in Figure 
4.10a compared to Figure 4.10c.   Figure 4.10b: Immunoblot of rSmpB with anti-B. hyodysenteriae 
5380 antisera.  Lane 1, Whole Cell lysate; Lane 2, Flow through; Lane 3, Column Wash Fraction; Lane 
4 & 5, rSmpB Elution.   Figure 4.10c: Anti-GST Immunoblot of rSmpB.   Lane 1, MW Marker; Lane 2, 
GST-SmpB. 
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Group Treatment Delivery Dose Route 
1 None None 0 None 
2 pVR1020 STM-1 1x109cfu Oral 
3 pCRsmpB STM-1 1x109cfu Oral 
4 pVRsmpB STM-1 1x109cfu Oral 
5 pMCsmpB STM-1 1x109cfu Oral 
6 pVR1020 DNA 50µg I.M. 
7 pVRsmpB DNA 50µg I.M. 
8 pMCsmpB DNA 50µg I.M. 
9 PBS Freund’s 0 I.P 
10 rGST Freund’s 50µg I.P 
11 rSmpB Freund’s 50µg I.P. 
 
Table 4.2: SmpB Vaccination Regime. 
Regime for the SmpB vaccine trials.   Each group comprised of 9 mice.   Mice were 
vaccinated at weeks 0,3 and 6.   Four weeks after the final vaccination, 3 mice were 
sacrificed for ELISPOT analysis of spleen lymphocytes.   The remaining 6 mice were 
challenged with B. hyodysenteriae 5380.   Two week following challenge, the mice were 
sacrificed and their caecum analysed for any pathological effects. 
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4.2.5.1  Analysis of SmpB-Specific Cytokine Secreting Cells. 
Four weeks after the final vaccination, three mice were sacrificed and the spleens 
removed for lymphocyte analysis by ELISPOT assay.    Compared to the controls of 
uninfected mice and unstimulated cells, delivery of pVR1020, pMCsmpB and pVRsmpB by 
STM-1 produced a significantly increased number of IL-4 producing cells (Figure 4.11a and 
Table 4.3a).   However, when compared to the STM-1 control, there was no significant 
increase in IL-4 producing cells of mice vaccinated with the recombinant STM-1.    A similar 
reason to that postulated for the ELISA result may be applicable here, i.e. shared epitopes 
between STM-1 and the E. coli used for recombinant protein production contributing to the 
increased IL-4 response.    
 
The injection of the pMCsmpB or pVRsmpB did not result in a significant increase in 
the number of IL-4 producing cells when compared to either the unstimulated cells, the 
uninfected control mice or the mice treated with pVR1020 (Table 4.3a).   Vaccination with 
rSmpB resulted in a significant increase in the number of IL-4 secreting cells compared to the 
unstimulated cells and PBS/Freund’s control (Figure 4.11a and Table 4.3a).   However, this 
was not significantly higher when compared to the rGST control, suggesting some of the 
induction of IL-4 was a result of rGST, not rSmpB (Table 4.3a). 
 
Overall, the IFN-γ response of spleen lymphocytes to exposure to rSmpB was not as 
strong as the IL-4 response, with many of the vaccination regimes producing less than 10 
positive cells per million (Figure 4.11b and Table 4.3b).   Although delivery of pVR1020 and 
pMCsmpB by both STM-1 and DNA vaccination resulted in an increase of IFN-γ producing 
cells compared to the unstimulated cells, only the delivery of pMCsmpB by STM-1 gave a 
significant response compared to the STM-1 control (Figure 4.11b and Table 4.3b). 
 
 145
4.2.5.2 Serum Antibody Responses. 
The largest serum antibody response was observed in the rSmpB vaccinated group 
compared to both the PBS control (p = 0.018)  and the rGST control (p = 0.049 ) (Figure 
4.12b).   Although the mean O.D. of the sera from the rSmpB vaccinated groups is not 
considerably different from the recombinant STM-1 and DNA vaccine groups, a higher sera 
dilution was used for the rSmpB ELISA as determined in Figure 4.12a.   Sera from groups 
vaccinated with recombinant STM-1 and DNA vaccines was diluted 1:10 for the ELISA, and 
the GST and rSmpB groups were diluted 1:10000 for the ELISA indicating a significantly 
greater humoral immune response in the recombinant protein vaccinated mice. 
 
None of the recombinant STM-1 vaccinated mice or the DNA vaccinated mice 
developed significant levels of SmpB specific serum IgG.   The presence of antibodies in the 
STM-1 control groups did not allow inferences to be made about the SmpB specific antibody 
response induced by recombinant STM-1 strains.   The presence of serum antibodies in 
control groups could be due to cross-reacting epitopes conserved between STM-1 and the E. 
coli BL21 that was used to produce the recombinant antigen used for the ELISA. 
 
Attempts were made to cleave the GST from the purified rSmpB fusion protein prior to 
vaccination, however this resulted in degradation of the protein, therefore the uncleaved 
protein was used.   Vaccination with rSmpB induced antibodies against GST as well as 
SmpB (Figure 4.12).   The antibodies raised by the vaccination of mice with rSmpB could 
react with both a 17kDa band in crude E. coli (pGEXsmpB) lysates (Figure 4.13), indicating a 
portion of the raised antibodies were able to bind to SmpB. 
 
4.2.5.3  Challenge of Vaccinated Mice with Brachyspira hyodysenteriae 5380. 
4.2.5.3.1 Caecum Pathological effects of Vaccinated Mice Following Challenge.  
When comparing the various SmpB vaccines to the control vaccine, some differences 
in the caecal weight is observed (Figure 4.14).   In Figure 4.14, the negative control consists 
of uninfected mice, giving a baseline for normal, healthy caecum.   The positive control was 
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PBS vaccinated mice challenged with 1x108cfu of B. hyodysenteriae 5380.   The caecum of 
mice vaccinated with rSmpB/Freund’s vaccines had significantly smaller caecum post 
challenge compared to the PBS and rGST controls (p value 0.01 and 0.005, respectively).   
No other treatment group gave a significant result compared to either the STM-1, DNA or 
PBS control.   The greatest difference in the caecal weights and pathological effects was 
obtained by vaccinating with rSmpB (Figure 4.14 and Figure 4.15), which corresponds with 
the greatest measured immune response (Figure 4.11 and Figure 4.12).   The Freund’s 
adjuvant control containing recombinant GST did not decrease the caecal weight (Figure 
4.14) nor pathological effects (Figure 4.15), indicating that despite a measurable immune 
response directed against GST, it did not influence the challenge outcome. 
 
There was no significant difference observed in the caecum pathological effects after 
infection with SmpB delivered by STM-1, by DNA vaccination, or by recombinant protein 
vaccination (Figure 4.15).   Although the rSmpB vaccination lowered the caecum pathological 
effects, the effect was not significant due to a large variation within the groups.  
 
4.2.5.3.2 Analysis of Haemolytic activity of Caecal Contents of Challenged Mice.  
None of the STM-1 vaccinated groups displayed significantly lower levels of 
haemolysis compared to the STM-1 control groups (Figure 4.16).   Some differences, 
however, were observed in the DNA and protein vaccinated groups (Figure 4.16).   A 
significant difference was observed in the haemolysis of the caecum contents from mice 
DNA vaccinated with pVRsmpB when compared to pVRMCP3 vaccinated groups (p value 
0.02), however this does not correlate with a measured immune response.   Similar to the 
caecum oedema, the mice vaccinated with GST-SmpB displayed much lower levels of 
haemolysis compared to the PBS and Freund’s-GST control groups (p value = 0.03 & 0.008 
respectively). 
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Figure 4.11: SmpB ELISPOT Assay for Cytokine Producing Cells. 
ELISPOT analysis of spleens from mice inoculated with SmpB vaccination regimes.   Mice (3) were 
vaccinated with SmpB (according to Table 4.2) and their spleens were removed for ELISPOT analysis. 
Figure 4.11a: Enumeration of SmpB-specific IL-4 producing cells.   Most SmpB vaccinations induced 
an IL-4 response upon in vitro exposure to rSmpB.   Figure 4.11b: Enumeration of SmpB-specific IFN-
γ producing cells.   Only pMCsmpB delivered by STM-1 induced an IFN-γ response upon in vitro 
exposure to rSmpB (p = 0.05). 
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a) Unstimulated Control/PBS STM-1/DNA#/GST* control 
STM-1 pVRMCP3 0.04 0.02 - 
STM-1 pCRsmpB% 0.09 0.08 0.46 
STM-1 pMCsmpB% 0.02 0.03 0.12 
STM-1 pVRsmpB% 0.04 0.03 0.27 
DNA pVRMCP3 0.14 0.12 - 
DNA pMCsmpB# 0.09 0.09 0.34 
DNA pVRsmpB# 0.09 0.07 0.27 
rSmpB* 0.005 0.012 0.066 
 
b) Unstimulated Control/PBS STM-1/DNA#/GST* control 
STM-1 pVRMCP3 0.002 0.002 - 
STM-1 pCRsmpB% 0.075 0.07 0.28 
STM-1 pMCsmpB% 0.05 0.05 0.05 
STM-1 pVRsmpB% 0.12 0.12 0.35 
DNA pVRMCP3 0.02 0.07 - 
DNA pMCsmpB# 0.04 0.06 0.08 
DNA pVRsmpB# 0.08 0.1 0.12 
rSmpB* 0.21 0.42 0.5 
 
Table 4.3: Statistical Analysis of SmpB ELISPOT assay. 
Table 4.3a: Table of IL-4 ELISPOT results showing significance compared to the corresponding 
control.   While most of the treatments induced a significant response (in bold) compared to the 
unstimulated cells (first column) or the untreated control mice (second column), none were significant 
compared to the STM-1, DNA vaccine, or GST controls.   Table 4.3b: Table of IFN-γ ELISPOT results 
showing significance compared to the corresponding control. While several of the treatments induced 
a significant response compared to the unstimulated cells (first column) or the untreated control mice 
(second column), only the STM-1(pCRsmpB) treatment induced a significant response when 
compared to the treatment control (third column). 
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gure 4.12: SmpB-Specific Serum IgG Response of Vaccinated Mice. 
ure 4.12a:   Titration of SmpB vaccinated mouse sera.   The mouse sera were pooled and serial 
utions were performed to determine the optimal titre for ELISA analysis of individual mice.   The 
tigen used in this ELISA was GST-SmpB, explaining the reactivity of sera from mice vaccinated with 
th rGST and rSmpB.   Figure 4.12b:   Appropriate dilutions were chosen from Figure 4.12a, and the 
ra from each mouse was analysed by ELISA.   The sera from mice vaccinated recombinant STM-1 
d DNA vaccines delivering SmpB were diluted 1:10, and the sera from GST and rSmpB vaccinated 
ce was diluted 1:10000.   The reaction of the STM-1 and DNA vaccine control sera could be 
ributed to cross-reacting antibodies induced by STM-1 or by contaminating E. coli proteins in the 
A vaccine preparation.   Vaccination with recombinant SmpB resulted in significantly elevated 
els of serum IgG compared to the PBS control (p = 0.018). 
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Figure 4.13: Anti-SmpB Immunoblot 
Immunoblot performed with pooled sera 
(10mg) was subject to SDS-PAGE and 
approximately ~28kDa represents GST, w
band slightly larger than ~17kDa is Sm
antibodies against GST and SmpB.   Lane 
spontaneous cleavage of the protein has o
~17kDa rSmpB bands 
  1 2Using Sera from SmpB Vaccinated Mice. 
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Figure 4.14: Caecum Weights of SmpB Vaccinated Mice Post Challenge. 
Mice (9 per group) were vaccinated according to the regime described in Table 4.2, and challenged 4 
weeks after the final vaccination.   The caecum of the challenged mice were isolated and weighed, 
and expressed as a percentage of the total bodyweight.   The negative control represents untreated, 
healthy mice. The PBS control is unvaccinated but challenged mice.   Only vaccination with 
recombinant SmpB lowered the caecum to bodyweight ratio compared to the PBS and rGST controls 
(p value 0.01 and 0.005, respectively). 
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Figure 4.15: Gross Caecum Pathological Effects of Vaccinated Mice Post Challenge. 
Mice (9 per group) were vaccinated according to the regime described in Table 4.2, and challenged 4 
weeks after the final vaccination.   The caecum of challenged mice were removed and scored for 
pathology according to Figure 4.1.   None of the recombinant STM-1 vaccines lowered the caecum 
pathological effects compared to the STM-1 control.   Intra-muscular vaccination with DNA vaccines 
encoding SmpB resulted in no significant difference between the vaccinated and control groups.   
Vaccination of mice with recombinant SmpB lowered the observed pathological effects relative to the 
PBS group, however there was large variation within the groups and the effect was not significant. 
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Figure 4.16 : Haemolytic activity of Caecal Contents from SmpB Vaccinated Mice. 
Mice (9 per group) were vaccinated according to the regime described in Table 4.2, and challenged 4 
weeks after the final vaccination.   Haemolysis observed after the caecum homogenates of 
challenged, SmpB vaccinated mice were streaked onto sliced SBA.   Vaccination with recombinant 
STM-1 delivering SmpB showed no effect on haemolytic activity.   DNA Vaccination with naked 
pVRsmpB significantly lowered the amount of haemolysis observed following challenge (p value 0.02).   
The mice vaccinated with GST-SmpB displayed much lower levels of haemolysis compared to the 
PBS and Freund’s-GST control groups (p value = 0.03 & 0.008 respectively). 
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4.3 Discussion. 
In this study, B. hyodysenteriae 5380 was investigated for its ability to infect and 
colonise C3H/HeJARC mice.   Although B. hyodysenteriae was not able to be recovered 
from the faeces of infected mice, the recovery of β-haemolytic bacteria that displayed 
spirochaete morphology post mortem revealed that B. hyodysenteriae 5380 could establish 
an infection in mice.   The inability to reliably and quantitatively enumerate the B. 
hyodysenteriae isolated from the caecum of infected mice meant that alternate methods to 
objectively score the severity of the infection had to be employed.   The caecal weight of 
infected mice was dependent on the dose of B. hyodysenteriae received, and was the only 
objective method of scoring the severity of the pathological effects of infection. 
 
The time point for the termination of the challenge experiment (2 weeks post infection) 
was chosen based on the literature (Nibbelink & Wannemuehler, 1991; Nibbelink & 
Wannemuehler, 1992).   After performing of the challenge experiments, it was shown by 
others that a shorter challenge time resulted in an increase of the severity of caecum 
pathological effects (Davis, 2002a).   Although a longer challenge time was used in this 
study, the caecum still displayed oedema, however in future experiments a shorter challenge 
time should be considered. 
 
The choice of mouse strain is important for the ability of B. hyodysenteriae to establish 
an infection (Nibbelink & Wannemuehler, 1991).   In studies to determine the susceptibility of 
mouse strains to B. hyodysenteriae infection, C3H/HeN mice displayed the most severe 
clinical signs (Nibbelink & Wannemuehler, 1991).   However, as sourcing C3H/HeN mice is 
difficult in Australia, C3H/HeJ mice were chosen as an alternative.   The C3H/HeJ mice carry 
a defective gene encoding Toll-like receptor-4, altering their response to LPS (Poltorak et al., 
1998; Totemeyer et al., 2003).   Prior to performing the SmpB immunogenicity trials, it was 
revealed that the C3H/HeJ mice sourced for the mouse model validation experiments were 
not representative of the C3H/HeJ strain; they had reverted to LPS responsiveness and were 
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renamed C3H/HeJARC mice.   The C3H/HeJACR mice were unavailable for subsequent 
experiments and strain C3H/HeJ was used.   In comparisons, between the experiments 
described here, there were few discernible differences in the responsiveness of the two 
strains. 
 
Several methods for the delivery SmpB were investigated for their ability to induce an 
immune response and afford protection upon challenge with virulent B. hyodysenteriae.   The 
SmpB protein was delivered as recombinant fusion protein, by STM-1 as a recombinant 
protein and as a DNA vaccine, and by direct injection of the naked DNA vaccine.   
Vaccination of mice with STM-1 expressing SmpB or carrying DNA vaccines encoding SmpB 
did not induce a measurable SmpB-specific humoral response as analysed by ELISA.   
Injection of the naked DNA vaccination intra-muscularly also did not induce a measurable 
smpB-specific antibody response.   Optimisation of the DNA vaccination may be necessary, 
as DNA vaccines generally induce relatively low humoral responses (Darji et al., 2000b). 
 
As indicated by the IL-4 ELISPOT and the ELISA results, recombinant STM-1 did not 
induce a carrier antigen specific immune response, as even the lymphocytes isolated from 
the control STM-1 vaccinated mice produced IL-4 in response to rSmpB exposure.   Shared 
epitopes between E. coli and STM-1 proteins may explain the reaction of STM-1 vaccinated 
control mice samples with rSmpB observed in both the ELISA and ELISPOT assays.    
 
Injection of naked pVRsmpB was the only DNA vaccine that induced a SmpB specific 
IL-4 proliferation significantly higher than that of the control mice.   The secreted nature of 
antigens expressed by pVR1020 should induce a primarily IgG1 antibody response, of which 
IL-4 plays a crucial role in regulating (Belardelli, 1995; Boyle et al., 1997; Eckmann & 
Kagnoff, 2001; Inchauspe et al., 1997; Yamamoto et al., 1996).   Despite the presence of an 
IL-4 response in the ELISPOT assay, no significant levels of SmpB-specific antibodies were 
detected, and no change in the caecum pathological effects compared to the control groups 
was observed. 
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The only detectable SmpB specific immune response induced by a recombinant STM-1 
vaccine in this study was observed in the IFN-γ ELISPOT assay.   The delivery of pMCsmpB 
by STM-1 induced a significant SmpB specific IFN- γ response.   Delivery of pMCsmpB by 
STM-1, not injection of pMCsmpB alone, induced the IFN-γ response, suggesting that the 
induction of IFN-γ was stimulated by the presence of STM-1 rather than MCP-3, or possibly a 
combination of the two.   Interferon Gamma plays a central role in mediating the activation of 
macrophages essential for the clearance of S. typhimurium from the host (Gordon et al., 
2005; Mizuno et al., 2003; Muotiala & Makela, 1993).   There is a diverse range of in vivo 
effects induced by MCP-3, including the migration of a broad range of immune cells including 
monocytes, T lymphocytes, eosinophils, basophils and dendritic cells (Butcher & Picker, 
1996; Menten et al., 2001; Mitra et al., 2004; Moser & Loetscher, 2001; Sozzani, 2005).   The 
production of an MCP-3 fusion protein in macrophages or bystander dendritic cells infected 
with the recombinant STM-1 may have amplified the IFN-γ response to detectable levels by 
attracting greater numbers of immune cells to the site of infection.    Despite the levels of 
IFN-γ induced by STM-1(pMCsmpB) vaccination detected in this study, there was no affect 
on caecal weights, pathological effects or haemolysis of the caecum contents after 
challenge. 
 
The most effective method of inducing a SmpB specific immune response was by 
vaccination with rSmpB delivered in Freund’s Adjuvant, with high numbers of IL-4 secreting 
splenocytes and high titres of antibody being detected in vaccinated mice.   While cleavage 
of the GST moiety from SmpB was unable to be achieved, Western  blot analysis 
demonstrates that antibodies against SmpB were raised.   This vaccination method was also 
the only regime that lowered the observed pathological effects and caecal weight upon 
challenge, indicating that an immune response directed against SmpB may contribute to 
protection from SD.   Vaccination with rSmpB did not induce any IFN-γ secreting cells as 
demonstrated by ELISPOT analysis of spleen lymphocytes.   This suggests that any change 
in the pathological effects induced by infection with B. hyodysenteriae 5380 may be a result 
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of a SmpB-specific antibody response detected by ELISA and Immunoblot analysis.   This 
emphasises the importance of inducing antibodies to a mucosal pathogen such as B. 
hyodysenteriae, as the only vaccination regime that induced IFN-γ (pMCsmpB delivered by 
STM-1) did not affect the pathological effects after challenge, and humoral response was 
detected in this vaccinated group.   The importance of anti-SmpA antibodies has previously 
been demonstrated (Thomas & Sellwood, 1992), and a similar importance may be attributed 
to anti-SmpB antibodies. 
 
It was observed in this study that SmpB vectored by STM-1 was largely unable to 
induce an SmpB-specific immune response, whether delivered as a heterologous antigen 
expressed by STM-1, or delivered as a DNA vaccine by STM-1.   Furthermore, the only 
SmpB specific immune response induced by a recombinant STM-1 vaccines (the IFN-γ 
response induced by STM-1(pMCsmpB)) was not able to reduce the pathological effects 
after challenge, suggesting the immune response was not large enough or not appropriate 
for protection against SD.   The lower pathological effects observed in the STM-1 control 
mice could be a result of previous exposure to STM-1 before challenge with B. 
hyodysenteriae.   The induction of a mucosal immune response after vaccination with STM-1 
may result in larger numbers of host immune cells than normal in the GALT.   There is 
precedence for this effect, as prior exposure to Mycobacterium tuberculosis or Toxoplasma 
gondii can protect from Plasmodium yoelii infection (Haque et al., 1999; Matsumoto et al., 
2000; Page et al., 2005; Scott et al., 2004). 
 
The lack of an immune response induced by recombinant STM-1 delivering SmpB may 
be the result of several factors.   The metabolic load placed upon the organism by 
maintenance of the plasmid, combined with the attenuation of the organism can affect the 
growth of the recombinant vaccine which can in turn affect the induced immune response 
(Cheah et al., 1987; Dunstan et al., 2003; Galen & Levine, 2001; Glick, 1995; Knodler et al., 
2005; Smith & Bidochka, 1998).   Factors such as the copy number of the expression vector, 
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and the nature and level of expression of the heterologous antigen can effect the growth of 
the recombinant vaccine.  
 
The metabolic load on a recombinant organism greatly effects the growth rate (Cheah 
et al., 1987; Chen et al., 2005; Dunstan et al., 2003; Galen & Levine, 2001; Garmory et al., 
2002; Knodler et al., 2005).   The recombinant STM-1 in this study clearly were effected by 
the maintenance of expression vectors and expression of the encoded protein, as indicated 
by the ~6 hours to reach mid-log phase in growth experiments.   The slower growth would 
possibly allow the host to clear the vaccine strain before a large carrier-antigen specific 
immune response can be induced.   The results of the macrophage survival study support 
this theory, as one of the vaccine strains in particular was unable to replicate within the 
phagosome.   However, it must be kept in mind that the behaviour of bacteria during in vitro 
invasion assays may not reflect the in vivo performance (Garmory et al., 2002).   The 
persistence of recombinant STM-1 in infected mice is an area for further study. 
 
Also of importance for the generation of an immune response is maintenance of the 
plasmid encoding the heterologous antigen in the absence of any selective pressure 
(Dunstan et al., 2003; Garmory et al., 2003).   The loss of the plasmid by the removal 
antibiotics in the host would result in less exposure of the host to the antigen.   In this 
investigation the three vaccines strains of STM-1 had lower levels of plasmid retention 
compared to the control plasmids over the five days of the stability study.   Therefore any 
further studies regarding the persistence of STM-1 carrying heterologous antigens must 
consider not just recovery of the STM-1 from the host, but also the percentage of cells 
retaining the plasmid encoding the heterologous antigen.   The use of antibiotic pressure by 
incorporating antibiotics into the mouse diet may also improve the stability of the plasmids. 
 
The choice of plasmid also has a large influence on the stability of the plasmid 
(Dunstan et al., 2003).   The pCRsmpB plasmid is constitutively expressed whereas plasmids 
based on the CMV promoter should not express until the plasmid transfects the host cells.   
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The constitutive expression of the protein should increase the metabolic load on the 
organism, increasing the inclination towards loss of the plasmid (Corchero & Villaverde, 
1998).   Methods that may be used to optimise the delivery of heterologous antigens by 
STM-1 will be further discussed in Chapter 5. 
 
The animal model used in this study (infection of C3H/HeJ mice) was optimised to 
increase the observed pathological effects upon challenge with B. hyodysenteriae.   In 
strains of mice innately resistant to S. typhimurium, which includes C3H/HeJ mice, initial 
growth of the S. typhimurium is slow (O'Brien et al., 1984; O'Brien et al., 1985; Totemeyer et 
al., 2003).   C3H/HeN mice are able to control the infection in the spleen, unlike the C3H/HeJ 
mice which die when the bacterial load in the spleen increases uncontrollably as a result of 
the TLR4 receptor mutation (O'Brien et al., 1984; O'Brien et al., 1985; Poltorak et al., 1998; 
Totemeyer et al., 2003).   Although S. typhimurium infection of C3H/HeJ mice is lethal, the 
initial slow growth of S. typhimurium in this mouse strain combined with the attenuation and 
metabolic load increase of the recombinant STM-1 vaccines may allow clearance of the 
vaccine strain before the induction of a significant carrier antigen specific immune response. 
 
Despite the inability of STM-1 to induce a significant carrier antigen specific immune 
response in this study, STM-1 has previously been shown to be able to induce such as 
immune response (Bachtiar et al., 2003).   A model antigen, ovalbumin, was able to induce a 
specific immune response when delivered by STM-1, including CD8+ T lymphocyte and IgA 
immune responses.   The ability of STM-1 to induce an ovalbumin specific immune response, 
yet not a SmpB specific immune response demonstrates that the nature of the antigen, and 
not only the plasmid (the plasmids used by Bachtiar et al. were also based on the CMV 
promoter), may be important for the induction of a strong immune response by STM-1.   The 
nature of the encoded antigen has been previously demonstrated to influence the growth of 
the recombinant organism (Corchero & Villaverde, 1998). 
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There is precedence for vaccination with recombinant outer membrane proteins of B. 
hyodysenteriae providing protection from challenge.   Vaccination of swine with recombinant 
His-tagged BmpB lowered the incidence of disease by approximately 50% following 
challenge with B. hyodysenteriae (La et al., 2004).   In the same experiment, vaccination with 
a maltose-binding protein/BmpB fusion did not induce an immune response nor confer any 
protection against challenge.   This suggests that the mode of purification used to isolate 
recombinant protein for vaccination purposes may play a critical role in the immune response 
induced.   Considering the innate instability of the GST-SmpB fusion protein and the 
degradation following thrombin treatment, evaluation of other methods of purifying SmpB is 
crucial for any further experiments.   Purification of His-tagged SmpB was attempted, 
however degradation of the His-SmpB protein was observed during the purification process 
(George Moutafis, personal communication). 
 
The discovery of SmpB and its relationship to SmpA (See Chapter 3) allows the 
possibility of vaccination with these proteins as the suspected sequence variation or 
duplication of smpA (Turner et al., 1995) has been explained.   As vaccination with purified 
recombinant SmpB alleviated some of the pathological effects observed following B. 
hyodysenteriae challenge, further studies into the immunogenicity and protection is swine 
may be important.   Vaccination with SmpB will only ever protect swine from approximately 
half the strains of B. hyodysenteriae, as that is the limit of its distribution.   However, as no 
studies have been conducted regarding the immunogenicity of SmpA and the protection 
induced following vaccination, combined vaccination with both SmpA and SmpB may provide 
protection against all strains.   Furthermore, most experimented vaccines to date have only 
afforded partial, if any protection against challenge (Davis et al., 2005; Diego et al., 1995; 
Fernie et al., 1983; Hampson et al., 1993; La et al., 2004; Olson et al., 1994; Waters et al., 
1999a).   Complete protection may only be possible by vaccinating with a combination of 
proteins and cell components to which SmpB and SmpA may contribute 
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Chapter 5 – An Evaluation of the Immunogenicity and 
Protective Responses to Recombinant HlyA Vaccination. 
 
5.1 Introduction. 
The B. hyodysenteriae β-haemolysin HlyA was investigated for its ability to invoke an 
immune response and protect mice against Swine Dysentery.   There are four putative 
haemolysins produced by B. hyodysenteriae, TlyA, TlyB, TlyC And HlyA (Hsu et al., 2001; ter 
Huurne et al., 1994).   The HlyA haemolysin was chosen for investigation as, of these four, it 
was the only protein that was discovered by purifying native β-haemolysin from B. 
hyodysenteriae and directly linking the N-terminal sequence of the haemolytic protein to the 
encoding gene (Hsu et al., 2001).  
 
The HlyA haemolysin is a predicted 8.93 kDa protein that is haemolytic when 
expressed in E. coli (Hsu et al., 2001).   Sequence analysis (BLAST) of hlyA revealed 
sequence similarity with Acyl Carrier Proteins (ACPs) from several different bacteria, 
however no similarity with known haemolysins was identified (Hsu et al., 2001).   The HlyA 
haemolysin contains a phosphopantetheine binding motif indicating that HlyA binds lipids 
through a thioester intermediate in a similar way to acyl carrier proteins (Mayo & Prestgard, 
1985; Rawlings & Cronan, 1992).   Initially hlyA was identified only in B. hyodysenteriae and 
not in non-haemolytic Brachyspira spp., a finding which supported its role as a haemolysin 
(Hsu et al., 2001).   Recent investigations have identified hlyA in the weakly haemolytic B. 
pilosicoli (Zuerner et al., 2004), which suggests that other factors besides the presence of 
hlyA contribute to the haemolytic phenotype.   The weakly haemolytic phenotype of B. 
pilosicoli, despite the presence of a functional hlyA, was speculatively explained by 
differences in regulation of hlyA in the two species  (Zuerner et al., 2004).    
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With the discovery of hlyA, the role of the TlyA, TlyB and TlyC proteins in haemolysis 
was questioned (Hsu et al., 2001).   It was proposed that TlyA, TlyB and TlyC are regulatory 
proteins that could upregulate a cryptic haemolysin in E. coli, altering the phenotype (Hsu et 
al., 2001).   The activity of the proteins may be similar in B. hyodysenteriae.   However the 
discovery of a haemolysin in Mycobacterium tuberculosis with sequence similarity to TlyA 
suggests that at least one of TlyA, TlyB and TlyC may play a more central role in haemolysis 
(Wren et al., 1998).   There is potentially more than one haemolysin produced by B. 
hyodysenteriae, which would also explain the size differences of proposed haemolytic 
proteins observed in several studies (Hsu et al., 2001; Hutto & Wannemuehler, 1999; Kent et 
al., 1988; Knoop, 1981; Muir et al., 1992; Saheb et al., 1980). 
 
The production of toxins by pathogenic bacteria often contributes to the observed 
pathological effects of the disease (Fernandez Miyakawa et al., 2005; Firoved et al., 2005; 
Hutto & Wannemuehler, 1999; Kennedy et al., 2005; Lysons et al., 1991; Nizet, 2002).   An 
immune response generated against pathogenic toxins often reduces or eliminates the 
activity of the toxin, and is often enough to prevent the disease (Barry et al., 2003; Batzloff et 
al., 2003; Hauer et al., 2006; Naito et al., 2000; Taranger et al., 1999).   In the case of SD, 
the importance of toxins has been demonstrated through the avirulence of putative 
haemolysin knock-out mutants and by the production of SD like pathological effects after 
administration of purified haemolysin preparations to the  ileum and colon of swine (Binek et 
al., 1995; Hyatt et al., 1994; Hyatt & Joens, 1997a; Hyatt & Joens, 1997b; Lysons et al., 
1991; ter Huurne et al., 1992; ter Huurne et al., 1993; ter Huurne et al., 1994).    
 
Mutants lacking tlyA were avirulent when administered to swine, and afforded partial 
protection after challenge with wild-type B. hyodysenteriae (Hyatt et al., 1994).   Many of the 
early  experiments were performed without knowledge of which putative β-haemolysin (TlyA, 
TlyB, TlyC or HlyA) was being studied, so it is unknown which biochemical properties belong 
to which haemolysin (Kent et al., 1988; Knoop, 1981; Lemcke & Burrows, 1982; Lysons et 
al., 1991; Saheb et al., 1980; Takahashi et al., 1987).   Furthermore these early experiments 
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to characterise the molecular weight of the native β-haemolysin identified many varying 
apparent molecular sizes, from 96kDa to 10kDa (Hsu et al., 2001; Hutto & Wannemuehler, 
1999; Kent et al., 1988; Knoop, 1979; Muir et al., 1992; Saheb et al., 1980), compounding 
the confusion surrounding which is the protein or proteins responsible for the β-haemolysis 
induced by B. hyodysenteriae.  
 
As noted above, vaccination against toxin molecules may be a viable strategy to 
protect against disease.   In this context, several vaccination regimes were used to 
investigate the immunogenicity of the HlyA haemolysin and the protection conferred by 
vaccination.   Stratagems chosen were recombinant protein and DNA vaccination, as well as 
delivery of protein and DNA vaccines by attenuated bacterial vaccine.   Recombinant HlyA 
was expressed in STM-1 by inserting hlyA into pCR2.1, under the control of its own 
promoter.   The DNA vaccines chosen were pVR1020 and pVRMCP-3, whose characteristics 
have been discussed in Chapter 4.   Recombinant, purified HlyA (rHlyA) was also injected as 
a subunit vaccine to test the immunogenicity of the protein itself. 
 
 
The aims of the studies described here  were: 
 
1) To analyse the activity of recombinant B. hyodysenteriae HlyA β-haemolysin 
2) To clone hlyA into various expression vectors, 
3) To compare several vaccination methods for the induction of immune responses: 
a) Recombinant protein vaccination, 
b) DNA vaccination, 
c) Delivery of recombinant HlyA by STM-1. 
d) Delivery of DNA vaccines encoding HlyA by STM-1. 
5.2 Results. 
5.2.1 Construction of HlyA Expression Vectors. 
Expression of HlyA by STM-1 was achieved by cloning hlyA coding regions with the 
upstream promoter regions into pCR2.1.   The primers HlyA1 and HlyA2 were designed and 
the PCR was optimised.   The conditions for this PCR were 92°C for 2 mins followed by 35 
cycles of 92°C for 30s, 53°C for 30s, and 72°C for 1 min, with a final elongation at 72°C of 7 
mins.   The PCR product was directly cloned into pCR2.1 according to the manufacturers 
instructions (Figure 5.1).   The orientation and integrity of the inserted hlyA in pCRhlyAP was 
confirmed by DNA sequence characterisation.   The lack of antisera against native HlyA did 
not allow the confirmation of expression of HlyA from pCRhlyAP within transformed bacteria. 
 
Two PCR primers (HlyAORF1 and HlyAORF2) were designed to exclude the ATG start 
codon of hlyA to facilitate cloning in frame with the ATG start codon of pVR1020 and 
pVRMCP3.   The conditions for this PCR were 92°C for 2 mins followed by 35 cycles of 92°C 
for 30s, 50°C for 30s, and 72°C for 1 min, with a final elongation at 72°C of 7 mins.   The 
HlyAORF PCR product was inserted into the PCR2.1 TA cloning vector according to the 
manufacturers instructions.   The integrity of the hlyA ORF in pCRhlyA was confirmed by 
DNA sequence characterisation.     
 
Following digestion of pCRhlyA with BamHI, the hlyA fragment was excised and 
purified from an agarose gel after electrophoresis.   The hlyA insert was cloned into BamHI 
digested pVR1020 and pVRMCP3 to give pVRhlyA (Figure 5.2a) and pMCPhlyA, 
respectively (Figure 5.3a).   To confirm the orientation of the inserted hlyA in the expression 
plasmids, the primers HlyAORF2 and VR1020-1 were used.   After PCR amplification, only 
plasmids with hlyA inserted in the correct orientation produced a product (Figure 5.2b and 
Figure 5.3b).   The orientation and integrity of the insert in the isolated recombinant clones 
was confirmed by DNA sequence characterisation. 
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Before the expression vectors containing hlyA could be used in immunisation 
experiments utilising STM-1, the vectors pCRhlyAP, pVRhlyA and pMCPhlyA passaged 
through S. typhimurium LT2 to stabilise the plasmids.   The plasmids were then re-isolated 
and transformed into S. typhimurium STM-1 prior to evaluation and vaccination (Figure 5.4). 
 
5.2.2 Maintenance of HlyA Expression Vectors in STM-1. 
The maintenance of expression plasmids in S. typhimurium STM-1 was characterised 
by performing plasmid stability studies.   After performing the trials in triplicate, it was shown 
that the three plasmids containing hlyA were less stable than the empty vectors.   Following 
4-5 days of culture (~50 generations), the expression vectors were only present in <5% of 
STM-1, whereas the control plasmids were still present in ~50% of S. typhimurium STM-1 
(Figure 5.5).   The effect of plasmid maintenance on S. typhimurium STM-1 was further 
characterised by in vitro macrophage survival studies.   The murine macrophage line J774 
was infected with STM-1 harbouring the hlyA expression plasmids, and the presence of 
STM-1 was assayed at 0, 2, 8 and 24 hours in triplicate (Figure 5.6).   Unlike the smpB 
expression vectors (Chapter 4), the presence of the hlyA expression vectors did not effect 
the ability of STM-1 to invade and replicate inside macrophages in vitro. 
 
5.2.3 Production and Evaluation of Recombinant HlyA. 
5.2.3.1  Production and purification of Recombinant HlyA. 
Insertion of hlyA into pRSET-A was accomplished by digesting pCRhlyA with BamHI, 
and purifying the hlyA fragment from an agarose gel after electrophoresis.   The purified hlyA 
fragment was then ligated with BamHI digested pRSET-A, to give pRShlyA (Figure 5.7).   
The orientation of hlyA in pRShlyA was confirmed by DNA sequence characterisation.   The 
recombinant, His-Tagged HlyA (rHlyA) was purified by immobilised metal affinity 
chromatography (IMAC) (Figure 5.8a).   The purification of rHlyA was optimised, and 100mM 
Imidazole was chosen for elution of rHlyA from the column.   Purification of the correct sized 
product was confirmed by the results of an Anti-His Immunoblot (Figure 5.8b). 
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Figure 5.6: Survival of STM-1 harbouring HlyA Vaccines Inside J774 Macrophages. 
 Following infection of J774 macrophages with the recombinant STM-1 vaccines, the viable cell count 
increased quickly to ~1x103 cfu at 2 hours.   The viable cell count then steadily decreased to almost 0 
at 24 hours.   None of the hlyA expression vectors repressed the growth of STM-1 inside the J774 
macrophages. 
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5.2.3.2  Activity of Recombinant HlyA. 
The activity of the recombinant HlyA was analysed by plating the recombinant E. coli 
on SBA, and by performing haemolysin assays.   The plasmids pCRhlyA and pRShlyA were 
both analysed for the ability to alter the phenotype of E. coli Top10F’ and BL21, respectively.   
The presence of recombinant HlyA was not able to alter the phenotype of the recombinant E. 
coli (Figure 5.10a, b, c and d).   Haemolysis was observed over the two days of the trial, 
however similar amounts of haemolysis was also observed in the control E. coli.   Several 
additional strains of E. coli were also tested (JM109, HB101, DH5a, Top10F, BL21, InvF), 
with no increase in the haemolytic activity conferred. 
 
The lack of increased haemolysis observed was inconsistent with that seen by Hsu et 
al. (2001), who found that hlyA altered the haemolytic phenotype of E. coli.   The possibility is 
that other genes in the fragment cloned by Hsu et al. contributed to the changed haemolytic 
phenotype.   To determine if this was the case, the primers hlyAclus1 and hlyAclus2 were 
designed to amplify a larger fragment of the genome surrounding hlyA, including one gene 
either side (fabF and fabG).   The conditions for this PCR were 92°C for 2 mins followed by 
35 cycles of 92°C for 30s, 50°C for 30s, and 72°C for 1 min, with a final elongation at 72°C of 
7 mins.   The hlyAclus PCR product was then cloned into pCR2.1 according to the 
manufacturers instructions (Figure 5.9).   Despite the presence of hlyA, fabF and fabG no 
alteration of the phenotype was observed in the recombinant E. coli (Figure 5.10). 
 
The haemolysis induced by rHlyA and native B. hyodysenteriae extracts was further 
analysed by performing a haemolysin assay, twice, in triplicate (Figure 5.11).   Haemolytic 
activity was observed in the B. hyodysenteriae 5380 and P18A whole cell extracts, as well as 
in the rHlyA sample supplemented with CaCl2 (Figure 5.11a).   This initially suggested that 
the rHlyA has some haemolytic activity.   However, further analysis of the haemolytic activity 
revealed that the presence of CaCl2 combined with PBS was resulting in a positive 
haemolytic score (Figure 5.11b).   Therefore, the presence of the rHlyA in the assay was 
probably not contributing to the haemolysis observed in Figure 5.11a. 
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Figure 5.10: Haemolytic Activity of E. coli Expressing HlyA on Sheep Blood Agar. 
Figure 5.10a: Haemolytic activity of E. coli BL21 on SBA. Figure 5.10b: Haemolytic activity of E. coli 
Top10F’ on SBA. Figure 5.10c: Haemolytic activity of E. coli BL21 (pRShlyA) on SBA. Figure 5.10d: 
Haemolytic activity of E. coli Top10F’ (pCRhlyAP) on SBA. Figure 5.10e: Haemolytic activity of E. coli 
Top10F’ (pCRhlyAclus) on SBA 
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Figure 5.11: Haemolysin assay for HlyA. 
Figure 5.11a: Haemolytic activity of various protein extracts performed in triplicate.   Significant 
haemolytic activity was observed in the two B. hyodysenteriae strains, and the rHlyA supplemented 
with CaCl2 (p value 0.0017) compared to the E. coli Top10F control Figure 5.11b:   Haemolysin assay 
demonstrating that the observed haemolysis in the rHlyA sample supplemented with CaCl2 most likely 
is a result of the presence of CaCl2 in the PBS.   Error bars are included, but do not display due to 
their size. 
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5.2.4  HlyA Vaccination Trials. 
The immunogenicity and potential protection induced by HlyA vaccination was 
investigated by inoculating mice 3 times over a 6 week period with either 1x109 cfu 
recombinant STM-1, 100µg of DNA or 50µg of rHlyA (Table 5.1).   Four weeks following the 
final vaccination, 3 mice were sacrificed, their spleens removed and ELISPOT assays 
performed to enumerate HlyA-specific cytokine producing cells.   The remaining mice were 
challenged with 1x 108 cfu of B. hyodysenteriae 5380.   Two weeks post challenge, the mice 
were sacrificed and their caecum were scored for pathological effects, removed, weighed 
and the caecum contents cultured.   Blood samples were taken prior to challenge to evaluate 
the antibody response induced by HlyA. 
 
5.2.4.1  Analysis of HlyA-Specific Cytokine Secreting Cells. 
Four weeks after the final vaccination, three mice were sacrificed and the spleens 
removed for lymphocyte analysis by ELISPOT assay.   Results are presented in Figure 5.12, 
with several control groups.   The unstimulated cells determines the baseline number of IL-4 
and IFN-γ producing lymphocytes from vaccinated mice.   The control mice show the number 
of IL-4 and IFN-γ producing lymphocytes from unvaccinated mice.   Low numbers of IL-4 and 
IFN-γ secreting cells were produced by unstimulated lymphocytes and lymphocytes from 
control mice, as was expected.   Vaccination of mice with rHlyA resulted in a significant 
increase in the number of IL-4 and IFN-γ producing cells compared to the PBS/Freund’s 
control (p value 0.0021 and 0.0023 respectively) (Figure 5.12).   ELISPOT analysis of STM-1 
vaccinated and DNA vaccinated mice generated negative results. 
 
5.2.4.2 Serum Antibody Responses. 
Serum from each mouse group was pooled and 1:10 serial dilutions were performed.   
Each of the dilutions was analysed by ELISA using the rHlyA as the immobilised protein 
(Figure 5.13a).   This information was used to determine the dilution of sera used for each 
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mouse when analysed individually.   A dilution of 1:100 was chosen for mice inoculated with 
the recombinant STM-1 vaccines, and a dilution of 1:100000 was chosen for the mice 
inoculated with rHlyA.   This indicates that the mice vaccinated with rHlyA had a much higher 
rHlyA specific antibody response than those inoculated with recombinant STM-1 vaccines. 
 
The largest serum antibody response was observed in the rHlyA/Freund’s vaccinated 
group when compared to the PBS/Freund’s control (p value 0.00019) (Figure 5.13b).   
Inoculation of mice with pVRhlyA and pMChlyA resulted in significantly elevated HlyA-
specific serum antibody levels (p values 0.017 and 0.0025 respectively) compared to the 
DNA vaccine control mice (Figure 5.13b). 
 
As with the SmpB immunogenicity trials (Chapter 4), the reactivity of serum from mice 
in the STM-1 control groups did not allow inferences to be made about the HlyA specific 
antibody response induced by recombinant STM-1 strains.   The presence of serum 
antibodies in control groups could be due to cross-reacting epitopes conserved between 
STM-1 and E. coli BL21 proteins contaminating the recombinant antigen used for the ELISA. 
 
5.2.4.3  Challenge of HlyA Vaccinated mice with Brachyspira hyodysenteriae. 
5.2.4.3.1 Caecum Pathological effects of Vaccinated Mice Following Challenge.  
The caeca of HlyA vaccinated mice infected with B. hyodysenteriae were harvested 
and weighed (Figure 5.15).   The negative control in Figure 5.15 represents healthy, 
unchallenged mice and gives a baseline for normal caecum.   Challenge of mice vaccinated 
with STM-1(pMChlyA) resulted in a significant increase in the mean caecal weight compared 
to the STM-1 control (p value 0.031).   Challenge of mice vaccinated with recombinant STM-
1 (pCRhlyAP) resulted in a decrease in the mean caecal weight to below that of the STM-1 
control (p value 0.037) (Figure 5.15).   No other STM-1 vaccination group lowered the caecal 
weight significantly. 
 
 
 180
 
 
Group Treatment Delivery Dose Route 
1 None N/A N/A N/A 
2 pVR1020 STM-1 1x109cfu Oral 
3 pVRhlyA STM-1 1x109cfu Oral 
4 pMChlyA STM-1 1x109cfu Oral 
5 pVR1020 DNA 50µg I.M. 
6 pVRhlyA DNA 50µg I.M. 
7 pMChlyA DNA 50µg I.M. 
8 PBS Freund’s 0 I.P 
9 rHlyA Freund’s 50µg I.P. 
 
Table 5.1: HlyA vaccination regime. 
Regime for the HlyA vaccine trials.   Each group comprised of 9 mice.   Mice were vaccinated 
at weeks 0, 3 and 6.   Four weeks after the final vaccination, 3 mice were sacrificed for 
ELISPOT analysis of spleen lymphocytes.   The remaining 6 mice were challenged with B. 
hyodysenteriae 5380.   Two week following challenge, the mice were sacrificed and their 
caecum analysed for any pathological effects. 
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Figure 5.12: Enumeration of HlyA-Specific Cytokine Secreting by ELISPOT Assay. 
Mice (3) were vaccinated with HlyA according to the regime set out in Table 5.1.   Four weeks 
post vaccination, spleens were harvested and analysed by ELISPOT.  Figure 5.12a:   Vaccination 
of mice with rHlyA resulted in a significant increase in the number of IL-4 producing cells enumerated 
by ELISPOT assay (p value 0.0021).   Figure 5.12b: Vaccination of mice with rHlyA resulted in a 
significant increase in the number of IFN-γ producing cells enumerated by ELISPOT assay (p value 
0.0023).   ELISPOT analysis of STM-1 vaccinated and DNA vaccinated mice showed no increase in 
enumeration over control cells (not shown). 
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Figure 5.13: HlyA-Specific Serum IgG Response of HlyA vaccinated mice. 
Figure 5.13a: Serial 1:10 dilutions were made of pooled sera and analysed by ELISA.   The largest 
antibody response was observed in the rHlyA group, which was diluted 1:100000 for subsequent 
ELISA analysis using individual sera.   A smaller antibody response was observed in mice vaccinated 
with pVRhlyA, which was diluted 1:100 for subsequent ELISA analysis.   The antigen used in this 
ELISA was recombinant HlyA Figure 5.13b: ELISA of HlyA-specific serum antibodies from mice 
inoculated with HlyA vaccines.   None of the STM-1 vaccines generated a significant HlyA-specific 
HlyA immune response.   Inoculation with pVRhlyA and pMChlyA showed significantly elevated HlyA-
specific serum antibody levels (p = 0.017 and 0.0025 respectively).   The largest antibody response 
was observed in the rHlyA/Freund’s inoculated mice (p value 0.00019). 
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Figure 5.14: Anti-HlyA Immunoblot using Sera from HlyA Vaccinated Mice. 
Antisera raised in mice vaccinated with rHlyA/Freunds (diluted 1:2000) was used for Immunoblot 
analysis of a lysate from E. coli expressing HlyA  (10mg).   This confirms that HlyA can be expressed 
in E. coli under the control of its own promoter regions.   The larger bands at ~30kDa are assumed to 
be multimers of the rHlyA.   Lane 1, MW Marker; Lane 2, E. coli (pCRhlyAP). 
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Vaccination with the DNA vaccines encoding HlyA did not result in significantly lower 
mean caecal weight following challenge compared to the DNA vaccine control (Figure 5.15).   
A similar trend was observed in the caecum pathological measurements.   There was no 
significant difference in the caecum pathological changes between the STM-1 control groups 
and the recombinant STM-1 vaccine groups following challenge with B. hyodysenteriae 
(Figure 5.16).   Similarly, there was no significant difference in the caecum pathological 
changes between the pVRhlyA and pVR1020 DNA vaccine mice after challenge. 
 
Compared to the PBS/Freund’s control, vaccination with rHlyA delivered in Freund’s 
significantly lowered the mean caecal weight (Figure 5.15) but not the caecal pathological 
changes (Figure 5.16) following challenge with B. hyodysenteriae (p value 0.0056).   This 
correlated to the largest observed titre of HlyA specific serum antibodies (Figure 5.13) and 
cytokine producing cells (Figure 5.12). 
 
5.2.4.3.2 Haemolytic Activity of Caecal Homogenates of challenged mice.  
The haemolytic activity observed after streaking the caecum contents onto sliced SBA 
showed similar patterns to the caecal weight and pathological changes.   There was no 
significant difference in the haemolytic activity of caecal homogenates from STM-1 control 
mice and recombinant STM-1 vaccine inoculated mice (Figure 5.17).   Similarly, there was no 
difference in the haemolytic activity of caecal homogenates from the DNA vaccine control 
mice and mice vaccinated with DNA vaccines encoding hlyA.   Unlike the results of the 
caecal weight and pathological changes, vaccination with recombinant HlyA did not 
significantly lower the haemolytic activity of caecal homogenates following challenge 
compared to the PBS/Freund’s control (p value 0.055). 
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Figure 5.15: Caecum Weights of HlyA Vaccinated Mice after Challenge. 
Caecum to bodyweight ratio of 6 HlyA vaccinated mice challenged with B. hyodysenteriae 5380, 
expressed as a percentage of the total bodyweight.   The negative control represents untreated, 
healthy mice.   The PBS/Freund’s control mice were vaccinated with a placebo and challenged.   The 
recombinant STM-1 (pCRhlyAP) vaccine lowered the caecal weight to below that of the STM-1 control 
(p value 0.037).   No other STM-1 vaccination group lowered the caecal weight significantly, however 
STM-1(pMChlyA) increased the caecal weight significantly compared to the STM-1 control (p value 
0.031).   Neither of the DNA vaccines encoding HlyA lowered the caecal weight compared to the DNA 
vaccine control.   Vaccination with rHlyA delivered in Freund’s lowered the caecal weight significantly 
compared to the PBS control (p value 0.0056). 
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ure 5.16 : Gross Caecum Pathological changes of Vaccinated Mice Post Challenge.  
 caecum pathological changes of 6 HlyA vaccinated mice challenged with B. hyodysenteriae 5380.   
e of the STM-1 delivered HlyA vaccines significantly lowered the observed pathological changes 
pared to the STM-1 control.   DNA vaccination with expression vectors encoding HlyA did not 
ce the pathological effects observed significantly.   Although vaccination of mice with recombinant 
 lowered the observed pathological effects, this was not significant compared to the PBS/Freunds 
trol group. 
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ure 5.17 : Haemolytic Activity of Caecal Homogenates from HlyA Vaccinated Mice. 
molysis observed after the caecum homogenates of 6 challenged, HlyA vaccinated mice were 
aked onto sliced SBA.   None of the HlyA expression vectors delivered by STM-1 reduced the 
molysis significantly.   None of the HlyA expression vectors delivered by DNA vaccination reduced 
haemolysis significantly.   Vaccination of mice with recombinant HlyA did not significantly lower the 
molysis compared to the PBS control group following challenge (p value 0.055). 
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5.3 Discussion. 
In this study, recombinant, Histidine tagged HlyA was purified by IMAC and 
demonstrated good levels of recovery and purity.   The purified protein was identified as the 
correct product by anti-His tag immunoblot, however the rHlyA did not react with anti-B. 
hyodysenteriae 5380 antisera, suggesting either possible structural differences between 
native and recombinant HlyA, or a lack of antibody production to HlyA during SD.   The rHlyA 
was also analysed for haemolytic activity using several methods, however no experiment 
performed in this study demonstrated that the rHlyA protein had any haemolytic activity.   
This contradicts earlier experiments where cloning of hlyA and expression in E. coli altered 
the haemolytic phenotype (Hsu et al., 2001).   The lack of haemolytic activity when the 
protein was purified as a His-tagged protein could be due to several reasons.   The His-tag 
may interfere with the correct folding or processing of rHlyA, or may interfere with the 
acylation of the toxin.   However, in this study, even recombinant HlyA expressed in E. coli 
without the presence of the His-tag was non-haemolytic, suggesting that the His-tag itself 
does not abrogate haemolytic activity.  
 
The HlyA haemolysin is present in both the haemolytic B. hyodysenteriae and the non-
haemolytic B. pilosicoli.    It was postulated that different levels of expression of HlyA 
between the two strains, or different acylation of HlyA may explain the different phenotypes 
(Zuerner et al., 2004), however this was not experimentally confirmed by analysing the 
expression of the genes in the two strains.   Upon the discovery of HlyA, it was suggested 
that the TlyA haemolysin may be a regulatory protein that upregulates a cryptic haemolysin 
in E. coli, in a similar manner to the SlyA ‘haemolysin’ in S. typhi (Hsu et al., 2001).   The 
inability to demonstrate any haemolytic activity in this study, combined with the discovery of a 
haemolysin in M. tuberculosis with similarity to TlyA, may suggest that HlyA may only be 
indirectly involved with the haemolytic process (Wren et al., 1998). 
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The B. hyodysenteriae HlyA β-haemolysin shows high levels of similarity to various 
Acyl Carrier Proteins (ACPs) from a variety of different organisms.   These ACPs perform a 
myriad of metabolic tasks including lipid metabolism and toxin acylation (Branen et al., 2003; 
Magnuson et al., 1993b; Rock & Jackowski, 1982; Stanley et al., 1998; Tang et al., 1997; 
Worsham et al., 2003).   The essential role of lipids for the toxicity of HlyA haemolysin from 
E. coli, a member of the RTX toxin family has been well documented (Herlax & Bakas, 2003; 
Koronakis & Hughes, 1996; Stanley et al., 1998).   An acyl-transferase (HlyC) is required for 
the formation of a functional haemolysin, transferring a fatty acid molecule from an acyl-ACP 
(Issartel et al., 1991; Koronakis & Hughes, 1996).   As with the E. coli ACP, HlyA may only 
play a role in the modification of the β-haemolysin, with the actual β-haemolysin encoded by 
a different gene not present in B. pilosicoli, possibly TlyA. 
 
Furthermore, the original experiments demonstrating that HlyA alters the haemolytic 
phenotype of E. coli cloned several fragment of B. hyodysenteriae DNA ranging from 4 to 5.5 
kb that reacted with the degenerate probe (Hsu et al., 2001).   It may be possible that other 
genes encoded in the cloned fragment contribute to the haemolytic phenotype.   However, 
the inability to find an E. coli strain that was non-haemolytic over the 2 days required for the 
assay (Hsu et al., 2001) made demonstrating the haemolytic ability of HlyA with or without 
the flanking genes impossible.   The similarity between the genome surrounding hlyA and the 
gene cluster in other organisms involved in fatty acid synthesis, not haemolysis, suggests 
that the role of HlyA and the E. coli ACP are very similar (Kutchma et al., 1999; Rawlings & 
Cronan, 1992; Zuerner et al., 2004).   The introduction of new ACPs, possibly carrying novel 
acyl groups, into E. coli may alter the haemolytic ability of any cryptic haemolysins latent in 
E. coli.   It has been shown that altering the lipid moiety can dramatically effect membrane 
interactions of acylated peptides, which was also used to explain difference in the haemolytic 
activity between B. hyodysenteriae and B. pilosicoli (Peitzsch & McLaughlin, 1993; Zuerner 
et al., 2004).   Further experiments utilising recombinant E. coli containing only hlyA, as was 
used in this study, should further clarify the role of HlyA in haemolysis.    
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Recombinant haemolysin was used to vaccinate mice via several different methods:   
(i) Recombinant protein vaccination, (ii) DNA vaccine delivery by STM-1 and (iii) 
heterologous antigen expression by STM-1.   Of the three methods used, the greatest 
response induced was by the recombinant HlyA inoculation in Freund’s adjuvant.   The same 
trend was observed through the antibody ELISA and the ELISPOT assays.   This immune 
response also corresponded to a significant decrease in the caecal weight of vaccinated 
mice challenged with B. hyodysenteriae.   Whether the decrease in caecum oedema is a 
result of the presence of the high titres of antibodies or the ability of lymphocytes to produce 
IFN-γ or IL-4 in response to exposure to rHlyA is unknown. 
 
Inoculation of mice with DNA vaccines encoding HlyA induced significantly elevated 
levels of anti-HlyA antibodies as observed by ELISA.   Mice vaccinated with pVRhlyA had 
higher antibody responses compared to mice inoculated with pMChlyA.  The secreted nature 
of antigens expressed from the pVR1020 expression vector should induce a primarily Th2 
antibody immune response (Boyle et al., 1997; Inchauspe et al., 1997; Kaufmann & Hess, 
1999).   Despite the low HlyA-specific antibody response observed in the pMChlyA 
vaccinated groups, there is evidence that MCP-3/CCL7 fusion proteins can induce systemic 
and mucosal antibodies (Biragyn et al., 2002; Serezani et al., 2002).   The ELISPOT analysis 
of spleen cells isolated from mice inoculated with pVRhlyA and pMChlyA resulted in 
negligible induction of cytokine secreting cells, so it is not possible to correlate the antibody 
production with an IL-4 response. 
 
None of the recombinant STM-1 vaccines stimulated an overt HlyA-specific antibody 
response.   Despite the lack of a measurable antibody response, inoculation with STM-
1(pCRhlyAP) lowered the caecum oedema significantly compared to the STM-1 control.   
Over the two immunogenicity and challenge trials performed, HlyA and SmpB, this was the 
only group vaccinated with a recombinant STM-1 that lowered the caecal weights.   Again, 
this could not be correlated with either the presence of HlyA-specific antibodies by ELISA or 
cytokine producing cells by ELISPOT analysis.  
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There was no difference between the caecal weight and pathological effects following 
challenge of mice vaccinated with STM-1 control and the recombinant STM-1 vaccines.   A 
similar trend for the STM-1 vaccines was observed during the immunogenicity trials 
described in Chapter 4.   The control STM-1 vaccinated mice were included to give a 
baseline of mice not vaccinated with a B. hyodysenteriae antigen.   Two effects may be 
responsible for the observed results.   Vaccination with recombinant STM-1 encoding HlyA 
may not induce a measurable HlyA specific immune response, but nevertheless a response 
is induced which can reduce the pathological effects upon challenge.   Alternatively, 
vaccination with STM-1 prior to challenge with B. hyodysenteriae may recruit immune cells to 
the GALT which could lower the pathological effects observed after challenge.   This 
response would be non-specific to B. hyodysenteriae.   As discussed in Chapter 4, this effect 
has been observed in sequential infections with Mycobacterium spp. and Plasmodium yoelii 
(Page et al., 2005; Scott et al., 2004).  
 
The general lack of a carrier antigen specific immune response after vaccination with 
recombinant STM-1 has already been discussed in relation to the SmpB immunogenicity and 
challenge trials.   The inherent instability of the HlyA expression vectors observed in this 
study may lower the immune response to the carrier antigen.   However, unlike the 
macrophage survival studies performed in Chapter 4, the presence of HlyA-encoding 
expression vectors in STM-1 did not effect the survival of the STM-1 inside J774 
macrophages.   It has been demonstrated that several cloning constructs can be detrimental 
to the ability of S. typhimurium to invade and multiply within macrophages (Abromaitis et al., 
2005; Chen et al., 2005; Dunstan et al., 2003).   When considering the in vitro macrophage 
survival studies in this and previous chapters, it must be kept in mind that in vitro assays may 
not necessarily reflect the behaviour of the vaccines in vivo (Garmory et al., 2002).   
Strategies to enhance the heterologous antigen specific immune response of mice 
vaccinated with recombinant STM-1 will be discussed in Chapter 7. 
 
 192
In this study, high levels of anti-rHlyA antisera and cytokine producing splenocytes 
were observed after inoculation of mice with rHlyA.   This corresponded to a significant 
decrease in the weight of caecum after challenge with B. hyodysenteriae.   A significant 
difference in the caecal weight of STM-1(pCRhlyAP) vaccinated mice was observed, 
however the general trend of lower caecal weight in all STM-1 vaccinated mice including the 
controls casts doubts upon the contribution of rHlyA delivered in this way.   The lessening in 
severity of pathological changes may indicate that with more research towards optimising 
and amplifying the immune response, HlyA may contribute towards a vaccine when 
combined with other antigens or adjuvants. 
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Chapter 6 – Outer Membrane Variation 
6.1 Introduction. 
The discovery of sequence variability at the smpA locus led to investigations into other 
known outer membrane proteins (OMPs) of B. hyodysenteriae.   Few other outer membrane 
proteins of B. hyodysenteriae have been identified and those that are known are encoded by 
homologous multi-gene clusters such as vspABCD, vspEFGH and blpAEFG.   The function 
of these genes, and the reason behind their duplication is unknown.   It may be that these 
genes encoding proteins involved in immune evasion.   Investigations into the variation in the 
OMPs of B. hyodysenteriae will allow inferences to be made about the cross-strain protection 
induced by any future vaccines. 
 
The vspABCD and vspEFGH multi-gene clusters encode eight 39kDa paralogous outer 
membrane proteins (Gabe et al., 1998; McCaman et al., 2003).   However, the presence of 
eight homologous genes, of which only one has been found to be expressed led 
investigators to believe the encoded proteins are involved in host immune response 
avoidance or environmental adaptation.   Another paralogous four-gene cluster, blpAEFG, 
which has now been shown to contain bmpB (blpA is identical to bmpB), encodes outer 
membrane lipoproteins with highly similar sequences (Cullen et al., 2003; La et al., 2005).   
Unlike the two vsp clusters, blpAEFG has been found in other species of Brachyspira such 
as B. innocens (La et al., 2005).   Like the vsp clusters, the function of the proteins encoded 
by blpAEFG is unknown, but the presence of blpAEFG in a porcine commensal such as B. 
innocens makes it unlikely the products of these genes are involved in virulence.   These 
genes may however be involved in intestinal colonisation as B. innocens and B. 
hyodysenteriae share the same colonisation site.   Despite the existence of homologs of 
bmpB (i.e. blpE, blpF and blpG), inoculation of swine with recombinant BmpB has been 
shown to reduce the occurrence of Swine Dysentery (SD) (La et al., 2005).   If the purpose of 
the homologs is not host immune avoidance, the homologs may encode proteins that induce 
cross reactive antibodies upon vaccination. 
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The use of any of the proteins encoded by these paralogous multi-copy genes as a 
vaccine may be limited.   As the proposed function of the multiple similar genes is antigenic 
variation, B. hyodysenteriae may eventually adapt to any host immune response directed 
against these proteins.   However, the actual function of the protein encoded by these 
clusters is unknown, and may not be antigenic variation.   The discovery of the bitABCDEF 
cluster involved in iron acquisition is one example of the presence of multiple similar proteins 
not involved in antigenic variation (Dougard et al., 1999).    
 
At this time, smpA and smpB (See Chapter 3) are the only two identified genes 
encoding outer membrane proteins that do not belong to paralogous multi-gene clusters.   
The majority of known outer membrane proteins, the BmpB, Vsp, Blp and Bit proteins, are 
encoded by genes belonging to multi-gene clusters.   This suggests that the presence of 
paralogous multi-gene clusters may be common in B. hyodysenteriae.   Despite the 
possibility of the host immune response adapting to the proteins encoded by multi-copy 
genes, they may be an important component of a future vaccine if the function is not simply 
antigenic variation. 
 
The aims of the studies described in this chapter are: 
 
1) To identify any sequence variation within the blpAEFG, vspABCD and vspEFGH gene 
clusters by PCR-Restriction Fragment Length Polymorphism (RFLP). 
2) To further characterise any clusters displaying polymorphisms by DNA-DNA 
hybridisation. 
3) To analyse the outer membrane of B. hyodysenteriae by SDS-PAGE and 2D gel 
electrophoresis. 
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6.2 Results. 
6.2.1 PCR and RFLP analysis of the blpAEFG cluster. 
PCR Primers blpAEFG1 and blpAEFG2 were designed based on the published 
sequence (Genbank Accession #AY158073) to amplify a ~5 kbp fragment of the blpAEFG 
cluster and the PCR condition optimised.   The Expand long template PCR system (Roche) 
was used to amplify the gene cluster.   The conditions of amplification were 92°C for 2 mins 
followed by 10 cycles of 92°C for 10 s, 48°C for 30 s then 68°C for 8 min.   These initial 
cycles were followed by 25 cycles of 92°C for 15 s, 48°C for 30sec then 68°C for 8 min with a 
20 s elongation time increase per cycle with final elongation step was performed at 68°C for 
7 min.   All strains, with the exception of B234, analysed exhibited a ~5 kb PCR product 
(Figure 6.1a).   Analysis by RFLP using HindIII showed no large polymorphisms within this 
cluster, generating the expected sized fragments upon digestion (Figure 6.1b). 
 
6.2.2 PCR-RFLP analysis of the vspABCD cluster. 
PCR Primers vspABCD1 and vspABCD2 were designed based on the published 
sequence to amplify a ~5 kbp fragment of the vspABCD cluster from B. hyodysenteriae B204 
(Genbank Accession #AF012102) (Figure 6.2).   The Expand long template PCR system was 
used to amplify the cluster.   The conditions of amplification were 92°C for 2 min followed by 
10 cycles of 92°C for 10 s, 55°C for 30 s and 68°C for 8 min.   The next 25 cycles were 92°C 
for 15 s, 55°C for 30 s and 68°C for 8 min with a 20 s increase per cycle.   A final elongation 
step was performed at 68°C for 7 min. 
 
B. hyodysenteriae B204 generated the expected PCR product of 5 kb (Figure 6.3a).   
Several of the analysed strains produced different sized products.   B. hyodysenteriae P18A 
and A1 produced a ~4.5 kb PCR product, and B. hyodysenteriae 5380 generated a ~3 kb 
product. B. hyodysenteriae R7273 generated a larger than expected PCR product of ~7 kb. 
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1.16 .1: PCR and RFLP of the blpAEFG Gene Cluster. 
.1a: PCR analysis of the blpAEFG cluster in B. hyodysenteriae. Lane 1, P18A; Lane 2, B234; 
204; Lane 4, Y32; Lane 5, B78T; Lane 6,FMV-189; Lane 7, T70A; Lane 8, B8044; Lane 9, 
ne 10, B169; Lane 11, 8930; Lane 12, Williams B; Lane 13, G131. Figure 6.1b: RFLP of 
 cluster of B. hyodysenteriae. All PCR products analysed in Figure 6.1a were digested with 
ane 1, MW marker; Lane 2, P18A; Lane 3, B78T; Lane 4, B8044; Lane 5, 8930; Lane 6, 5380; 
169; Lane 8, T70A; Lane 9, Y32; Lane 10, FMV-189; Lane 11, G131; Lane 12, Williams B; 
 B204. 
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Figure 6.2 : Schematic representation of the vspABCD cluster. 
Diagram of the vspABCD cluster of B. hyodysenteriae B204.   The four vsp genes are shown in red.   
The vspABCD PCR product depicted in Figure 6.3 is shown in magenta.   The vspAB PCR product 
depicted in Figure 6.4 is shown in blue.   The vspCD PCR product depicted in Figure 6.5 is shown in 
green. 
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re 6.3: PCR and RFLP of the vspABCD Gene Cluster. 
e 6.3a: PCR analysis of the vspABCD cluster in B. hyodysenteriae. Lane 1, MW marker; Lane 2, 
ane 3, 8930; Lane 4, Vld; Lane 5, 5380; Lane 6, B169; Lane 7,T70A; Lane 8, P18A; Lane 9, 
; Lane 10, Williams B; Lane 11, B234; Lane 12, R7273; Lane 13, Y32; Lane 14, B8044; Lane 15, 
 Lane 16, B204. Figure 6.3b: RFLP of vspABCD cluster of B. hyodysenteriae. Selected PCR 
cts from Figure 6.3a were digested with Sau3AI. Lane 1, MW marker; Lane 2, 5380; Lane 3, 
; Lane 4, B204; Lane 5, B169; Lane 6, B8044; Lane 7, G131; Lane 8, Williams B; Lane 9, T70A; 
10, B78T; Lane 11, Y32; Lane 12, B234.  
 198
 
6 
 
  
2.8 
 
1.99 
1.7 
 
1.16 
1.09 
 
0.8 
 
0.5 
0.46 
 
0.33 
 
0.26 
0.24 
 
Figure
B. hyod
of fragm
Lane 5
B204; L
AluI dig
Vld; La
Lane 1
  1 2 3 4 5 6 7 8 9 10 11 12 ) 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 1b)a11.5 
 
5.1 
4.5 
 
2.8 
 
1.99 
1.7 
 
1.16 
1.09 
 
0.8 
 
 
0.5 
0.46  6.4: PCR and RFLP of vspA and vspB. 
ysenteriae PCR product amplified using the VspAB primer set. Figure 6.4a: PCR amplification 
ent of vspABCD cluster. Lane 1, MW marker; Lane 2, 8930; Lane 3, FMV-189; Lane 4, Vld; 
, R7273; Lane 6, T70A; Lane 7,Williams B; Lane 8, A1; Lane 9, Y32; Lane 10, G131; Lane 11, 
ane 12, B8044; Lane 13, P18A; Lane 14, 5380; Lane 15, B234; Lane 16, B169. Figure 6.4b: 
est of selected PCR products from Figure 6.4a. Lane 1, MW marker; Lane 2, 8930; Lane 3, 
ne 4, R7273; Lane 5, T70A; Lane 6, Williams B; Lane 7, Y32; Lane 8, G131; Lane 9, B204; 
0, B8044; Lane 11, B234; Lane 12, B169. 
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gure 6.5: PCR and RFLP of vspC and vspD. 
R analysis of vspC and vspD amplified using the VspCD primer set. Figure 6.5a: PCR amplification 
fragment of vspABCD cluster. Lane 1, MW marker; Lane 2, 8930; Lane 3, R7273; Lane 4, 5380; 
ne 5, G131; Lane 6, B204; Lane 7, P18A; Lane 8, Y32; Lane 9, Vld; Lane 10, B169; Lane 11, 
illiams B; Lane 12, A1; Lane 13, FMV-189; Lane 14, B234; Lane 15, B8044; Lane 16, T70A. Figure 
b: AluI digest of selected PCR products from Figure 6.5a. Lane 1, MW marker; Lane 2, 8930; Lane 
Vld; Lane 4, R7273; Lane 5, T70A; Lane 6, Williams B; Lane 7, A1; Lane 8, Y32; Lane 9, G131; 
ne 10, B204; Lane 11, B8044; Lane 12, P18A; Lane 13, 5380; Lane 14, B234; Lane 15, B169. 
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, 5380; Lane 7, B169; Lane 8; T70A; Lane 9, FMV-189; Lane 10 Williams B; Lane 11, G131. 
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Analysis of the entire vspABCD cluster by RFLP after digestion with Sau3AI revealed 
several polymorphisms (Figure 6.3b).   B. hyodysenteriae P18A lacked a ~330 bp fragment 
observed in most strains, which would account for the size differences observed in Figure 
6.3a.   Similarly, B. hyodysenteriae 5380 (which had the smallest PCR product) was missing 
several DNA fragments.   Upon RFLP analysis, two more strains were identified that have 
variations in the vspABCD cluster, although these do not visibly affect the size of the PCR 
product.   B. hyodysenteriae  B169 and B234 generated a ~220 bp DNA fragment not 
present in other strains (Figure 6.3b). 
 
6.2.3 Analysis of the VspAB and VspCD PCR products. 
To further characterise and localise the sequence polymorphisms in the vspABCD 
gene cluster, two PCR primer sets, VspAB and VspCD, were developed to amplify smaller 
regions of the vspABCD cluster and the PCR optimised (Figure 6.2).   The amplification 
conditions of the VspAB PCR were 92°C for 2 mins followed by 35 cycles of 92°C for 30 s, 
58°C for 30 s, and 72°C for 2 min, then a final elongation at 72°C for 7 min. The amplification 
conditions of the VspCD PCR were 92°C for 2 min followed by 35 cycles of 92°C for 30 s, 
65°C for 30 s, and 72°C for 2 min, then a final elongation at 72°C for 7 min. 
 
Primers VspAB1 and VspAB2 amplified a 1.9 kb fragment containing a region of the 
vspA and vspB genes.   B. hyodysenteriae strains FMV-189, A1, P18A and 5380 did not 
generate a PCR product, indicating sufficient variations in vspA and vspB to prevent primer 
binding (Figure 6.4a).   The ~500 bp product present in A1 and P18A, and to a lesser extent 
B8044 and B234, is most likely a result of cross priming amongst the highly similar vsp 
genes.   All other strains generated the same 1.9 kb fragment.   Analysis of the PCR product 
amplified by the VspAB primer set by RFLP showed that two other strains (B234 and B8044) 
display sequence variation in this area of the vspABCD cluster, although not sufficient 
enough to prevent primer binding (Figure 6.4b). 
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A second primer set consisting of VspCD1 and VspCD2 was designed to amplify a 
portion of the vspABCD cluster containing parts of the vspC and vspD genes.   Two strains, 
5380 and FMV-189 did not generate a PCR product with these primers, indicating sufficient 
polymorphism in the vspC and vspD genes to alter or remove the primer binding sites (Figure 
6.5a).   All other strains generated the same 1.5 kb fragment (B. hyodysenteriae vld 
produced a faint product), with the same RFLP pattern upon digestion with AluI (Figure 6.5b).    
 
The amplification of the VspCD PCR product in B. hyodysenteriae P18A, but the lack of 
amplification of VspAB infers that the variation is a result of large polymorphisms in the 
VspAB region and smaller polymorphisms in vspC and vspD.    Similar inferences can be 
made regarding the large variations in B. hyodysenteriae 5380 depicted in Figure 6.4. The 
lack of PCR products after amplification with either the VspAB and VspCD primer sets infers 
large variations, deletions or inversions in B. hyodysenteriae 5380. 
 
6.2.4 Sequence Characterisation of the vspABCD Gene Clusters. 
Attempts were made to directly sequence B. hyodysenteriae P18A and 5380 from the 
vspABCD 5 kb PCR product, however despite multiple attempts clear results were not 
obtained.   This was attributed to the nature of the cluster, where the presence of repetitive 
sequence leads to multiple priming.   Other methods were used to attempt to elucidate the 
sequence of the vspABCD cluster of B. hyodysenteriae 5380 and P18A (Section 6.2.5). 
 
The product of the VspAB and VspCD PCRs from several strains of B. hyodysenteriae 
were determined by DNA sequence characterisation.   The vspABCD clusters of B. 
hyodysenteriae B8044 and B234, which both displayed sequence variation as shown in 
Figure 6.4, Figure 6.5 and Figure 6.6 was characterised (~95% sequence similarity between 
B204 and B234 and B8044).   Several nucleotide polymorphisms were identified over the 
entire length of the cluster, however no deletions or inversions were found (Sequence 
included in Appendix 1).   This is in agreement with the conserved size of the entire cluster in 
these strains (Figure 6.3).   Multiple attempts were made to sequence the VspCD PCR 
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product from B. hyodysenteriae P18A, however no sequence data was returned.   The cross-
priming effect mentioned earlier whereby the primer binds to similar sequences in the 
multiple, similar genes may account for the failure of direct sequence characterisation.   In all 
instances attempts were made to design primers with high levels of specificity, however this 
was not always possible. 
 
Sequence characterisation of the vspC and vspD region of B8044 revealed a single 
nucleotide polymorphism that is predicted to alter the expression of an encoded protein.   
The introduction of a premature stop codon in vspC truncates the translation of the encoded 
protein (Figure 6.7b). 
 
6.2.5 Insertion of vspABCD Fragments into pBluescript. 
B. hyodysenteriae P18A and 5380, which displayed the largest polymorphisms in the 
vspABCD cluster (Figure 6.3), did not generate  PCR products from the VspAB or VspCD 
primer sets (Figure 6.4 and Figure 6.5).   In order to sequence the vspABCD cluster of B. 
hyodysenteriae P18A and 5380 the PCR product depicted in Figure 6.3 was digested with 
BglII, and with BglII/PstI and the fragments cloned into pBluescript.   Despite several 
attempts, only one clone was isolated from a P18A vspABCD BglII/PstI-digested ligation 
(Figure 6.8).    
 
The BglII/PstI fragment inserted into pBluescript was ~800 bp in length and DNA 
sequence characterisation revealed several nucleotide polymorphisms compared to the 
published B. hyodysenteriae B204 vspABCD cluster (Figure 6.9).   The cloned 800 bp 
fragment was from BglII/PstI digested B. hyodysenteriae 5380 DNA, however BglII/PstI 
fragment in the vspABCD cluster from B. hyodysenteriae B204 is predicted to be 1.9 kb.   
There is no evidence in the B. hyodysenteriae P18A sequence of a deletion (Figure 6.9), 
suggesting that the  different RFLP pattern depicted in Figure 6.6 is a result of the 
introduction of a additional BglII site halfway through vspA. 
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gure 6.7:Variation in the vspABCD Cluster of Brachyspira hyodysenteriae B8044. 
ure 6.7a: B. hyodysenteriae B8044 displays sequence polymorphisms in vspC that alter the 
nslation of the protein.   The ORF1 is similar to the beginning of vspC, however a stop codon 
maturely ends ORF1 (Indicated by an arrow). The ORF2 is similar to  the remainder of vspC. The 
F 3 shows sequence similarity with vspD.   The entire sequence of B8044 and B234 is shown in 
pendix 1.   For comparison, the B204 region is shown in Figure 6.7b.   The nucleotide similarity 
er the sequenced area is 95% between B204 and B8044. 
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Figure 6.8: Construct Containing a vspA
Figure 6.8a: The vspABCD cluster was digeste
hyodysenteriae strains were chosen for analysis
VspAB or VspCD PCR products. Figure 6.8b
obtained from the BglII/pstI fragment, and the
here. 
 BglIBCD BglII/PstI Fragment. 
d with BglII/PstI and cloned into pBluescript.   Two  B. 
, P18A and 5380, as they were unable to produce the 
: Only one clone from B. hyodysenteriae P18A was 
 BglII/PstI digested recombinant plasmid is depicted 
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a) 
VspABCD      321 gtaccgcctaataaactagaatataaagatggtatttgttttattgattcattattttta 
P18A vspAB     1 gtaccgcctaataaactagaatataaagatggtatttgttttattgattcattattttta 
 
VspABCD      381 gataattcttgcatcaaatatgttaagttttttaaaataggtatgaattttgatgaatat 
P18A vspAB    61 gataattcttgcatcaaatatgttaagttttttaaaataggtatgaattttgatgaatat 
 
VspABCD      441 atttcttcttctatattttttgtgctattaaaacaagaaaataaaatttttcctattgtg 
P18A vspAB   121 atttcttcttctatattttttgtgctattaaaacaagaaaataaaatttttcctattgtg 
 
vspABCD      501 ctttttccagtgttattctctccggctattacagtaataccatctattgttatattagct 
P18A vspAB   181 ctttttccagtgttattctctccggctattacagtaataccatctattgttatattagct 
 
vspABCD      561 tctttgattttagaaaaattttttatattcaattccattatattttatcctttaataatt 
P18A vspAB   241 tctttgattttagaaaaattttttatattcaattccattatattttatccttaaataatt 
 
vspABCD      621 ctgttattattataacataaaaaatatttaataaaaatatattaattttcattaaatcta 
P18A vspAB   301 cttttattattataacataaaaagtatttaataaaaatatattaattttcattaaatctc 
 
vspABCD      681 attcttgagctattttatatttttagtataataaaaaatataaacttcaatttaggtatg 
P18A vspAB   361 attcttgagctattttatatttttagtataataaaaaatataaacttcaatttaggtatg 
 
vspABCD      741 tataatgaaaaagttttttctaattatgacagtattattaagtatgtcatattgttcaat 
P18A vspAB   421 tacaatgaaaaagttttttctaattatgacagtattattaagtatgtcatattctttaat 
 
vspABCD      801 ttttggtatgtatggagatcaggacgattggattgattttcttacagacggcaatcagtt 
P18A vspAB   481 atttggtatgtatggagatcaggacgattggattgattttcttacagacggcaatcagtt 
 
vspABCD      861 tagagctagaatggatcaattaggatttgttttaggtaatagtactattaaaggtacttt 
P18A vspAB   541 tagagctagaatggatcaattaggatttgttttaggtaatagtactattaaaggtacttt 
 
vspABCD      921 cggtttt 
P18A vspAB   601 cggtttt 
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Figure 6.9: Sequence Analysis of the B. hyodysenteriae P18A vspABCD Insert. P18A ( vspA 618 bps)
200 400 600
PstI
SfcI DraI Psi I
VspI
Sml I BsrGI SspI ScaI XhoII
ORF1 vspA
b) 
Sequence of the 800bp insert in pBvsp18 in Figure 6.8.   Despite the sequence variations inferred 
from the RFLP analysis of the vspABCD cluster, only minor sequence variation was observed in the 
vspA area of the cluster despite the lack of a PCR product observed in Figure 6.4 (VspAB). 
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6.2.6 DNA-DNA Hybridisation Analysis of vspABCD. 
DNA-DNA hybridisation was performed using labelled vspABCD PCR product from B. 
hyodysenteriae B204 (Figure 6.10).  All strains, except B. hyodysenteriae B8044, reacted 
with the vspABCD probe, indicating that despite the polymorphisms the sequences are 
sufficiently similar to allow hybridisation.   None of the strains that reacted with the probe 
displayed large size variations in the reacting fragment Figure 6.10. 
 
6.2.7 PCR and DNA-DNA Hybridisation Analysis of vspEFGH. 
The PCR primers VspEFGH1 and VspEFGH2 were designed to amplify the entire ~6 
kb vspEFGH cluster based on the published sequence of B. hyodysenteriae B204 (Genbank 
accession #AY027775), and the PCR condition optimised.   The conditions of amplification 
were 92°C for 2 mins followed by 10 cycles of 92°C for 10 s, 55°C for 30 s and 68°C for 10 
min.   The next 25 cycles were 92°C for 15 s, 55°C for 30 s and 68°C for 10 min with a 20 s 
increase per cycle.   A final elongation step was performed at 68°C for 7 min.   Unlike the 
vspABCD PCR, only B. hyodysenteriae B204 generated a vspEFGH PCR product (Figure 
6.11).   This PCR product was confirmed by RFLP analysis to be the correct product. 
 
To determine if the sequence of the other strains was similar to B. hyodysenteriae 
B204 the vspEFGH PCR product was labelled and used as a probe for DNA-DNA 
hybridisation after EcoRV digestion of B. hyodysenteriae genomic DNA.    All tested strains, 
with the exception of B. hyodysenteriae B8044, reacted strongly with the B204 vspEFGH 
probe (Figure 6.12a).   To investigate the relationship between the vspEFGH clusters in 
several stains, a second DNA-DNA blot was performed after HindIII digestion.   This revealed 
much larger sequence variation in the vspEFGH cluster compared to the vspABCD cluster 
(Figure 6.12b).    
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ure 6.10: DNA-DNA Hybridisation of the vspABCD Gene Cluster. 
 probe used in this DNA-DNA hybridisation blot was the vspABCD PCR product from B. 
dysenteriae B204 depicted in Figure 6.3a.   B. hyodysenteriae DNA was digested with HindIII.   
e 1, B204; Lane 2, P18A; Lane 3, 8930; Lane 4, 5380; Lane 5, B8044; Lane 6, B78T; Lane 7, A1; 
e 8, T70A; Lane 9, WAA1; Lane 10, Vld; Lane 11, R7273; Lane 12, G131.   The size of the B. 
dysenteriae P18A and 5380 bands are slightly smaller than B. hyodysenteriae B204, reflecting to 
smaller PCR products depicted in Figure 6.3a. 
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re 6.11: PCR of the vspEFGH Gene Cluster.  
analysis of the entire vspEFGH cluster in B. hyodysenteriae.   Several strains were analysed by 
 however only B. hyodysenteriae B204 produced a PCR product.   Lane 1, MW marker; Lane 2, 
; Lane 3, P18A; Lane 4, A1; Lane 5, 5380; Lane 6, B204; Lane 7,R7273; Lane 8, G131; Lane 9, 
 Lane 10, T70A; Lane 11, B169; Lane 12, B234; Lane 13, Vld; Lane 14, Y32; Lane 15, Williams 
ne 16, FMV-89; Lane 17, 8930; Lane 18, MW Marker. 
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ure 6.12: DNA-DNA Hybridisation Analysis of the vspEFGH Gene Cluster.    
re 6.12a: EcoRV digest of the vspEFGH cluster.   All strains reacted with the vspEFGH probe 
hesised from the PCR product depicted in Figure 6.11, with the exception of B8044. Figure 6.12b: 
III digest of the vspEFGH cluster.   HindIII digests at several places in the vspEFGH sequence, 
iding information about the polymorphisms in the cluster.   One strain, Vld, showed the same 
ern as B204 however did not generate a PCR product, indicating some sequence variation.   
eral other electrophoretic types are visible across the other strains.    Lane 1, B204; Lane 2, P18A; 
e 3, 8930; Lane 4, 5380; Lane 5, B8044; Lane 6, B78T; Lane 7, A1; Lane 8, T70A; Lane 9, WAA1; 
e 10, Vld; Lane 11, R7273; Lane 12, G131. 
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B. hyodysenteriae B204 and Vld displayed the same RFLP pattern in Figure 6.12b.   
However, Vld did not produce the PCR product, indicating only partial sequence 
conservation between these strains.   The variation in Vld was presumably enough to prevent 
primer binding, resulting in no amplification as depicted in Figure 6.11.   B. hyodysenteriae 
8930, 5380, R7273 and G131 showed similar RFLP patterns as B204, however one DNA 
fragment was missing.   B. hyodysenteriae P18A, A1, T70A and WAA1 showed a 
significantly different RFLP pattern compared to B204.   B. hyodysenteriae B8044 reacted 
weakly with the probe, and generated a unique RFLP pattern. 
 
6.2.8 Pulse Field Gel Electrophoresis. 
To determine if the presence of smpA or smpB or the variation in vspABCD or 
vspEFGH was linked to the Electrophoretic Types (ET) of the strains, Pulse Field Gel 
Electrophoresis was performed on MluI digested DNA from several B. hyodysenteriae strains 
(Figure 6.13).   The PFGE analysis resulted in clear ET for several different strains, however 
several of the bands may be doublets.   A Phylogenetic tree was created using the method of 
unweighted pair group method with arithmetic averages (UPGAMA) in the program Quantity 
One (BioRad) (Figure 6.14).  
 
B. hyodysenteriae P18A, A1 and WAA1 displayed similar restriction fragments, while B. 
hyodysenteriae 5380 displayed a unique ET.   B. hyodysenteriae B8044, which had a unique 
smpA sequence and did not hybridise with the smpA probe from B204 (See Chapter 3), had 
a unique ET further emphasising the differences of this strain (Figure 6.14).   This does not 
indicate that these strains are unique, as only a small group of B. hyodysenteriae strains 
were tested. 
 
There appears to be a limited correlation between the presence of smpA or smpB and 
the ET observed after PFGE analysis and RFLP of the vspEFGH cluster (Table 6.1).   B. 
hyodysenteriae P18A, A1 and WAA1, which all contain smpA, produced the same ET after 
PFGE and RFLP analysis of vspEFGH.   Most (85%) of the strains clustered into ETs 2 and 
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3 after PFGE analysis contained smpB, with the exception of B204 (smpA).   B. 
hyodysenteriae B8044, which has already been discussed in relation to the presence of 
smpA, had a unique ET.   However, with the exception of B. hyodysenteriae P18A, WAA1 
and A1, there was no consistent pattern between the vspEFGH RFLP ETs and smpB, smpA 
and the PFGE ETs. 
 
6.2.9 Variation in Outer Membrane Proteins by SDS-PAGE. 
Variation in the genes encoding outer membrane proteins has been demonstrated 
across strains.   As only a few genes encoding outer membrane proteins are known in B. 
hyodysenteriae outer membrane preparations were analysed to detect any differences at a 
global level.   Analysis by SDS-PAGE of TritonX-100 enriched outer membrane extracts of B. 
hyodysenteriae P18A and 5380 was performed (Figure 6.15).   Several different bands were 
detected, of particular interest was the difference in bands at around 16 kDa (smpA/smpB 
size).   However, several band differences were detected between the two strains analysed. 
 
As there were many proteins in the 30-50 kDa range that were inseparable by SDS-
PAGE, 2D gel electrophoresis was performed.   The resulting gels showed large differences 
in the protein expression profile in the outer membrane (Figure 6.16).   There are several 
noticeable differences in the 16kDa region of the 2D gel analysis, in particular the absence of 
a prominent 16kDa band at a pH of ~7 in the B. hyodysenteriae B204 gel.  What can be 
inferred from this preliminary 2D-gel analysis is that the expression of OMPs in two strains of 
B. hyodysenteriae is quite different.   This has implications for vaccine development, as any 
useful vaccine must protect against heterologous strains of B. hyodysenteriae. 
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rformed on MluI digested genomic DNA. Lane 1, MW Marker; Lane 2, B204; Lane 3, 5380; 
18A; Lane 5, 8930; Lane 6, B8044; Lane 7, A1; Lane 8, T70A; Lane 9, Vld; Lane 10, R7273; 
 B86; Lane 12, B78T; Lane 13, G131; Lane 14, WAA1.   Several different ETs are visible 
e strains. 
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Figure 6.14: Phylogenetic tree of B. hyodysenteriae strains analysed by PFGE. 
PFGE analysis segregated the strains into several distinct groups. B. hyodysenteriae B204, 
vld and B78T comprise one distinct clade on the phylogenetic tree, as do B. hyodysenteriae 
G131 and B86.   B. hyodysenteriae B8044, reflective of its behaviour during the DNA-DNA 
hybridisation studies, was not clustered closely with any other strains.   B. hyodysenteriae 
5380, although displaying no unique characteristics when analysed previously, also 
appeared to be less closely related to other strains.   There were no other discernible 
groupings within the phylogenetic tree.   The scale at the top represents percentage similarity 
between the strains. 
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Strain PFGE ET vspEFGH ET smpA smpB 
B8044 4 4 + - 
B204 3 2 + - 
B78T 3 1 - + 
Vld 3 2 - + 
G131 2 1 - + 
5380 2 1 - + 
T70A 2 3 - + 
8930 2 3 - + 
R7273 2 1 - + 
P18A 1 3 + - 
WAA1 1 3 + - 
A1 1 3 + - 
 
Table 6.1: Distribution of smpA or smpB compared to the PFGE and RFLP types. 
There appears to be a limited correlation between the presence of smpA or smpB and the ET 
observed after PFGE analysis and RFLP of the vspEFGH cluster.   Strains that were subjected to 
PFGE analysis in Figure 6.13 were assigned a number based on the pattern of bands (PFGE ET in 
above table).   Similarly, strains that were subjected to RFLP analysis of vspEFGH in Figure 6.12b 
were assigned a number based on the pattern of bands (vspEFGH ET in above table).   B. 
hyodysenteriae P18A, A1 and WAA1 produced a unique ET after PFGE and RFLP of vspEFGH.   
These same strains also contained only smpA.   Most (85%) of the strains clustered into ETs 2 and 3 
after PFGE analysis contained smpB, with the exception of B204.   B. hyodysenteriae B8044, which 
has already been discussed in relation to the presence of smpA, had a unique ET.   However, with the 
exception of B. hyodysenteriae P18A, WAA1 and A1, there was no pattern between the vspEFGH 
RFLP ETs and smpB, smpA and the PFGE ETs. 
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Figure 6.15: SDS-PAGE of Outer Membrane Proteins. 
SDS-PAGE of TritonX-100 enriched outer membrane preparations from B. hyodysenteriae 5380 (Lane 
2) and P18A (Lane3).    Lane 1 is SeeBlue Plus2 pre-stained marker.   There are several noticeable 
differences in the outer membrane profile, particularly around the 16kDa range (arrow).   There are 
many bands in the 30-50kDa range, which may represent the vspABCD, vspEFGH, blpAEFG gene 
products as well as the flagella proteins. 
 217
 pI range 0 3 
a) 
 
b) 
 
Figure
Figure
similari
membr
electro
visible 
hyodys
 
  6.16: 2DGE of Brachyspira hyodysenteriae Outer Membran
 6.16a: B. hyodysenteriae 5380.   Figure 6.16b: B. hyodysenteria
ties observed in Figure 6.15, there are obvious differences in 
ane proteins between these two strains when the proteins are sep
phoresis.   Furthermore there are multiple proteins of the same MW (~
in Figure 6.16a, suggesting that multiple vsp genes may be expresse
enteriae. 1148
 
98 
 
64 
 
50 
 
36 
 
22 
 
16 
 
6 
148
 
98 
 
64 
 
50 
 
36 
 
22 
 
16 
 
6 
e Proteins. 
e P18A.    Despite the 
the expression of outer 
arated further by 2D gel 
40kDa) but varying pI are 
d in certain strains of B. 
218
 219
6.3 Discussion 
Investigations into the outer membrane of B. hyodysenteriae revealed notable 
variations of the genomes of several B. hyodysenteriae strains, and the expression of 
different outer membrane proteins as analysed by 2D gel electrophoresis. 
 
The blpAEFG cluster was the most conserved cluster in B. hyodysenteriae observed in 
this investigation.    Furthermore, the blpAEFG cluster is the only set of genes investigated 
that is also found outside of the B. hyodysenteriae species, in B. innocens (Cullen et al., 
2003; La et al., 2005).   Neither smpA or smpB, nor the vspABCD, vspEFGH or bitABCDEF 
clusters have yet been discovered in species other than B. hyodysenteriae (Dougard et al., 
1999; McCaman et al., 2003; Sellwood et al., 1989).   These observations indicate that while 
the colonisation of the intestine is shared with B. innocens, these unique genes of B. 
hyodysenteriae may be essential for the development of disease.   It may be that the unique 
genes of B. hyodysenteriae are under greater environmental (immune) pressure than those 
that are shared with B. innocens and therefore accumulate greater genetic variations.  
 
The genes encoding the Variable Surface Proteins (vsp) displayed higher frequencies 
of nucleotide substitutions than the blpAEFG cluster.   This investigation focussed on the 
vspABCD cluster as this cluster was more amenable to study.   The presumed larger 
variation in vspEFGH, which resulted in no PCR product will require different techniques and 
is a subject for further investigation.   The vspABCD cluster showed moderate sequence 
variations in some strains as demonstrated by RFLP analysis (Figure 6.3b).   In particular, B. 
hyodysenteriae P18A, 5380, A1 and R7273 displayed quite different PCR products and 
RFLP fragments.   B. hyodysenteriae P18A and 5380, which have already been discussed in 
relation to smpA and smpB (Chapter 3), displayed the largest number of polymorphisms in 
the vspABCD cluster compared to B. hyodysenteriae B204, the strain from which the 
published vspABCD sequence was characterised. 
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Attempts were made to sequence the vspABCD cluster from B. hyodysenteriae 5380 
and P18A by subcloning.   Despite several attempts only one clone was isolated from P18A, 
which corresponded to the smallest RFLP fragment depicted in Figure 6.6, lane 2 (0.8kb).   
As this fragment was the BglII/PstI digest, which corresponds to the fragment containing 
vspA and vspB, it was predicted that in B. hyodysenteriae B204 this fragment should be the 
largest fragment of 1.9kb (Figure 6.6).   It is assumed that a nucleotide polymorphism results 
in the formation of a BglII site in B. hyodysenteriae P18A vspB, which generates a smaller 
fragment upon RFLP analysis.   Despite the size differences in the PstI/BglII fragments 
between B. hyodysenteriae P18A and B204, the small amount of sequence data obtained for 
B. hyodysenteriae P18A did not reveal any deletions.    
 
The lack of the production of a VspAB PCR product in B. hyodysenteriae P18A (Figure 
6.4), and the few mismatches in vspA (Figure 6.9) suggests that the reason for the lack of a 
VspAB PCR product is a result of variations surrounding the VspB Primer binding site.   
Investigations into the vspABCD cluster of B. hyodysenteriae 5380 and P18A as well as A1, 
vld and R7273 is an area for future study.   Further sequence characterisation by the 
generation of subclones of the vspABCD PCR products amplified from B. hyodysenteriae 
5380 and P18A would clarify the nature of the polymorphisms observed in this study. 
 
B. hyodysenteriae B8044 showed only slight sequence variation by PCR-RFLP and 
sequence characterisation but did not react with labelled vspABCD from B. hyodysenteriae 
B204 during DNA-DNA hybridisation (Figure 6.10).   It is tempting to attribute the lack of 
hybridisation to the slight sequence variation in B. hyodysenteriae B8044 vspABCD.    
However, in this case there are several strains that exhibit more polymorphisms at this locus 
(P18A, A1, 5380, vld and R7273) yet still react with the vspABCD probe from B. 
hyodysenteriae B204.   There is presumably another factor influencing the binding of DNA 
probes in this strain.  Several probes can react with the B8044 DNA, in particular the flaA 
and B8044 smpA probes (Chapter 3), however the vspABCD and vspEFGH probes were not 
able to react strongly with the B8044 DNA.   Strain B8044 also had a unique PFGE profile 
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(Figure 6.13), indicating a more distant relationship between B8044 and other tested strains 
of B. hyodysenteriae.   As only a select number of strains were tested in this study, B. 
hyodysenteriae strains with similarities to B8044 may still be found after further study. 
 
The largest observed difference in B. hyodysenteriae B8044 compared to B. 
hyodysenteriae B204 was in the region of vspC and vspD.   Although the sequence 
variations in this particular region was not enough to change the RFLP pattern or in theory to 
prevent binding of the DNA probe, the expression of vspC was affected.   A single base pair 
mutation in vspC introduced a premature stop codon to the coding region, resulting in a 
truncated protein if the gene was to be expressed.   However, as only VspH expression has 
been observed in vitro (McCaman et al., 2003), exactly how this mutation affects the outer 
membrane of B. hyodysenteriae B8044 is unknown.    
 
The vspEFGH cluster showed significantly more polymorphisms than vspABCD.   Only 
B. hyodysenteriae B204, which is the strain the vspEFGH primers were designed from, 
produced a PCR product (Figure 6.11).   Further analysis of vspEFGH by DNA-DNA 
hybridisation revealed that the cluster is present in all strains, except possibly B8044 (Figure 
6.12, see discussion above).   The larger variation in the vspEFGH cluster compared to the 
vspABCD cluster observed in this study is in agreement with the sequence characterisation 
of the clusters in B. hyodysenteriae B204 (McCaman et al., 2003).   It was suggested that the 
two clusters evolved at different rates (McCaman et al., 2003), however it is unknown why 
such extensive duplication or variation within the clusters occurred. 
 
The vsp clusters are thought to have evolved in order to avoid the host immune system 
or in response to environmental stress (Gabe et al., 1998; McCaman et al., 1999; McCaman 
et al., 2003).   Nucleotide polymorphisms are often induced  by environmental pressures 
such as the host immune system (Kunin & Ouzounis, 2003; Lawrence, 1999).   Many other 
bacteria utilise antigenic variation of outer membrane proteins, such as Treponema pallidum 
(Stamm & Bergen, 2000), Borrellia burgdoferi (Zhang & Norris, 1998) and various 
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Mycoplasma species (Lysnyansky et al., 1999; Lysnyansky et al., 2001).   The mechanism 
by which these organisms vary the sequence of their antigens is either by combinatorial gene 
conversion or phase variation combined with high-frequency genetic recombination. 
 
Gene conversion is the non-reciprocal transfer of sequence information.   Organisms 
that vary their antigens by this method contain only one expressed gene and a series of 
pseudogenes that are not expressed.   The pseudogenes donate some of their sequence to 
the expressed gene, changing the sequence.   The expressed gene can be converted by 
multiple pseudogenes at once creating yet more variation in the antigen sequence.    
 
Treponema pallidum contains 47 pseudogenes that can combine for at least 420,000 
variations of the antigen TprK (Centurion-Lara et al., 2004; Stamm & Bergen, 2000).   
However, despite the large sequence variation observed in T. pallidum tprK pseudogenes, 
none of the base pair mutations results in a premature stop codon (Centurion-Lara et al., 
2004).   This suggests that TprK is essential for T. pallidum (Centurion-Lara et al., 2004).   
The situation for vspABCD of B. hyodysenteriae is different, however.   This study identified a 
nucleotide mutation that would result in premature termination of transcription suggesting 
that VspC, at least, is not essential for the growth of B. hyodysenteriae or that the function of 
the eight proteins encoded by the vspABCD and vspEFGH clusters are redundant. 
 
At this stage there is no experimental evidence to support the variation of vspH via 
combinatorial gene conversion.   An alternative method of antigenic variation may be 
employed by B. hyodysenteriae, or secondly, the duplication of the vsp genes may serve a 
different purpose.   There are many methods of antigenic variation used by pathogens 
(Bhurga et al., 1995; Dybvig, 1993; Razin et al., 1998; van der Woude & Baumler, 2004).   
However, a common theme in other methods of variation is the genetic recombination of the 
coding regions and not simply the alteration of expression via phase variation (Lysnyansky et 
al., 2001; van der Woude & Baumler, 2004).   There is no evidence that the vsp genes 
undergo genetic recombination in addition to phase variation (which alone is unable to 
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generate sufficient variation to evade the host immune system).   Furthermore, 
immunological cross reactivity between VspA and VspH (Gabe et al., 1998; McCaman et al., 
1999; McCaman et al., 2003), suggests that the purpose of the duplication is not to generate 
antigenically unique proteins.  
 
There is precedence for genetic duplication in the alteration of function in B. 
hyodysenteriae.   The bitABC genes of B. hyodysenteriae encode three homologous genes 
that sequester iron from different sources in vivo (Dougard et al., 1999).   If the vsp genes 
were duplicated for a similar reason, i.e. the alteration of nutrient acquisition, each of the 
genes would contain it’s own promoter site and regulatory sequences to respond to different 
environmental stimulus.   The sequence similarity to various bacterial aspartases (Gabe et 
al., 1998; McCaman et al., 1999; McCaman et al., 2003) may suggest that the origin of the 
vsp genes is metabolic, although the reason for duplication of aspartase encoding genes is 
unknown. 
 
The variation in the outer membrane observed in this study has the potential to greatly 
effect the design of future vaccines against SD, given that components of the outer 
membrane of organisms are common inclusions in vaccine preparations.  
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Chapter 7– General Discussion 
 
The identification of smpB in this investigation has explained earlier work into the 
distribution of smpA amongst B. hyodysenteriae strains (Turner et al., 1995).   The discovery 
that B. hyodysenteriae strains contain either SmpA or SmpB, along with the predicted outer 
membrane localisation, lead to speculation concerning the potential of SmpB (or SmpA) to 
contribute to protection from swine dysentery.   This results presented in the previous 
chapters demonstrated that vaccination of mice with recombinant SmpB or HlyA can lower 
the pathological changes after challenge with B. hyodysenteriae.   However, as SmpB is 
present in only ~50% of strains (with the others expressing SmpA), simultaneous vaccination 
with both SmpA and SmpB may be required to provide adequate protection. 
 
As SD is primarily a disease of the colonic mucosa, it is thought that induction of a 
strong mucosal immune response should afford higher levels of protection than parental 
vaccination.   Certain adjuvants can increase the mucosal immune response, as can the 
delivery of the vaccine by certain attenuated bacteria.   Attempts were made in this study to 
deliver SmpB and HlyA by an attenuated S. typhimurium vaccine.   Such heterologous 
antigen vectoring has been shown to induce a strong mucosal immune response when used 
to vaccinate against other diseases (Arnold et al., 2004; Capozzo et al., 2004; Chen et al., 
2006; Kang et al., 2002; Parida et al., 2005; Vecino et al., 2002).    
 
S. typhimurium STM-1 has previously been shown to successfully deliver ovalbumin 
and DNA vaccines encoding ovalbumin and induce a strong ovalbumin-specific immune 
response (Bachtiar et al., 2003).   However, in this study, an immune response directed 
against the heterologous antigen was not observed after delivery of protein or DNA vaccines 
by STM-1.   It is assumed, based on plasmid stability trials, macrophage survival trials and 
observations on the growth of recombinant S. typhimurium vaccines, that the lack of an 
immune response is a result of instability of the antigen encoding plasmids and increased 
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metabolic load on the attenuated vaccine strain resulting in decreased growth of the 
vaccines.  
 
The metabolic burden placed upon the recombinant vaccine strain has already been 
discussed in relation to the lack of an immune response (Chen et al., 2005; Galen & Levine, 
2001; Garmory et al., 2002; Sbrogio-Almeida et al., 2004).   However, there are certain 
methods that may be utilised to overcome this potential problem, including in vivo regulation 
of expression (Bumann, 2002; Dunstan et al., 1999; Medina et al., 2000; Miller et al., 1993; 
Wang et al., 2003).   Promoters such as PnirB and PpagC, which control the expression of 
genes of the S. typhimurium Salmonella Pathogenicity Island involved in invasion of 
macrophages, allow expression of the antigen after invasion of macrophages (Chatfield et 
al., 1997; Husseiny & Hensel, 2005b; Tijhaar et al., 1994).   The purpose of using in vivo 
activated promoters is to lower the metabolic burden on the S. typhimurium vector during in 
vitro growth and processing of the vaccine strain, and to increase the stability of the 
expression vector. 
 
Other factors that must be considered when optimising the delivery of heterologous 
antigens by S. typhimurium strains are the nature of the antigen, the plasmid, and the nature 
of the attenuation of the S. typhimurium vector (Chen et al., 2006; Sbrogio-Almeida et al., 
2004).   The comparison of attenuated S. typhimurium vaccines suggests that mutation of 
different genes results in the induction of a different immune response (Chen et al., 2006; 
Raupach & Kaufmann, 2001; Sbrogio-Almeida et al., 2004).   The strength of the 
heterologous antigen-specific immune response correlates to the stability of the expression 
plasmid, not to increased copy number or expression (Dunstan et al., 2003).   This suggests 
that persistent exposure of the host to the heterologous antigen is more important than high 
levels of exposure.   This contradicts earlier experiments suggesting that the level of initial 
exposure of antigen is more important than persistent exposure (Cardenas & Clements, 
1993; Cardenas et al., 1994), so it is probable that the temporal nature of the expression is 
also important. 
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A method for increasing the retention of the gene encoding the heterologous antigen, in 
addition to the in vivo promoters already discussed, is the integration of the heterologous 
gene into the chromosome (Strugnell et al., 1990).   While severely reducing the copy 
number of the gene, integration greatly increases the stability and therefore the exposure of 
the host to the heterologous antigen.   Another factor which must be considered when 
designing an attenuated S. typhimurium vector vaccine is the presence of a selective marker.   
The increase in antibiotic resistance of pathogenic organisms is an area of major concern, 
and the incorporation of antibiotic selective markers into potential vaccines in undesirable.   A 
new system for expression of heterologous antigens combines the lack of an antibiotic 
selective marker with stable expression of the antigen from the host chromosome (Husseiny 
& Hensel, 2005a).   The Lambda Red system also has the advantage of introducing defined 
deletions into the chromosome during the recombination step.   Evaluation of the Lambda 
Red system for the delivery of B. hyodysenteriae antigens may result in an increase in the 
immune response induced as it would overcome the problems associated with plasmid 
stability that were observed in this study. 
 
The lessening of pathological changes after vaccination with rSmpB and rHlyA is 
promising for future research into these proteins.   The partial protection conferred by other 
B. hyodysenteriae proteins, such as BmpB (La et al., 2004), suggest that a multivalent 
vaccine may be required for increased protection against SD.   Investigations into the 
immunogenicity induced by vaccination with a combination of SmpA, SmpB and BmpB may 
reveal greater levels of protection.   The inclusion of other outer membrane components of B. 
hyodysenteriae may further increase the protection conferred after vaccination.    
 
Vaccination with recombinant HlyA and SmpB resulted in significant levels of specific 
antibodies and cytokine producing cells.   Considering the lack of a heterologous antigen 
specific immune response following delivery of antigens by S. typhimurium observed in this 
study and the potential importance of mucosal immunity to protect from SD, other methods of 
delivering B. hyodysenteriae antigens to the host mucosal immune system need to be 
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investigated (Yuki & Kiyono, 2003).   Protein antigens, when delivered mucosally, are 
generally poor immunogens and can induce immunological tolerance which is not desirable 
(Eriksson & Holmgren, 2002; Yuki & Kiyono, 2003).    
 
Several strategies for mucosal vaccination using protein antigens are being 
investigated, and may potentially increase the protection against SD after vaccination with 
SmpB or HlyA.   One strategy is to co-immunise with highly immunogenic toxins.   Genetic 
manipulation of the cholera toxin (CT) and heat-labile toxin (LT) from Vibrio cholera and E. 
coli can remove the toxicity while retaining the adjuvant activity (Douce et al., 1998; Douce et 
al., 1999; Holmgren et al., 2005; Marchetti et al., 1998; Peppoloni et al., 2003; Pizza et al., 
2001; Yamamoto et al., 1997).   Both LT and CT induce B7-1 and B7-2 expression on APCs 
which gives co-stimulatory signals to CD4+ T lymphocytes.   However, it is suggested that 
CT primarily induces a Th-2 response mediated by IL-4, and LT induces a IFN-γ dependent 
Th-1 response with an IL-4 independent Th-2 response (Freytag & Clements, 1999; 
Yamamoto et al., 2000; Yuki & Kiyono, 2003).   Oral co-administration of SmpB or HlyA 
combined with these adjuvants may result in increased antigen specific mucosal immunity.    
 
Activation of Toll-like receptor 9 by unmethylated bacterial CpG motifs (cytosine-
phosphate-guanosine) from bacterial DNA also has potential to induce both systemic and 
mucosal protein-specific immunity after co-administration with protein antigens via the oral 
route (Holmgren et al., 2005; McCluskie et al., 2001; Yuki & Kiyono, 2003).   The presence of 
CpG DNA upregulates the expression of B7-2 and promotes a Th-1 immune response.   Oral 
co-administration of protein antigens with CpG resulted in the induction of predominantly 
protein-specific IgG2a, mucosal sIgA and cell mediated systemic immunity (Gallichan et al., 
2001; McCluskie et al., 2000).   Considering the importance of CD8αα+ T lymphocytes and 
sIgA responses in immunity against SD (Section 1.5.1), oral co-administration of SmpB or 
HlyA with CpG with or without CT may provide increased levels of protection.   The lack of a 
heterologous antigen-specific immune response following vaccination with recombinant 
STM-1 in this study suggests that optimisation of the expression of antigen by STM-1 is 
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required, or alternative methods of targeting the mucosal immune system should be 
investigated.  
 
Despite the proposed antigenic variation of the vspABCD and vspEFGH genes, 
immunological cross reactivity has been observed between VspA and VspH (Gabe et al., 
1998; McCaman et al., 2003).   This cross reactivity suggests that the duplication of vspH is 
not to evade the host immune system.   Evaluation of the immune response induced by 
VspH, and any protection conferred, may support the inclusion of components of the vsp 
cluster is such a multivalent vaccine.   Furthermore, vaccination with components of iron 
transport proteins in other bacteria that bear high similarity to BitABCDEF confers protection 
against challenge with Streptococcus pneumoniae (Jomaa et al., 2005).   Investigations into 
the potential of these proteins to vaccinate against B. hyodysenteriae may reveal the 
induction of a similar protective immune response, and justify their inclusion in any 
multivalent vaccine. 
 
This study has identified several variations in the genes encoding outer membrane 
proteins of B. hyodysenteriae strains.   Considering the high level of genetic recombination 
events that have been proposed to influenced the B. hyodysenteriae genome (Zuerner et al., 
2004), and the presence of a defective phage in B. hyodysenteriae potentially involved in 
horizontal gene transfer (Humphrey et al., 1995; Humphrey et al., 1997; Stanton et al., 2003), 
variation of proteins exposed to the host immune system is not suprising.   The presence of 
smpB and not smpA in approximately half the B. hyodysenteriae strains tested provides 
further evidence of the high frequency of recombination events that have influenced the B. 
hyodysenteriae genome. 
 
The restriction of variation to genes specific for B. hyodysenteriae (i.e. vspABCD, 
vspEFGH, smpB and smpA) and not those also present in the closely related commensal, B. 
innocens, suggests that variation in outer membrane protein encoding genes may be 
important for the pathogenesis of B. hyodysenteriae.   Variation of antigens to evade the host 
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immune system, while common in spirochaetes, has been largely argued against in this 
study, using the reasoning that phase variation of eight genes (in the case of vspABCD and 
vspEFGH) is not enough to establish a persistant infection without some method of genetic 
recombination, which has yet to be observed in B. hyodysenteriae.   Alternative reasons for 
duplication of genes with high levels of similarity have been proposed, including alteration of 
function or ligand specificity.   Environmental (immune) pressures and exposure to microbial 
ecosystems in the host intestine could result in the accumulation of foreign genes and 
alteration of existing genes.   Such sources of material for genetic recombination may have 
resulted in the replacement of smpA with smpB. 
 
The variation in the outer membrane between B. hyodysenteriae strains that was 
observed in this study must be carefully considered in regards to the rational development of 
vaccines.   This variation may extend to other OMPs, as was observed in the 2D gel 
electrophoresis results.   The search for OMPs of B. hyodysenteriae that interact with the 
host is an important area of study for the design of vaccines, however given the proposed 
high level of recombination events in B. hyodysenteriae (Zuerner et al., 2004), the distribution 
and conservation of any OMPs identified must be investigated.   Any proteins of B. 
hyodysenteriae that are evaluated for their potential as a vaccine must by also evaluated for 
their distribution amongst B. hyodysenteriae strains. 
 
Both SmpB and HlyA have some potential as a vaccine component to protect against 
SD, as demonstrated by the reduced caecal weight and pathological changes upon 
challenge with B. hyodysenteriae.   As with all protection trials performed with the mouse 
model of SD, the results are indicative of a possible protective response.   To properly 
evaluate the potential of SmpB to protect from B. hyodysenteriae exposure, vaccination of 
swine, possibly in combination with SmpA, is essential. 
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Appendix 1 – B8044 and B234 vspABCD Sequence 
vspABCD      1081 CCTACTAGCGATAACTTTGGTTCTCATACTCCAGTACTTATGATTAATGCTTTAAATGAT 
B8044           1 ---------------TGGGGTTCTCATACTCCAGTACTTATGATTAATGCTTTAAATGAT 
B234            1 -----AAGCGAT-ACTTTGGTTCTCATACTCCAGTACTTATGATTAATGCTTTAAATGAT 
 
vspABCD      1141 AATTTGAGGATAGTTATTCCTGTGCAAATATTAGTACATAATGAAAGTATTGATCAACTT 
B8044          46 AATTTGAGGATAGTTATTCCTGTGCAAATATTAGTACATAATGAAAGTATTGATCAACTT 
B234           55 AATTTGAGGATAGTTATTCCTGTGCAAATATTAGTACATAATGAAAGTATTGATCAACTT 
 
vspABCD      1201 GGTTACTATAGAGATAATTATTTAGGTATAAGTACTGATACGCAAATAAGATATTATACA 
B8044         106 GGGTACTATAGAGATAATTATTTAGGTATAAGTACTGATACGCAAATAAGATATTATACA 
B234          115 GGGTACTATAGAGATAATTATTTAGGTATAAGTACTGATACTCAAATAAGATATTATACA 
 
vspABCD      1261 GGCATAGATGCTTTTAATGAAATAAGATTATATGTAAAATATGGGCAATTAGGATATAAA 
B8044         166 GGCATAGATGCTTTTAATGAAATAAGATTATATGTAAAATATGGGCAATTAGGATATAAA 
B234          175 GGTATAGATGCTTTTAATGAAATAAGATTATATGTAAAATATGGGCAATTAGGATATAAA 
 
vspABCD      1321 ATTAATCCGCATGATACTATAAATTATACACAAGAAGTTTTAGCAAGATCATTTGGTTTT 
B8044         226 ATTAATCCGCATGATACTATAAATTATACACAAGAAGTTTTAGCAAGATCATTTGGTTTT 
B234          235 ATTAATCCGCATGATACCAAAAATTATACGCAAGAAGTTTTAGCAAGATCATTTGGTTTT 
 
vspABCD      1381 GAAACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATCAATCCTTTTATT 
B8044         286 GAAACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATCAATCCTTTTATT 
B234          295 GAAACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATCAATCCTTTTATT 
 
vspABCD      1441 AAAGTAGCATATAATACAGCTTTGCATGGATATAGTACCATGGTAAGAGCATTGGATGGT 
B8044         346 AAAGTAGCATATAATACAGCTTTGCATGGATATAGTACCATGGTAAGAGCATTGGATGGT 
B234          355 AAAGTAGCATATAATACAGCTTTGCATGGATATAGTACCATGGTAAGATCATTGGATGGT 
 
vspABCD      1501 ATGTATGAAGAAATAGAAGGTTATTATCCAGATAGTCCTGCTCAATCATATGAAGATATT 
B8044         406 ATGTATGAAGAAATAGAAGGTTATTATCCAGATAGTCCTGCTCAATCATATGAAGATATT 
B234          415 ATGTATGAAGAAATAGAAGGTTATTATCCAGATACTATTGTTTCTCCACAAGTAAATATT 
 
vspABCD      1561 AATGTTAAATGGGATAAGAATCCTTATGATGTAACTGTGCAGGCAGTATTGGGAGTAACT 
B8044         466 AATGTTAAATGGGATAAGAATCCTTATGATGTAACTGTGCAGGCAGTATTGGGAGTAACT 
B234          475 AATGCTAAATGGGATAAGAATCCTTATGATGTAACTGTGCAGGCAGTATTGGGAGTAACT 
 
vspABCD      1621 GCTAATAGCGATATAGTATCACTTTATGTTGAGCCTTCTTTAGGTTATAGGGCTAAATAT 
B8044         526 GCTAATAGCGATATAGTATCACTTTATGTTGAGCCTTCTTTAGGTTATAGGGCTAAATAT 
B234          535 GCTAATAGCGATATAGTATCACTTTATGTTGAGCCTTCTTTAGGTTATAAGGCTAGATAT 
 
vspABCD      1681 TTAGGAAAATTAACATATGAAGATCCAGATGGAAAAGTTAATTTTGATTTTAAAGTTAAT 
B8044         586 TTAGGAAAATTAACATATGAAGATCCAGATGGAAAAGTTAATTTTGATTTTAAAGTTAAT 
B234          595 TTAGGAAAAATGCAATATGAAGATCAAGATGGAAAAGTTAATTTTGATTTTAAAGTTAAT 
 
vspABCD      1741 CATTATTTATCTTGGGGTGCTTATGCAGAGCTTTATATAACACCGGTAAAAGATTTAGAA 
B8044         646 CATTATTTATCTTGGGGTGCTTATGCAGAGCTTTATATAACACCTGTAAAAGATTTAGAA 
B234          655 CATTATTTATCTTGGGGTGCTTATGCAGAGCTTTATATAACACCGGTAAAAGATTTGGAA 
 
vspABCD      1801 TGGTATTTTGAAATGGATGTTAATAATAGTGATTCAGATTCTACAGGTATACCTGTTAGT 
B8044         706 TGGTATTTTGAAATGGATGTTAATAATAGTGATTCAGATTCTACAGGTATACCTGTTAGT 
B234          715 TGGTATTTTGAAATGGATGTTAATAATGGTGATTCAGATTCTACAGGAATACCTATTAGT 
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vspABCD      1861 TTTGCTTCTACTACAGGAATAACTTGGTATTTGCCAGAATTTTAATTATAAAGCAAATTT 
B8044         766 TTTGCTTCTACTACAGGAATAACTTGGTATTTGCCAGAATTTTAATTATAAAGCAAATTT 
B234          775 TTTGCTTCTACTACAGGAATAACTTGGTATTTGCCAGAATTTTAATTATAAAGCAAATTT 
 
vspABCD      1921 TATATGATAAAATAAAAAATGTGGGGTATTTATTATTAAAAAATAAATACCCCACATTTT 
B8044         826 TATATGATAAAATAAAAAATGTGGGGTATTTATTATTAAAAAATAAATACCCCACATTTT 
B234          835 TATATGATAAAATAAAAAATGTGGGGTATTTATTATAAAAAAATAAATACCCCACATTTT 
 
vspABCD      1981 ATTAAATAATTTTTTCAGTAATTTTACATTTATATATTTTTTAGTATAATAAAAA-TATA 
B8044         886 ATTAAATAATTTTTTCAGTAATTTTACATTTATATATTTTTTAGTATAATAAAAA-TATA 
B234          895 ATTAAATAATTTTTTAAATAATTTTACATTTATATATTTTTTAGTATAATAAAAAATATA 
 
vspABCD      2040 AACTTAAATTTAGGTATATACAATGAAAAAAATTTTTCTAATTATGACAGTATTATTAAG 
B8044         945 AACTTAAATTTAGGTATATACAATGAAAAAAATTTTTCTAATTATGACAGTATTATTAAG 
B234          955 AACTTCAATTTAGGTATGTATAATGAAAAAGTTTTTTCTAATTATGACAGTATTATTAAG 
 
vspABCD      2100 TATGTCATATTGTTCAATATTTGGTATGTATGGAGATCAGGACGATTGGATTGATTTTCT 
B8044        1005 TATGTCATATTGTTCAATTTTTGGTATGTATGGAGATCAGGACGATTGGATTGATTTTCT 
B234         1015 TATGTCATATTGTTCAATTTTTGGTATGTATGGAGATCAGGACGATTGGATTGATTTTCT 
 
vspABCD      2160 TACAGACGGCAATCAGTTTAGAGCTAGAATGGATCAATTAGGATTTGTTTTAGGTAATAG 
B8044        1065 TACAGACGGCAATCAGTTTAGAGCTAGAATGGATCAATTAGGATTTGTTTTAGGTAATAG 
B234         1075 TACAGACGGCAATCAGTTTAGAGCTAGAATGGATCAATTAGGATTTGTTTTAGGTAATAG 
 
vspABCD      2220 CACCATTAAAGGTACTTTCGGTTTTAGATCTCAGAGTTTATCAACTCAATTAGGATATAT 
B8044        1125 CACCATTAAAGGTACTTTCGGTTTTAGATCTCAGAGTTTATCAACTCAATTAGGATATAT 
B234         1135 TACTATTAAAGGTACTTTCGGTTTTAGATCTCAGAGTTTATTGACTCAATTAGGATATAT 
 
vspABCD      2280 TTTGGCTATATATAAAGATTATACTTATTTAGGAGCAACTATTTCCGGCGGTATAGGATA 
B8044        1185 TTTGGCTATATATAAAGATTATACTTATTTAGGAGCAACTATTTCCGGCGGTATAGGATA 
B234         1195 TTTGGCTATATATAAAGATTATACTTATTTAGGAGTAACTATTTCCGGAGGTATAGGATA 
 
vspABCD      2340 TACTTCTGAGGCTTTTAGTATAGGTTTAGGTTATAATTATACTACACCGCTTCCTATTAG 
B8044        1245 TACTTCTGAGGCTTTTAGTATAGGTTTAGGTTATAATTATACTACACCGCTTCCTATTAG 
B234         1255 TACTTCCGAGGCTTTTAGTATAGGTTTAGGTTATAATTATACTACCCCATTTCCTATTAG 
 
vspABCD      2400 TTATAACTTTGGTTCTCATACTCCTGTACTTATGATTAATGCTTTAAATGATAATTTGAG 
B8044        1305 TTATAACTTTGGTTCTCATACTCCTGTACTTATGATTAATGCTTTAAATGATAATTTGAG 
B234         1315 TTATAACTTTGGTTCTCATACTCCTGTACTTATGATTAATGCTTTAAATGATAATTTGAG 
 
vspABCD      2460 GATAGTTATTCCTGTACAAATATTAGTACATGATGGTAATATGAATATGACGGATAATAT 
B8044        1365 GATAGTTATTCCTGTACAAATATTAGTACATGATGGTAATATGAATATGACGGATAATAT 
B234         1375 GATAGTTATTCCTATACAAATATTAGTACATGATGGTAATATGAATATGACGGATAATAT 
 
vspABCD      2520 TAATTATTTATATAATTTTTTAGGTATAAGTACTGATACTCAAATAAGATATTATACAGG 
B8044        1425 TAATTATTTATATAATTTTTTAGGTATAAGTACTGATACTCAAATAAGATATTATACAGG 
B234         1435 TAATTATTTATATAATTTTTTAGGTATAAGTACTGATACGCAAATAAGATATTATACAGG 
 
vspABCD      2580 CATAGACGCTTTTAATGAAATAAGATTATATGTAAAATACGGACAATTAGGATATAAAGG 
B8044        1485 CATAGACGCTTTTAATGAAATAAGATTATATGTAAAATACGGACAATTAGGATATAAAGG 
B234         1495 TATAGATGCTTTTAATGAAATAAGATTATATATAAAATATGGACAATTAGGATATAAAGG 
 
vspABCD      2640 CGGTTCATATACGGATAAAAGTTATGATGAAGAATTTTTTGCAAGATCATTTGGTTTTGA 
B8044        1545 CGGTTCATATACGGATAAAAGTTATGATGAAGAATTTTTTGCAAGATCATTTGGTTTTGA 
B234         1555 CGGTTCATATACGGATAAAAATTATGAGGAAGAATTTTTTGCAAGATCATTTGGTTTTGA 
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vspABCD      2700 AACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATCAATCCTTTTATTAA 
B8044        1605 AACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATCAATCCTTTTATTAA 
B234         1615 AACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATTAATCCTTTTATTAA 
 
vspABCD      2760 AGTAGCATATAATACAGCTTTGCATGGATTTAGTACTATGGTAAGATCATTAGATAGTGT 
B8044        1665 AGTAGCATATAATACAGCTTTGCATGGATTTAGTACTATGGTAAGATCATTAGATAGTGT 
B234         1675 AGTAGCATATAATACAGTTTTGCATGGATTTAGTACTATGG------------------- 
 
vspABCD      2820 CATTGAAGAAATAGAAGGTTATAGTTCAGATCGTACCGCTAAAGCAGCAGGAAATATTAA 
B8044        1725 CA-TGAAGAAATAGAAG----TATGTCAGTTC---------------------------- 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      2880 TGCTAAATGGGATAAGAATCCTTATGATGTAACTGTGCAGGCAGTATTGGGAGTAACTGC 
B8044        1752 ------------------------------------------------------------ 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      2940 TAATAGCGATATAGTATCACTTTATGTTGAGCCTTCTTTAGGTTATAGGGCTAAATATTT 
B8044        1752 ------------------------------------------------------------ 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3000 AGGAAAATTAACATATGAAGATCCAGATGGAAAAGTTAATTTTGATTTTAAAGTTAATCA 
B8044        1752 ------------------------------------------------------------ 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3060 TTATTTATCTTGGTGTGCTTATGCAGA-GCTTTATATAACACCTG--TAAAAGATTTA-G 
B8044        1752 -----------GGTG-------GCAGACGCTTTATATAACACCTTGTTAAAAGATTTAAG 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3116 AATGGTATTTTGAAATGGATGTTAATAATAGTGATTCA-GATTCTACAGGTATACCTGTT 
B8044        1794 AATGGTATTTGGAAATGGATGTTAATTATAGTGATTCAAGATTCTACAGGTATACCTGTT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3175 AGTTTTGC-TTCTACTACAGGAATAAC-TTGGTATTTGCCAGAATTTTAATTATAAAGCA 
B8044        1854 AGTTTTGCCTTCTACTACAGGAATAACCTTGGTATTTGCCAGAATTTTAATTATAAAT-A 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3233 AATTTTATATGACAAAATAAAAAATGGGGCATTTATTATTAAAAAATAAATACCCCACAT 
B8044        1913 AAATTTATATGACAAAATAAAAAATGGGGCATTTATTATTAAAAAATAAATACCCCATTT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3293 TTTATTAAATAACTTCTTAAATAATTTTACATTT--ATATTTTATTAGTATAATAAAA-T 
B8044        1973 TTTATTAAATAACTTCTTAAATAATTTTACATTTTTATATTTTATTAGTATAATAAAAAT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3350 ATAAAGTTAAATTTAGGTGTGTACAATGAAAAAAAGTTTTCTAATTATGACAGTATTATT 
B8044        2033 ATAAACTTAAATTTAGGTGTGTACAATGAAAAAGTTTTTTCTAATTATGACAGTATTATT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3410 AAGTATGTCATATTGTTCAATATTTGGTATGTATGGAGATCAGGACGATTGGATTGATTT 
B8044        2093 AAGTATGTCATATTGTTCAATATTTGGTATGTATGGAGATCAGGACGATTGGATTGATTT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3470 TCTTACAGACGGTAATCAGTTTAGAGCTAGAATGGATCAATTTGGATTCGTTTTAGGTAA 
B8044        2153 TCTTACAGACGGTAATCAGTTTAGAGCTAGAATGGATCAATTTGGATTCGTTTTAGGTAA 
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B234         1716 ------------------------------------------------------------ 
 
vspABCD      3530 TAGCACCATTAAAGGTACTTTCGGTTTTAGATCTCAGAGTTTATCAACTCAATTAGGATA 
B8044        2213 TAGCACCATTAAAGGTACTTTCGGTTTTAGATCTCAGAGTTTATCAACTCAATTAGGATA 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3590 TATTTTGGCTATATATAAAGATTATACTTATTTAGGAGCAACTATTTCCGGCGGTATAGG 
B8044        2273 TATTTTGGCTATATATAAAGATTATACTTATTTAGGAGCAACTATTTCCGGCGGTATAGG 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3650 ATATACTTCTGAGGCTTTTAGTATAGGTTTAGGTTATAATTATACTACACCGCTTCCTAT 
B8044        2333 ATATACTTCTGAGGCTTTTAGTATAGGTTTAGGTTATAATTATACTACACCGCTTCCTAT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3710 TAGTGATAACTTTGGTTCTCATACTCCTGTACTTATGATTAATGCTTTAAATGATAATTT 
B8044        2393 TAGTGATAACTTTGGTTCTCATACTCCTGTACTTATGATTAATGCTTTAAATGATAATTT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3770 GAGGATAGTTATTCCTGTACAAATATTAGTATATAATGGTAATGTTCAAAAAGTTGATAA 
B8044        2453 GAGGATAGTTATTCCTGTACAAATATTAGTATATAATGGTAATGTTCAAAAAGTTGATAA 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3830 ACAAGGTAATATCTCTTATTCACATGATTATTTAGGTATAAGTACTGATACGCAAATAAG 
B8044        2513 ACAAGGTAATATCTCTTATTCACATGATTATTTAGGTATAAGTACTGATACGCAAATAAG 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3890 ATATTATACAGGTATAGATGCTTTTAATGAAATAAGATTATATGTAAAATATGGGCAATT 
B8044        2573 ATATTATACAGGTATAGATGCTTTTAATGAAATAAGATTATATATAAAATATGGACAATT 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      3950 AGGATATAAAAATGCTCCGTATGTTGGTAAGAATTATGAAGAAGAATTTTTTTCAAGGTC 
B8044        2633 AGGATATTAAGGCGGTTCATATACGGATAAAAGTTATGATGAAGAATTTTTTGCAAGATC 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      4010 ATTTGGTTTTGAAACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATCAA 
B8044        2693 ATTTGGTTTTGAAACAAGATTCTATTTTTTGAATACTGCTGTTGGAAATGTAACTATCAA 
B234         1716 ------------------------------------------------------------ 
 
vspABCD      4070 TCCTTTTATTAAAGTAGCATATAATACAGCTTTGCATGGATTTAGTACCATGATAAGAGC 
B8044        2753 TCCTTTTATTAAAGTAGCATATAATACAGCTTTGCATGGATTTAGTACTATGGTAAGATC 
B234         1716 -----------------------------------------------------TAAGAGC 
 
vspABCD      4130 ATTAGATAGTATGTTTGAACCAATAGAAGGTTATAGTTCAGATCGTCCTGTTTCATCACA 
B8044        2813 ATTAGATAGTGTCATTGAAGAAATAGAAGGTTATAGTTCAGATCGTACCGCTAAAGCAGC 
B234         1723 ATTAGATAGTATGG-TGAACCAATAGA--------------------------------- 
 
vspABCD      4190 AGCAAATATTAATGCTAAATGGGATAAGAATCCTTATGATGTAACAGTGCAGGCAGTATT 
B8044        2873 AGGAAATATTAATGCTAAATGGGATAAGAATCCTTATGATGTAACAGTGCAGGCAGTATT 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4250 GGGAGTAACCGCTAATAGCGATATAGTATCACTTTATGTTGAGCCTTCTTTAGGTTATAG 
B8044        2933 GGAAGTAACTGCTAATAGCGATATAGTATCACTTTATGTTGAGCCTTCTTTAGGTTATAG 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4310 GGCTAAATATTTAGGAAAATTAACATATGAAGATCCAGATGGAAAAGTTAATTTGGATTT 
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B8044        2993 GGCTAAATATTTAGGAAAATTAACATATGAAGATCCAGATGGAAAAGTTAATTTTGATTT 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4370 TAAAGTTAATCATTATTTATCTTGGGGGGCTTATGCAGAGCTTTATATAACACCGGTAAA 
B8044        3053 TAAAGTTAATCATTATTTATCTTGGGGTGCTTATGCAGAGCTTTATATAACACCTGTAAA 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4430 AGATTTGGAATGGTATTTTGAAATGGATGTTAATAATAGTGATTCAGATTCTACAGGAAT 
B8044        3113 AGATTTAGAATGGTATTTTGAAATGGATGTTAATAATAGTGATTCAGATTCTACAGGTAT 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4490 ACCTGTTAGTTTTGCTTCTACTACAGGAATAACTTGGTATTTGCCAGAATTTTAATTATA 
B8044        3173 ACCTGTTAGTTTTGCTTCTACTACAGGAATAACTTGGTATTTGCCAGAATTTTAATTATA 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4550 AAGCAAATTTTATATGACAAAATAAAAAATGNGGGNTATTTATTATTAAAAAATAAATAC 
B8044        3233 AAT-AAAATTTATATGACAAAATAAAAAAT--GGGGCATTTATTATTAAAAAATAAATAC 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4610 CCCGTTTTTTATTAAATAACTTCTTAAATAATTTTACATTTTTATATTTTATTAGTATAA 
B8044        3290 CCCATTTTTTATTAAATAACTTCTTAAATAATTTTACATTTTTATATTTTATTAGTATAA 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4670 TAAAA-TATAAAGTTAAATTTAGGTGTGTACAATGAAAAAGTTT---CTAATTATGACAG 
B8044        3350 TAAAAATATAAACTTAAATTTAGGTGTGTACAATGAAAAAGTTTTTTCTAATTATGACAG 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4726 TATTATTAAGTATGTCATATTGTTCAATATTTGGTATGTATGGAGATCAGGACGATTGGA 
B8044        3410 TATTATTAAGTATGTCATATTGTTCAATATTTGGTATGTATGGAGATCAGGACGATTGGA 
B234         1749 ------------------------------------------------------------ 
 
vspABCD      4786 TTGATTTTCTTACAGACGGTAATCAGTTTAGAGCTAGAATGGATCAATTTGGATTCGTTT 
B8044        3470 TTGATTTTCTTACAGACGGTAATCAGTTTAGAGCTAGAATGGATCAATTTGGATTCGTTT 
B234         1749 -------------------------------AGCTA------------------------ 
 
vspABCD      4846 TAGGTAATAACACCATTAAAGGTACTTTCGGTTTTAGATCTCAGAGTTTATCAACTCACT 
B8044        3530 TAGGTAATAGCACCATTAAAGGTACTTTCGGTTTTAGATCTCAGAGTTTATCAACTCAAT 
B234         1754 ------------------------------------------------------------ 
 
vspABCD      4906 TAGGCTATATTTTGTTAAATAATAATTTTGGTACTT-ATTTTGGAACAAC-TATATCATG 
B8044        3590 TAGGATATATTTTGGCTATATATAAAGATTATACTTTATTTAGGAGCCACCTATTTCCGG 
B234         1754 ------------------------------------------------------------ 
 
vspABCD      4964 -CGGTATAGGATATACTTCT--GAGGCTTTTAGTATAGGTATAGGTTATAATTATACTAC 
B8044        3650 GCGGTATAGGATATACTTCCTGGAGGCTTTTAGTATAGGTTTAGGTTATAATTATACTAC 
B234         1754 ------------------------------------------------------------ 
 
vspABCD      5021 ACCGCTTCCTATTAGTGATAACTTTGGTTCTCATACTCCTGTACTTATGATTAATGC-TT 
B8044        3710 ACCGCTTCCCTATAGTGATAACTTTGGGTTCCATACTCCTGTACTTATGATTAATGCCTT 
B234         1754 ------------------------------------------------------------ 
 
vspABCD      5080 TAAATGATAATTTGA-GGATAGTTATTCC-TGTACAAATATTAG-TATATAATGGTAATA 
B8044        3770 TAAATGAATATTTGAAGGATAGTTATTCCCTGTACAAATATTAGGTATATAATGGTAA-- 
B234         1754 ------------------------------------------------------------ 
Appendix 2 – Vectors  
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Figure A.1: pGEXsmpB 
This plasmid was constructed by George Moutafis (RMIT), and was used for the purification of 
recombinant SmpB. 
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